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Since Yamanaka and Takahashi first described the isolation of induced pluripotent 
stem cells (iPSCs) in 2006, researchers have invested a vast amount of time and 
resources into trying to understand the process of reprogramming. However, the 
exact mechanisms underlying the induction of somatic cells to pluripotency is still 
incompletely understood. With this in mind, a screening approach was undertaken 
to identify shRNA that enhance the reprogramming process. A retrovirus based 
system was used to knock down candidate genes during reprogramming of mouse 
embryonic fibroblasts (MEF) containing doxycycline-inducible reprogramming 
factors and a Nanog-GFP reporter, which is activated when cells become iPSCs. The 
initial round of screening with over 150 shRNA vectors successfully identified 
several shRNAs that enhance reprogramming. One of these shRNA vectors 
exhibited both faster reprogramming kinetics as determined by activation of the 
Nanog-GFP reporter 2 to 3 days earlier and increased reprogramming efficiency 
giving rise to >5 fold more GFP+ colonies when compared with a control. Cell 
surface marker analysis with flow cytometry demonstrated that changes in CD44 
and ICAM1 expression, which occur preceding Nanog-GFP expression, were also 
accelerated. Validation of this shRNA determined that the enhanced 
reprogramming phenotype is the result of an unknown off-target effect. Microarray 
and RNA-sequencing analysis was carried out to identify the off target gene with a 
view to investigate the functional importance of this knock down and its role in 
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CHAPTER 1 - Introduction 
 
1.1 Changing cellular potential 
 
1.1.1 Reversion to pluripotency through somatic cell nuclear transfer 
 
Early cell development studies focusing on fate changes during 
differentiation were key in paving the way for progression of modern day stem cell 
science.  In a study published 80 years ago, Hämmerling (1934) used Acetabularia, a 
green algae, to generate heterokaryons and the resulting organism comprised 
features characteristic of both donor species. This put forward the idea that 
morphogenetic products derived by the nucleus could transport to the cytoplasm 
thereby regulating differentiation. Following on from this, later work by Briggs and 
King (1952) revealed that transplantation of nuclei from Rana pipiens (frog) blastulas 
into enucleated eggs subsequently gave rise to embryos that had normal 
differentiation capacity. This indicated that during differentiation, the nuclei of cells 
are not irreversibly changed. Interestingly, when the nuclei from a different species 
of frog, Rana catesbeiana, were transplanted into enucleated eggs of Rana pipiens, 
blastulas formed but died shortly after arrest, which is consistent with the lethal 
nature of normally produced hybrids of these species. In a subsequent report, the 
same group carried out serial transplantation of nuclei from late gastrula endoderm 
in to enucleated eggs and determined that second and subsequent generation clones 
of nucleated eggs recapitulated development similarly to the first generation i.e. if 
the first transplanted egg developed normally so did clones generated from serial 
transplantations and alternatively, if the first transplanted egg arrested at 
gastrulation subsequent clones behaved similarly and so on (King and Briggs, 1956). 
This work provided some evidence that differentiation potential of nuclei can be 
stably inherited, and nuclear changes or defects may not be reset to a normal status 
with serial transplantation. Similar results were confirmed in Xenopus laevis 
(Gurdon, 1960) and a later report by Gurdon (1962) demonstrated that serial transfer 
of nuclei isolated from fully differentiated Xenopus intestinal epithelium cells into 
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enucleated eggs could give rise to normal feeding tadpoles. This pioneering work 
provided evidence for the first time that genetic information is maintained 
throughout the lifetime of a cell and furthermore, genetic changes incurred during 
normal development can be reverted back to the original state. These experiments 
were among the first reports of somatic cell nuclear transfer (SCNT) and almost 50 
years later this technique would be used to produce the first mammal to be cloned 
from an adult somatic cell, a lamb, nicknamed Dolly the sheep to due the mammary 
gland origin of the somatic nucleus used to clone her (Wilmut et al., 1997). The 
animal was deemed to be healthy with no genetic abnormalities or otherwise, and in 
addition went on to produce viable offspring of her own providing conclusive proof 
that differentiation of cells does not cause permanent or irreversible changes to the 
genome and that nuclei can be ‘reset’ to a totipotent embryonic state. Since this 
achievement, several other animals have been successfully cloned including pigs 
(Polejaeva et al., 2000), dogs (Lee et al., 2005), horses (Galli et al., 2003) and deer 
(Berg et al., 2007), among many others but there has been controversy surrounding 
use of the technique to clone animals due to the low efficiency of the method in 
producing viable animals in addition to abnormal development commonly 




1.1.2 Embryonic stem cells 
 
Since embryonic stem cells (ESCs) were first described 1981 (Evans and 
Kaufman, 1981) they have been anticipated to hold great promise for the future of 
regenerative medicine. ESCs have the characteristic hallmarks of unlimited self-
renewal whilst remaining in an undifferentiated state and maintain the pluripotent 
capacity to differentiate to cells of the three germ lineages, endoderm, mesoderm 
and ectoderm (Shufaro and Reubinoff, 2004; Nishikawa et al., 2007). ESCs were first 
derived from in vitro culture of mouse blastocysts and identified as proliferating 
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cells bearing similarities to embryonal carcinoma (EC) cells. These so called EK cells 
were found to be capable of differentiation both in vitro and in vivo as 
teratocarcinomas, and unlike all of the EC cell lines derived by the group they had a 
normal karyotype ruling out contamination of cultures by EC cells (Evans and 
Kaufman, 1981). Importantly, this group discovered that EK cells were found to 
contribute to chimeras capable of germ-line transmission (Bradley et al., 1984). Just a 
few months following the initial report, another group coined the term “embryonic 
stem cell” in a report describing a pluripotent cell line derived from the inner cell 
mass (ICM) of preimplantation mouse embryos (Martin, 1981). Clonal cell lines 
were found to be capable of differentiating in to an array of cell types through 
teratoma formation, supporting the previous report. These ESCs were maintained in 
an undifferentiated state for several passages in a medium condition by EC cells, 
suggesting that the medium contained some factor either promoting self-renewal or 
inhibiting differentiation. Indeed it was subsequently determined that leukemia 
inhibitory factor (LIF) could replicate the effect of “differentiation inhibitory activity 
(DIA)” in conditioned medium used to propagate ESCs (Smith et al., 1988; Williams 
et al., 1988). Addition of LIF to the culture medium prevented spontaneous 
differentiation of ESCs and negated the need for propagation on a fibroblast feeder 
layer. It was later discovered that bone morphogenic protein 4 (BMP4) in 
combination with LIF was sufficient to maintain self-renewal capacity of ESCs in the 
absence of serum in feeder-free conditions (Ying et al., 2003). These early studies 
paved the way for ESCs to be used as an invaluable model system to dissect the 
mechanisms of early development, pluripotency and fate decisions determining 
differentiation of cells. 
 Human embryonic stem cells (hESCs) with the potential to differentiate into 
cells representative of all three germ layers were derived 17 years later (Thomson et 
al., 1998). Despite these cells being established from the ICM of human embryos 
similarly to mouse ESCs (mESCs), however, their potential to self-renew was not 
supported by LIF and BMP (Thomson et al., 1998; Reubinoff et al., 2000). 
Morphologically, hESC colonies appeared flatter than their mouse counterpart and 
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unlike mESCs, hESCs express markers SSEA-4, TRA-1-81 and TRA-1-60 (Reubinoff 
et al., 2000; Ginis et al., 2004) and are capable of trophoblast differentiation 
(Thomson et al., 1998; Odorico et al., 2001; Edwards, 2002). FGF2 (bFGF) and 
activin/Nodal pathways were later found to support pluripotency and self-renewal 
of hESCs (Amit et al., 2000; Vallier et al., 2005; Schnerch et al., 2010) and feeder- and 
serum-free culture conditions were described with transforming growth factor beta 
(TGF-β) as a key requirement (Amit et al., 2004). Despite the differences between 
these two model systems, hESCs have also become a useful tool for stem cell 
research and drug discovery.  
More recently, pluripotent stem cell lines have been established from post-
implantation mouse embryos, termed epiblast stem cells (EpiSCs). Interestingly, 
despite expression of typical mESC markers such as SSEA-1, Oct4 and Nanog, these 
cells are epigenetically distinct and exhibit characteristics similar to hESCs, 
including flattened colony morphology, incompetence for single cell passaging and 
dependence on activin/Nodal signalling (Brons et al., 2007; Tesar et al., 2007). Two 
states of pluripotency have since been designated by Nichols and Smith (2009) to 
describe these distinct cell types with the ESC-like traits of ICM derived cells termed 
the “naïve” state and epiblast derived EpiSC-like cells existing in a “primed” state. 
The naïve state represents cells that possess true pluripotency. That is, they express 
a full panel of pluripotency markers, both X chromosomes remain active and they 
can contribute to all germ lineages in blastocyst chimeras. On the other hand, 
primed cells express core pluripotency factors including Oct4, Sox2 and Nanog but 
lack expression of many other pluripotency markers, may have limited and 
potentially biased capacity for differentiation, contain an inactive X chromosome 
and do not contribute to chimeras in the conventional way without additional 
manipulation (Nichols and Smith, 2009). However, it has been reported that EpiSCs 
can contribute to chimera formation either in a permissive environment, with 
genetic manipulation or by selection of a permissive subpopulation of cells (Huang 
et al., 2012; Han et al., 2010; Ohtsuka et al., 2012).  
 
 5 
1.1.2.1 2i can support pluripotent stem cell derivation and maintenance  
One of the most famous pluripotent culture conditions comes from the lab of 
Austin Smith and is named ‘2i’ after its composition of two inhibitors. Ying et al. 
(2008) coined the term “ground state pluripotency” as the intrinsic ability for ESC to 
self-renew regardless of external influence. This was demonstrated by culturing 
ESCs in a combination of three small molecule inhibitors (3i) CHIR99021 (CHIR), 
SU5402 and PD184352, which blocked glycogen synthase kinase 3 (GSK3), FGF 
receptor and ERK signalling, respectively. This defined culture condition 
maintained ESCs in a self-renewing, pluripotent state in the absence of serum or 
BMP, in a similar fashion to undefined conventional ESC media, and germline-
competent chimeras were obtained even from the non-permissive CBA mouse 
strain, which has been reported to be difficult to isolate ESCs from in conventional 
culture conditions (Buehr and Smith, 2003). A few months later, Smith and 
colleagues reported that manipulation of intracellular signalling by addition of 
PD0325901 (PD03), a potent ERK inhibitor, and CHIR (termed “2i” conditions) in 
addition to LIF could drive both neural stem cell (NSC) and MEF derived pre-iPSCs 
to a fully reprogrammed state as indicated by activation of endogenous Oct4 
expression, conversion of XaXi to XaXa and contribution to chimeras (Silva et al., 
2008a).  
Previously, only a certain number of mouse strains were deemed 
“permissive” for ES cell derivation in conventional mESC culture conditions 
containing LIF and either serum or the growth factor BMP (Buehr et al., 2008), 
including 129, BALB/C and C57BL/6 (Hanna et al., 2010b). Attempts to establish 
ESCs from “non-permissive” species or mouse strains, for example, rats and 
nonobese diabetic (NOD) mice, in mESC conditions has previously been 
unsuccessful and only EpiSCs could be derived from these animals, in the presence 
of activin and FGF (Brons et al., 2007; Buehr et al., 2008). This was resolved by 
Nichols et al. (2009) who derived ESCs from NOD mice using 2i culture conditions 
and more recently a report by Czechanski et al. (2014) outlined a method by which 
ESCs could be derived by any mouse strain, including those from which ESCs failed 
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to be derived. Interestingly, it was subsequently determined that the response to LIF 
signalling underscored the permissibility of a mouse strains to give rise to mESCs 
and in permissible strains the JAK-Stat3 pathway was preferentially activated, 
whereas the MAP kinase pathway was hyperactivated in response to LIF in 
nonpermissive strains (Ohtsuka and Niwa, 2015). 
The increasing availability of pluripotent cell lines, particularly human 
derived lines, presented great promise for gaining mechanistic insight into 
developmental questions as well as advancing medical research and drug 
discovery. However, a major obstacle for both research and clinical use of hESCs is 
their controversial source since hESCs are usually derived from healthy surplus 
embryos resulting from fertility treatments. Consequently there is a distinct lack of 
disease models without the need for further genetic manipulation of the cells. 
However, embryos obtained from preimplantation genetic diagnosis (PGD) 
screening represent an alternative source of hESCs with somewhat fewer ethical 
difficulties that already carry mutations for specific diseases. These hESCs are used 
for modelling human diseases such as Huntington's disease, cystic fibrosis, 
Duchenne and Becker muscular dystrophies and fragile X syndrome, among others 
(Stephenson et al., 2009). In addition to issues surrounding ethics, there is the matter 
of potential recipient rejection of ESC derived tissue. Nonetheless, progress has been 
seen in studies of hESCs to treat animal disease models including Parkinson’s 
disease (Ben-Hur et al., 2004) and retinal disease (Lamba et al., 2006). Some years 
ago the U.S. Food and Drug Administration (FDA) approved the first clinical trial 
using hESCs to treat patients with spinal cord injury (Couzin, 2009). 
 
 
1.1.3 Induced pluripotent stem cells 
 
Researchers have long been interested in developing strategies to generate 
pluripotent cells from differentiated cells which would allow generation of patient 
specific derived stem cells for clinical use or disease modelling. Methods to generate 
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such pluripotent cells have included cell fusion of somatic cells with pluripotent 
cells such as ESCs, SCNT and exposure of somatic cells to ESC extracts (Hakelien et 
al., 2002; Landsverk et al., 2002; Cowan et al., 2005; Do and Schöler, 2004; Rathbone 
et al., 2013). Shinya Yamanaka hypothesized that the factors that play important 
roles in the maintenance of stem cell identity would also play key roles in inducing 
pluripotency in somatic cells. This was the basis on which Yamanaka and colleagues 
performed their pioneering experiments leading to successful reprogramming of 
adult somatic cells to pluripotent cells (Takahashi and Yamanaka, 2006). They used 
retroviral transfection of four reprogramming factors; c-Myc, Klf4, Sox2 and Oct3/4 
(herein Oct4), to reprogram mouse embryonic and adult fibroblasts to a pluripotent 
state. By using the embryonic specific (but dispensable) gene Fbx15 as a marker of 
reprogrammed cells, the first attempt to create pluripotent cells generated cells 
which had ESC-like morphology, Nanog gene expression and were pluripotent by 
teratoma formation but revealed poorly up-regulated pluripotency gene expression, 
incomplete DNA demethylation at the Oct4 and Nanog promoters and failed to 
efficiently silence transgene expression. These cells were termed induced 
pluripotent stem cells, or iPSCs, as they demonstrated pluripotency despite not 
being fully reprogrammed. The following year, the same group reported an 
improvement in the technology, generating germ-line competent iPSCs by selecting 
for Nanog expression, that exhibited ESC-like DNA methylation patterns at 
pluripotency and imprinted loci (Okita et al., 2007).  
iPS cells share hallmark features of mouse ES cells including pluripotency 
gene expression, DNA methylation state, activation of both X chromosomes (XaXa) 
in female lines and contribution to germ-line competent chimeras upon injection 
into blastocysts (Boland et al., 2009; Okita et al., 2007; Wernig et al., 2007). In 
addition, all-iPSC mice have been generated by tetraploid complementation (Zhao 
et al., 2009; Kang et al., 2009), suggesting that iPSCs have the ability to re-capitulate 
normal development compared to ESCs. However, more recently, higher rates of 
tumorigenesis were reported in all-iPSC mice produced using cells generated with 
oncogenes (Tong et al., 2011), highlighting the risks involved with using these cells 
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for clinical medicine. Subsequently, several groups have reported the generation of 
iPSC lines by using various other transcription factors including Nanog, Lin28, 
Esrrb and Nr5a2, in both human and mouse systems (Yu et al., 2007; Feng et al., 
2009; Heng et al., 2010), with other approaches using synthetic modified mRNA 
(Warren et al., 2010) or proteins (Kim et al., 2009; Zhang et al., 2012) to generate 
reprogrammed cells. 
It has been reported that there is a temporal requirement for exogenous 
factor expression during reprogramming. Using a doxycycline (dox)-inducible 
reprogramming system, Stadtfeld et al. (2008b) reported that exogenous factor 
dependency is reduced/abolished around day 8 of the reprogramming process; 
down regulation of transgene expression by removing dox at day 7 or earlier 
prevented the progression of colonies to a fully reprogrammed iPSC-like state. 
However, if dox was removed on day 8 or later, some of the colonies present in the 
culture progressed to fully reprogrammed iPSCs. In addition, it was observed that 
maintaining transgene expression for 10 days increased the number of colonies that 
successfully underwent reprogramming. Consequently, two iPSC populations could 
be identified and defined as ‘stable’ or ‘unstable’, depending on their independence 
or reliance on dox-mediated transgene expression in order to maintain an 
undifferentiated, ES-like phenotype (Hanna et al., 2009a; Hanna et al., 2010a).  
Following the establishment of reprogramming technology by Yamanaka 
and colleagues, Professor Sir Ian Wilmut made the announcement of his decision 
not to pursue his work into nuclear transfer as a method of generating human 
cloned embryos, instead favouring the reprogramming method of generating iPSCs 
as a more efficient and socially acceptable technique to produce human pluripotent 
stem cells. Remarkably, iPSC biology saw rapid translation to the clinic when in 
2013 plans for the first clinical trial using human iPSCs was approved by the 
Japanese government to generate retinal pigmented epithelial (RPE) cells for 
transplantation into patients with macular degeneration. The study, led by Dr. 
Masayo Takahashi from the RIKEN Center for Developmental Biology, carried out 
the first transplantations in September 2014, a mere 7 years after the first report on 
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iPSCs was published. This initial trial is intended to demonstrate safety of iPSC 
transplantation, rather than the expectation that it will improve the condition, but if 
successful subsequent stages of the clinical study will endeavour to restore eyesight 
in patients. Nonetheless this study will pave the way for clinical application of 
































1.2 Methods of iPSC generation 
 
iPSC generation is famously inefficient and somatic cells from different 
tissues and species reprogram differently (Gonzalez et al., 2011). The majority of 
published studies use fibroblasts for reprogramming experiments, however, mouse 
embryonic fibroblasts (MEFs) reprogram significantly faster than human dermal 
fibroblasts (hDFs), taking around 10 or 20 days, respectively. Time is not the only 
variant when it comes to reprogramming capacities but moreover, the requirement 
of factors can vary drastically from one cell type to another. For example, CD133+ 
cells from cord blood and human fibroblasts can be reprogrammed with only Oct4 
and Sox2 (Meng et al., 2012; Huangfu et al., 2008b), and MEFs can be reprogrammed 
with only Oct4 and Klf4 in addition to small molecules, albeit all with lower 
efficiencies than four factor reprogramming. Since reprogramming technology was 
first reported a number of different systems have been described which generate 




1.2.1 Retrovirus and lentivirus 
 
The first reports of iPSC generation from both mouse and human cells used 
retroviruses to deliver the reprogramming factors to (Takahashi and Yamanaka, 
2006; Takahashi et al., 2007; Okita et al., 2007; Wernig et al., 2007; Maherali et al., 
2007; Aoi et al., 2008). It is widely know that retroviruses are silenced in ESCs 
(Macfarlan et al., 2011; Wolf and Goff, 2007; Rival-Gervier et al., 2013; Wolf and 
Goff, 2009; Hotta and Ellis, 2008) and the use of retroviral based vectors to deliver 
the reprogramming factors to cells utilises this distinct feature since successful 
reprogramming relies on cells becoming independent of exogenous factors and 
establishing endogenous gene expression networks in order to become fully mature 
iPSCs. A consideration of retroviral-mediated reprogramming is that it requires 
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dividing cells for transduction of the virus, which was abrogated in later studies 
using lentiviruses to deliver the reprogramming factors. Although lentiviruses are a 
subclass of retrovirus, they can infect both dividing and non-dividing cells 
(Vodicka, 2001) and many groups utilised this virus to successfully reprogram both 
fetal and adult human cells and mouse cells (Yu et al., 2007; Zhao et al., 2008; Mali et 
al., 2008; Stadtfeld et al., 2008b). A further improvement was made with the 
introduction of lentiviral polycistronic vectors capable of expressing the 
reprogramming factors from a single vector, with translation of individual proteins 
facilitated by self-cleaving 2A peptide separation of each gene (Shao et al., 2009; 
Carey et al., 2009; Sommer et al., 2009). This single vector system greatly reduced 
the extent of potential insertional mutagenesis upon viral integration and made 
four-factor expression more homogeneous. 
 
 
1.2.2 Adenovirus reprogramming 
 
  Stadtfeld et al. (2008c) reported successful reprogramming of mouse 
fibroblast and liver cells using adenovirus based vectors to transiently express the 
reprogramming factors. Because the adenovirus does not integrate into the genome, 
the iPSCs generated were exogenous factor free, and proved that reprogramming 
does not require insertional mutagenesis. However, almost a quarter of the iPSC 
lines analysed were tetraploid, suggesting that adenoviral-mediated 
reprogramming may induce a cell fusion event rendering cells karyotypically 
abnormal. Zhou and Freed (2009) later achieved reprogramming of human 
embryonic fibroblasts, with repeated infection of adenoviral reprogramming factors, 
after 25-30 days. However, similarly to the former report, despite a high multiplicity 
of infection (MOI) the efficiency of iPSC generation was extremely low. This was 
likely due to rapid clearance of the virus from cells with each generation, making 
this method technically challenging and unlikely that patient-specific iPSCs will be 
generated in this way for clinical application.  
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1.2.3 Sendai virus reprogramming 
 
Sendai virus (SeV) is a negative-sense single stranded RNA virus, which 
replicates in the cytoplasm with no DNA intermediate.  Consequently there is no 
genome integration. This makes SeV a very attractive alternative to other viruses 
typically used for delivery of reprogramming factors to cells, as reported by Fusaki 
et al. (2009). This group successfully and efficiently generated human iPSCs at rates 
of up to 1%, which faithfully up-regulated pluripotency genes and exhibited DNA 
methylation patterns similar to human embryonal carcinoma cells. Importantly, 
complete depletion of SeV was confirmed with increasing time and passage 
number. This method showed such promise that it is now available as the 
commercially available CytoTune™ reprogramming kit sold by Life Technologies. 
 
 
1.2.4 piggyBac transposon-mediated reprogramming 
 
Several groups reported a virus-free, transgene integration-free method of 
reprogramming using the piggyBac (PB) transposon, a mobile genetic element, to 
deliver the reprogramming factors to cells (Woltjen et al., 2009; Kaji et al., 2009; Yusa 
et al., 2009). This is an attractive system for use in genome engineering since the 
transposon requires only two simple conditions to allow for insertion or excision of 
DNA; transgenes must be flanked by inverted terminal repeats (ITRs) and 
expression of PB transposase is required. PB transposase recognises the ITRs 
catalysing excision of the DNA, which is subsequently inserted into TTAA-specific 
target sites (Fraser et al., 1996). Woltjen et al. (2009) demonstrated that both mouse 
and human embryonic fibroblasts could be reprogrammed using doxycycline (dox)-
inducible PB reprogramming factors and following transposase-mediated excision 
of the transgenes, 90% of clones achieved seamless excision of the factors and were 
restored to wild type. Importantly, endogenous expression of the four factors was 
maintained following transgene removal. Kaji et al. (2009) demonstrated that MEF 
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could be reprogrammed by transfection of a single polycistronic vector encoding the 
four reprogramming factors linked by 2A peptides with an efficiency of 2.5% (based 
on stable transfection efficiency and number of Nanog positive colonies). The 
presence of two flanking loxP sites allowed for transgene removal leaving behind 
only a small vector footprint, providing an improvement on viral integration 
methods of reprogramming. This system was then modified, incorporating the PB 
transposon to reprogram human embryonic fibroblasts, providing further evidence 
that integration-free human iPSCs can be generated. This technology was further 
improved by Yusa et al. (2009) who employed negative selection to identify 
transposon-free iPSC clones generated using a PB polycistronic vector carrying four 
or five factors. 
 
 
1.2.5 Protein-mediated reprogramming 
 
 Zhou et al. (2009) reported generation of iPSCs from MEF by repeated 
transduction of recombinant proteins that contained a fused arginine-tag, allowing 
the proteins to pass across the cell membrane. The efficiency of reprogramming in 
this instance was extremely low, with only a few Oct4-GFP+ colonies being obtained 
per 5x104 cells, and addition of VPA was required for activation of Oct4-GFP, 
however the successful colonies were shown to be truly pluripotent exhibiting DNA 
methylation status similar to ESCs at endogenous Oct4 and Nanog promoters, 
pluripotent gene expression and contribution to tissues of the three germ layers 
both in vitro and in vivo. The laborious requirement for several applications of the 
proteins was negated by Cho et al. (2010) who reprogrammed adult mouse 
fibroblasts with just a single dose of ESC-derived extracted proteins. After 4-7 days 
only a few colonies were observed and upon subsequent passaging onto feeders 
numerous secondary colonies were generated. Subsequently, Kim et al. (2009) used 
direct protein transduction to generate human iPSCs in the absence of small 
molecules but this system was also reported to be less efficient, by 10-fold, and 
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taking twice as long to produce colonies as traditional virus-mediated 
reprogramming. The common denominator of all of these studies is the drastic drop 
in reprogramming efficiency achieved using a protein-mediated method, 
nonetheless, these findings demonstrate that iPSCs can be produced without the 
need for DNA introduction and genomic manipulation of cells, which is attractive 
in the clinical context. 
 
 
1.2.6 mRNA-mediated reprogramming  
 
In 2010, Warren et al. and others reported the use of synthetic mRNA as an 
integration free, efficient method of reprogramming (Warren et al., 2010; Yakubov et 
al., 2010). Introduction of RNA into cells can trigger an immune response mediated 
by single stranded RNA (ssRNA) sensors including RIG-I, and PKR, a repressor of 
protein translation (Pichlmair et al., 2006; Hornung et al., 2006; Nallagatla et al., 
2008). For this reason, Warren et al. (2010) used in vitro transcribed mRNAs 
containing substitutions of cytidine and uridine ribonucleoside bases with naturally 
occurring modified nucleosides 5-methylcytidine (5mC) and pseudouridine (psi), in 
addition to B18R, an interferon inhibitor, to avoid invoking the innate immune 
response in cells, as seen with the use of viral delivery of reprogramming factors. In 
the most optimum conditions, requiring five reprogramming factors and low 
oxygen culture, a reprogramming efficiency of over 4% was observed, compared 
with 0.04% using retrovirus in this study and with the best viral methods reporting 
around 1% efficiency (Fusaki et al., 2009). A range of fetal, neonatal and adult cells 
were reprogrammed demonstrating the wide applicability of this method to 
different tissues, and furthermore, this approach lacks the requirement to screen 
clones for viral clearance or vector integration making this an attractive 
reprogramming system in the context of regenerative medicine. However, it 
involved a labour intensive strategy of daily transfection of mRNA over a course of 
more than two weeks, detracting from the likelihood of practical application in a 
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clinical context. The same group later reported an improved process and were able 
to generate hESC-like colonies with only 6 days of transfections (Warren et al., 
2012), and with further refinement this could be a viable and attractive 
reprogramming strategy with the increasing demand for patient-specific iPSC 
generation in both research and clinical contexts.  
 
 
1.2.7 Episomal-mediated reprogramming  
 
 Yu et al. (2009) demonstrated an alternative method to generate transgene 
free iPSCs, taking advantage of the extrachromosomal replication property of 
Epstein-Barr virus derived oriP/EBNA1 episomal vectors. These vectors are 
reported to replicate only once per cell cycle and remain non-integrating in 99% of 
transfected cells. Importantly, upon removal of drug selection, the vector is cleared 
from cells at a rate of approximately 5% per cell division making this a desirable 
tool for generation of transgene-free iPSCs. In this study human foreskin fibroblasts 
required transfection of three episomal vectors encoding seven genes in total, OCT4, 
SOX2, NANOG, KLF4, SV40 large T (SV40LT) and LIN28, to generate iPSCs at an 
extremely low efficiency of up to 0.0006%. Subsequently, the same group achieved 
episomal reprogramming of bone marrow derived mononuclear cells with a greater 
efficiency 0.035% (Hu et al., 2011). Other modifications to the episomal 
reprogramming method include successful reprogramming of cord blood 
mononuclear cells using only a single polycistronic vector to express five factors 
(Chou et al., 2011) and substitution of C-MYC and NANOG with nontransforming 
L-MYC in addition to an shRNA targeting p53 has enhanced reprogramming 






1.2.8 Other methods of reprogramming 
 
1.2.8.1 microRNA-mediated reprogramming  
Impressively, reprogramming induced by expression of only micro-RNA 
302-367 (miR-302/367) was reported to be more than 100 fold more efficient than 
traditional four factor reprogramming and Oct4-GFP+ colonies were evident as 
early as 6 or 7 days post lentiviral transduction of miR-302/367 (Anokye-Danso et 
al., 2011). This system was reported to be extremely efficient, with almost 80% of 
colonies expressing Oct4-GFP by day 8, however, certain prerequisites were 
necessary including low Hdac2 levels, which could be induced with valproic acid 
(VPA).  
Shortly after this report, another group found that direct transfection of 
mature double stranded miRNAs could reprogram mouse adipose stromal cells 
(mASCs) (Miyoshi et al., 2011). Candidate miRNAs were determined by comparison 
of miRNA expression in mouse ESCs and iPSCs with mASCs. miRNAs that were 
expressed more than 2-fold higher in the ESCs and iPSCs, including members of the 
mir-200c, mir-302s and mir-369s families, were used in reprogramming 
experiments. Nanog-GFP+ colonies were observed 15 days after transfection, 
however the efficiency was extremely low, with only a few colonies generated per 
5x104 transfected cells, at an efficiency similar to the original retrovirus-mediated 
reprogramming report of approximately 0.01% (Takahashi and Yamanaka, 2006). 
Human ASCs and dermal fibroblasts were also successfully reprogrammed using 
this method, albeit at an even lower efficiency than observed in the mouse cells, 
however, the clones generated appeared to be bona fide iPSCs by the standard 
accepted characterisation of ESC-like morphology, pluripotency marker expression, 
and teratoma formation (Miyoshi et al., 2011). 
Interestingly, these studies have been the only reports of such miRNA-only 
reprogramming to the best of my knowledge. Other studies have failed to 
corroborate these findings including a report by Lu et al. (2012) that found the 
introduction of miR-302/367 was insufficient to generate iPSCs from MEFs, although 
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it was found that in addition to the traditional reprogramming factors, this and 
other miRNAs promoted reprogramming. Notably, these studies used two different 
methods of miRNA expression, with lentiviral and PB vectors used, respectively, 
which could explain the differences in reprogramming success. A second study was 
unable to reprogram human ASCs using only miRNA-302, but the authors 
determined that this could be down to the differences in methodology, starting 
somatic cell type or the absence of miRNA-367 (Hu et al., 2013) which was reported 
to be key in activating Oct4 by Anokye-Danso et al. (2011). These inconsistencies 
highlight the need for reproducibility not only due to the extent of variation 
between both reprogramming systems and individual laboratories but to ensure 
that high standards are maintained in the quality of peer-reviewed journal 
publications in order to prevent misleading or false data from being published as far 
as possible. 
Irrespective of the uncorroborated claims reported by Anokye-Danso et al 
(2008), addition of ESC-specific cell cycle-regulating (ESCC) micro RNAs to 
conventional Yamanaka 4 factor mediated reprogramming has been reported as 
having a substantial positive effect on reprogramming efficiency in both mouse and 
human cells. Subramanyam et al (2011) added the human orthologues of ESCCs 
miR-302 (hsa-miR-302b) and miR-291 (hsa-miR-367) to 3- and 4-factor 
reprogramming and observed a 10 to 15-fold increase in colony number. Soon after, 
Liao et al (2011) reported up to 100-fold enhancement of reprogramming efficiency 
with the addition of ESCC miRNA clusters miR-106a-363 and miR302-367 to 3- or 4-
factor mediated reprogramming of MEFs. These authors proposed that the 
mechanism underlying this enhancement was through regulation of cell cycle, 
mesenchymal-to-epithelial transition and epigenetic regulators.  
 
1.2.8.2 Stimulis-triggered factor free reprogramming  
Recently, a remarkable phenomenon was reported by Obokata et al. (2014b), 
who observed that splenic CD45+ cells could revert to a pluripotent state when 
exposed to low-PH treatment in the absence of any exogenous factors. These lineage 
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committed somatic cells reprogrammed to stimulus-triggered acquisition of 
pluripotency (STAP) cells exhibiting hallmarks of pluripotency including 
pluripotency marker expression, ESC-like DNA methylation signatures at Oct4 and 
Nanog loci, and contribution to germ-line competent chimeras. However, STAP 
cells differed from ESCs as they could not self-renew indefinitely in traditional LIF + 
FBS or 2i containing ESC culture conditions, single-cell dissociation did not give rise 
to robust ESC-like colonies, Esrrb expression remained low and H3K27me3 dense 
foci was observed in 40% of female STAP cells indicative of an inactivated X 
chromosome. These data indicated that STAP cells were a different type of 
pluripotent cell to ES or iPS cells (Obokata et al., 2014b). Interestingly, STAP cells 
could be converted to an ESC-like state when cultured with LIF and the peptide 
hormone adrenocorticotropic hormone (ACTH), a known facilitator of ESC clonal 
expansion (Ogawa et al., 2004). Further investigation revealed that Oct4-GFP+ STAP 
cells could be derived from an array of somatic tissue types including brain, lung, 
muscle, liver and fibroblast cells, at varying efficiencies, and even more remarkably 
were found to contribute to both embryonic and placental tissues in vivo when 
treated with Fgf4 (Obokata et al., 2014a). 
The initial excitement of this novel discovery has since been met with a slew 
of controversy and criticism, largely triggered by the lack of reproducibility by a 
number of labs around the world, in addition to some of the published data 
appearing to be fraudulently reported. Although the authors continued to stand by 
their findings for a time, the articles were subsequently retracted by Nature in June 
2014, with even Obokata being unable to reproduce her own experiment. 
Accordingly, this method of reprogramming is not likely to be pursued until the 
method can be independently verified, if indeed the phenomenon of STAP is true. 
 
1.2.8.3 Reprogramming with Mbd3 knock down  
Recently, Rais et al. (2013) reported successful elimination of the stochastic 
heterogeneity of reprogramming by achieving nearly 100% reprogramming 
efficiency obtained through a “deterministic and synchronous” process. Methyl-
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CpG-binding domain protein 3 (Mbd3) is a core member of the nucleosome 
remodelling and deacetylation (NuRD) complex and mediates repression of genes. 
Mbd3 depletion in Mbd3fl/- epiblast stem cells (EpiSCs) resulted in more than 90% 
reversion to ES cells. Astonishingly, the authors went on to describe achievement of 
100% reprogramming efficiency by day 8 of reprogramming, as characterised by 
activation of Oct4-GFP+, when doxycycline inducible four factor, Mbd3fl/- MEFs 
(Mbd3 depleted) were reprogrammed as single-cell cultures in 2i/LIF conditions. 
Furthermore, similarly high efficiencies were achieved for reprogramming of a 
number of other terminally differentiated or progenitor cell types including 
haematopoietic stem cells, pro-B cells, monocytes and neural precursor cells. This is 
somewhat consistent with another report that knock down of Mbd3 enhances 
reprogramming (Luo et al., 2013) (albeit at far lower efficiency than the study by 
Rais et al. (2013)) and that overexpression of Mbd3 inhibits reprogramming by 
repressing ESC-specific genes including Oct4 and Nanog However, conflicting 
results of the Rais et al. (2013) study were later reported by dos Santos et al. (2014) 
who determined that NuRD function was required for EpiSC reprogramming and 
in fact up-regulation of Mbd3 facilitated conversion to iPSCs. Furthermore, Mbd3 
overexpression was found to increase efficiency in certain reprogramming contexts, 
including MEF-derived pre-iPSC, in conjunction with Nanog expression. Of note, 
the Mbd3fl/- cells used in the first study were derived in the lab of Dr. Brian 
Hendrich, one of the authors of the conflicting paper, yet Rais et al. (2013) reports 
that Mbd3 levels in these cells is hypomorphic expressing around 20% of wild type 
levels, whereas dos Santos et al. (2014) find nearly wild type levels expressed. In 
addition, Onder et al. (2012) found no positive effect on reprogramming with 
shMbd3. These groups could not confirm the results published by the Hanna group 






1.2.9 Secondary reprogramming 
 
Tetracycline responsive promoters have been used for years as a tool for 
regulated gene expression in mammalian cells (Gossen and Bujard, 1992; Gossen et 
al., 1995). This system operates through binding of the reverse tetracycline 
transactivator (rtTA) protein to the tetO operator sequence only in the presence of 
tetracycline or one of its derivatives, for example doxycycline (dox), activating 
downstream gene expression. Reprogramming factors whose expression is 
controlled by the tetO promoter provides a tool by which exogenous factor 
expression can be initiated by introduction of dox to the culture medium. So-called 
dox-inducible reprogramming systems have been successfully reported to generate 
iPSCs in virus- and PB-mediated contexts (Brambrink et al., 2008; Stadtfeld et al., 
2008a; Stadtfeld et al., 2008b; Kaji et al., 2009; Woltjen et al., 2009; Hou et al., 2013).  
Utilising this technique Wernig et al. (2008) used rtTA-expressing MEFs to 
generate iPSCs carrying dox-inducible lentiviral reprogramming vectors. These 
primary iPSCs were used to generate chimeric mice whose MEFs were then isolated 
to provide somatic cells carrying identical reprogramming factor transgene 
integrations, controlled by doxycycline inducible promoters. This enabled a 
genetically homogeneous population of cells to be reprogrammed following 
treatment with dox to initiate re-expression of reprogramming factors and was 
termed “secondary reprogramming”. Secondary iPSCs from MEFs were generated 
at a 50-fold increased efficiency of up to 4% using this system, and in addition, 
many other cell types were successfully reprogrammed including keratinocytes, 
muscles, neural progenitors and mesenchymal stem cells. This system was 
subsequently described for human somatic cells, differentiated via teratoma 
formation, with up to 2-3% reprogramming efficiency being achieved. These studies 
also provided support for the earlier report in mouse that there is a temporal 
requirement for transgene expression and variations in transgene re-expression 
levels correlates with reprogramming efficiency (Hockemeyer et al., 2008; Maherali 
et al., 2008). Many groups have since utilised secondary reprogramming systems as 
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a more homogeneous and efficient means to study reprogramming kinetics (Hanna 






























1.3 Culture conditions for reprogramming 
 
1.3.1 The role of small molecules in reprogramming 
 
Reprogramming is renowned for being inefficient with initial estimates of 
reprogramming efficiency being as low as 0.01%. The reason for such low efficiency 
of conversion of somatic cells to iPS cells is unclear, however, regulation of gene 
expression in ES cells is tightly controlled and even modest changes in gene 
expression can result in altered phenotype. For example, in ES cells, Oct4 levels 
should be maintained within a small range of endogenous levels to maintain an 
undifferentiated state (Niwa et al., 2000). Therefore it is plausible that the exact 
levels of each of the four factors required lies within a tight range and that only in a 
small number of cells does the right combination of expression levels occur enabling 
reprogramming of this subset. Consequently a number of small molecules have 
been implicated in supporting the reprogramming process. Many small molecules 
and other factors known to enhance reprogramming are summarized in Table 1.1, 
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Table 1.1. List of small molecules and factors reported to have a positive effect on 
reprogramming.  
 24 
Two of the most commonly reported small molecules used in 
reprogramming are the DNA methyltransferase inhibitor 5’-azacytidine (5’-azaC) 
and the histone deacetylase (HDAC) inhibitor valproic acid (VPA). Huangfu et al. 
(2008a) showed that both of these drugs have been shown to increase 
reprogramming efficiency by tenfold and a hundred fold, respectively, with VPA 
also capable of replacing c-Myc during reprogramming. Some studies focusing on 
unstable or “non-permissive” cell lines have identified other small molecule drugs 
that aid reprogramming or replace expression of some or all of the ectopic 
reprogramming factors, including Wnt3a, CHIR99021 (CH, a GSK3 inhibitor), 
Kenpaullone (KP, a GSK3β and CDK1/cyclin B inhibitor) and 2i (CH and PD184352, 
an inhibitor of the ERK cascade) (Ying et al., 2008; Buecker et al., 2010; Hanna et al., 
2009a; Shi et al., 2008; Hanna et al., 2010a). 
Reports of unstable or so called “metastable” iPSCs have been reported 
recently in both mouse and human systems and these in addition to ‘partially 
reprogrammed’ lines that have been established based on morphology and/or 
reporter expression during intermediate stages of the reprogramming process 
(Sridharan et al., 2009) have been useful for investigating the obstacles blocking 
complete reprogramming. Mikkelsen et al. (2008) previously reported the 
generation of “partially reprogrammed” cell lines which show up-regulation of only 
a limited number of stem cell associated genes but incomplete down-regulation of 
lineage specific factors in addition to DNA hypermethylation at a number of 
pluripotency associated loci including Nanog, Dppa5 and Rex1. Interestingly, the 
addition of the DNA methyltrasferase inhibitor 5’-azaC rapidly drove these cells to 
a stable fully reprogrammed iPS state. In addition, generation of hiPSCs named 
“hLR5” that can be maintained in conventional mES cell media conditions has been 
reported, although continuous expression of five exogenous reprogramming factors 
(Oct4, Sox2, Klf4, c-Myc and Nanog) is required for their maintenance (Buecker et 
al., 2010). However, these cells failed to re-activate expression of the endogenous 
reprogramming factors and interestingly, the cells are intrinsically “metastable” and 
revert to a conventional hiPSC phenotype once ectopic factor expression is 
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removed. Finally, using doxycycline (dox)-inducible lentiviral vectors, Hanna et al. 
(2009a) were able to establish pluripotent cell lines (ESCs and iPSCs) from NOD 
mice (previously considered to be non-permissive for derivation of ESCs) with 
constitutive expression of Klf4 or c-Myc. Small molecule inhibitors could replace the 
requirement for Klf4 or c-Myc, including Wnt3a, CH, KP (which has been reported 
to replace Klf4 during reprogramming) and 2i. The same group later reported the 
stabilization of Dox-dependant “naïve” human ESCs only in the presence of 
PD/CH/LIF and with the constitutive expression of Klf4 and Oct4 or Klf4 and Klf2 
(Hanna et al., 2010a). These reports suggest that there is an intermediate stage 
during reprogramming whereby cells are able to maintain a reprogrammed state 
under certain stabilizing conditions, however, due to incomplete transcriptional 
remodelling during the reprogramming process this state can only be artificially 
maintained by additional factors and collapses upon ectopic factor/drug removal. 
The first reports of iPSC generation cultured reprogramming cells on a layer 
of inactivated feeders in conventional ESC medium containing LIF and serum 
(Takahashi and Yamanaka, 2006; Okita et al., 2007), although now iPSCs are 
typically grown on gelatin-coated vessels. A number of feeder-free and xeno-free 
media are now available for maintenance of iPSCs including Knock-Out DMEM 
with Knock-Out Serum Replacement (KOSR), N2B27, ESF7 and others (Ying et al., 
2003; Cheng et al., 2004; Furue et al., 2005; Yamasaki et al., 2013) and over the years 
a number of small molecules have been reported to enhance reprogramming when 
added to basal culture media. A few of these will be discussed here. 
 
1.3.1.1 iCD1 chemically defined medium promotes iPSC generation 
Chen et al. (2011a) described a chemically defined, serum-free medium 
comprising over 74 components, which was reported to support highly efficient 
three factor (OKS) reprogramming of MEFs at an efficiency of 10% by day 8, with 
few pre-iPSCs generated. Interestingly, c-Myc was found to only increase 
reprogramming efficiency slightly in the iCD1 culture condition, contrary to other 
reports, and in addition the authors were able to reprogram with Oct4 alone, albeit 
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at drastically reduced kinetics and efficiency. Although this medium is defined, it 
comprises too many components to easily determine those that are responsible for 
the enhanced reprogramming kinetics. In addition, the medium comprises small 
molecules known to enhance reprogramming such as vitamin C and CHIR and the 
later report by Bar-Nur et al. (2014) corroborates these findings, with OSKM + AGi 
resulting in approximately 10% efficiency by day 7 (see below). 
 
1.3.1.2 AGi promotes homogeneous iPSC generation 
More recently, CHIR has been implicated as a component of another 
inhibitor cocktail found to promote reprogramming. OKSM expression for as little 
as 48 hours was sufficient to generate iPSCs from granulocyte-macrophage 
progenitors (GMPs) when treated with a duo of small molecules called AGi, 
comprising Ascorbic acid and GSK3-β inhibitor CHIR. These iPSCs expressed an 
Oct4-GFP reporter within 2 days of OKSM expression and Nanog expression was 
observed 7 days after this (Bar-Nur et al., 2014). Single-cell analysis of GMP 
reprogramming with AGi revealed almost 100% of clones activated Oct4-GFP after 
merely 5 days and control conditions (OKSM alone) also reached nearly 100% 
efficiency, but after 30 days – this is consistent with previous reports that 
reprogramming is a stochastic process where almost all cells are reprogrammable if 
given enough time (Hanna et al., 2009b). Interestingly, the authors described that 
genes from all stages of reprogramming – somatic, transient and pluripotency genes 
as well as miRNAs – were regulated in the expected manner but with vastly 
accelerated kinetics through the reprogramming process, providing a possible 
functional mechanism underlying AGi enhancement and a more synchronous 
reprogramming culture. Both ascorbic acid (vitamin C) and GSK3-β inhibition have 
separately been reported to promote generation of iPSCs so it is somewhat 
unsurprising that treatment of both small molecules exerts an enhancing effect (Li 




1.3.1.3 Tgf-β signaling inhibition and reprogramming 
In an attempt to uncover small molecules that could replace Sox2 in the 
reprogramming factor cocktail, an inhibitor of Tgf-β signalling, E-616452, was 
identified. This chemical, aptly named RepSox, was shown to eliminate the 
requirement for Sox2 by facilitating Nanog induction in incompletely 
reprogrammed cells, termed “RepSox responsive” intermediates (Ichida et al., 2009). 
Microarray data generated by the authors showed a strong up-regulation of Nanog 
in these cell lines upon treatment with RepSox and in addition, the ability of RepSox 
to replace Sox2 was abolished with administration of a Nanog shRNA to the cells. 
Interestingly, RepSox was also shown to replace c-Myc and in fact, inhibition of Tgf-
β signalling by alternative chemical or neutralizing antibody measures replicated 
this result with similar or greater efficiencies of reprogramming than four factors 
together. Another small molecule screening identified nonsteroidal anti-
inflammatory drugs (NSAIDs) and anticancer drugs that can replace c-Myc and/or 
Sox2 during reprogramming, at least in part by inhibition of MEF-associated gene 
COX2 (Yang et al., 2011). 
Around the same time, Maherali and Hochedlinger (2009) reported similar 
results using Alk5 inhibitor (Alk5i) treatment in conjunction with a dox-inducible 
reprogramming system. Here the authors abolished the need for either Sox2 or c-
Myc in the presence of Alk5i, and the strongest effect was observed when Alk5i was 
administered from the earliest stages of reprogramming, suggesting there may be a 
temporal requirement for suppression of Tgf-β signalling to be effective. In both 
studies, the effect of Tgf-β signalling inhibition was found to be stronger than that of 
c-Myc expression on reprogramming efficiency and together these studies highlight 
the role of the Tgf-β signalling as a barrier to reprogramming.  
Taken together, these studies provide evidence that an apparent block to 
pluripotency resulting from exogenous stimuli can be overcome with simple small 
molecule inhibition in a defined manner, allowing cells to reach their complete 
pluripotential, and providing a more defined platform for which to dissect the 
mechanisms of reprogramming. 
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1.4 Key events during reprogramming 
 
1.4.1. Early, intermediate and late stages occur during reprogramming 
 
The first obvious signs of reprogramming occur almost immediately with 
changing somatic cell morphology being the first indicator, concurrent with an 
increase in cell proliferation (Smith et al., 2010). Down-regulation of somatic cell 
markers such as Thy1 follows, with subsequent up-regulation of pluripotency 
related genes such as SSEA-1 (Stadtfeld et al., 2008b). SSEA-1 is a commonly used 
marker of pluripotent cells in studies of reprogramming, however, incompletely 
reprogrammed pre-iPSCs express SSEA-1. Moreover pre-iPSCs sorted for SSEA-1 
revealed inhibitory DNA methylation at pluripotency loci including Oct4, Nanog, 
Stella, Dppa5, Utf1 and Rex1 indicating that this marker is merely descriptive rather 
than indicative of iPSCs (Sridharan et al., 2009; Mikkelsen et al., 2008). Of the four 
reprogramming factors, c-Myc was found to predominantly function in the early 
transition of reprogramming to modulate gene expression and in particular has 
been shown to strongly repress somatic-associated genes such as Thy1. The role for 
c-Myc as an early effector was supported by observations that expression of c-Myc 
for only 5 days, with constitutive expression of OSK, gave rise to alkaline 
phosphatase (AP) positive colonies which only marginally increased with continued 
expression of c-Myc (Sridharan et al., 2009).  
Throughout normal development, cells undergoing differentiation to 
various cell fates transition from an epithelial cell type to a mesenchymal identity. 
On the contrary, during the early to intermediate stages of reprogramming of 
terminally differentiated cells such as fibroblasts, a reversal of this transition is 
required; a so called mesenchymal to epithelial transition (MET) (Li et al., 2010). 
This process is indispensible and marks an early transition stage towards 
pluripotency during reprogramming, marked by distinct morphological changes 
concurrent with down-regulation of epithelial repressors such as Snail and up-
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regulation of epithelial markers such as E-cadherin by Oct4 and Sox2 or Klf4, 
respectively (Batlle et al., 2000; Cano et al., 2000; Li et al., 2010).  
At the cusp of the intermediate to late stages of reprogramming, a subset of 
progressing cells have been reported as being “partially reprogrammed” (Meissner 
et al., 2007; Mikkelsen et al., 2008) and these so-called pre-iPSCs are a unique system 
in which to investigate the transition to the late stage of reprogramming. They are 
cells which have undergone reprogramming but failed to fully transition to iPSCs 
and are characterised by ESC-like morphology, often expressing high levels of 
exogenous factors and somatic genes are usually down-regulated but not all 
pluripotency genes are up-regulated, particularly those usually expressed at the 
latter phase of reprogramming (Plath and Lowry, 2011; Mikkelsen et al., 2008; 
Sridharan et al., 2009). Most commonly Oct4 and Nanog expression is lacking, 
explained by incomplete resetting of the epigenetic landscape resulting in 
hypermethylated DNA, particularly within these gene promoters as well as other 
pluripotency loci including Utf1, Dppa5, Rex1, Gdf3 and Stella (Mikkelsen et al., 
2008). This pre-iPSC state can be converted to one of full pluripotency by a number 
of treatments including administration of vitamin C, overexpression of Nanog, or 
inhibition of certain pathways with small molecules including 5-aza-cytidine (AZA, 
inhibiting DNA methyltransferases), E-616452 (RepSox, inhibiting TGF-β 
signalling), or 2i (inhibiting MAPK and GSK3 signalling) (Mikkelsen et al., 2008; 
Silva et al., 2008a; Ichida et al., 2009; Esteban et al., 2010; Silva et al., 2009).  
Towards the end of reprogramming, ESC-like colonies are clear and the 
pluripotency gene network is laid down including endogenous expression of 
reprogramming factors, rendering the iPSCs transgene independent (Plath and 
Lowry, 2011). During stabilization of the pluripotency transcriptional network, it 
has been identified that Oct4, Sox2 and Klf4 predominantly target regulators of 
pluripotency at the later stages of reprogramming, with Oct4 and Sox2 co-targeting 
genes strongly expressed in ESCs/iPSCs with around half of these targets also 
occupied by Klf4 (Sridharan et al., 2009). Key regulators of pluripotency, including 
Nanog and Oct4 have been shown to be ubiquitinated in pluripotent ES cells but not 
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differentiating ES cells suggesting that protein abundance is tightly and actively 
regulated in these conditions (Buckley et al., 2012). Endogenous Sox2 activation is a 
key late event and up-regulation of telomerase and re-activation of the silent X 
chromosome are characteristic of stable, fully reprogrammed iPSCs (Stadtfeld et al., 
2008b; Maherali et al., 2007; Plath and Lowry, 2011; Takahashi and Yamanaka, 2006). 
Brambrink et al. (2008) described sequential activation of pluripotency markers as 
identifiers of reprogramming progression with AP expression evident early in 
reprogramming followed by SSEA-1 up-regulation during the intermediate phase 
and finally Oct4 and Nanog activation at the late stage. Using a fluorescence 
activated cell sorting (FACS) approach, O'Malley et al. (2013) used two novel cell 
surface markers, ICAM-1 and CD44, in combination with a Nanog-GFP reporter, to 
follow the progression of cells undergoing reprogramming and identified that 
reprogramming cells followed a systematic route from MEFs to iPSCs. A high-
resolution “route map” was established and subpopulation analyses revealed 
subsets of genes with distinct expression patterns, including transient up-regulation 
of several genes involved in epidermis/keratinocyte development. This data was 
supported by several other published data sets, which together provide some 
evidence that the reprogramming process is more complex than simply a reversion 
of normal cell development/differentiation. 
 
 
1.4.2 Exogenous factor expression during reprogramming 
 
Reprogramming is most commonly induced by simultaneous introduction of 
Oct4, Sox2, Klf4 and c-Myc to somatic cells of interest. However, the timing of 
addition of reprogramming factors has been reported to influence the progression of 
the cells towards a pluripotent state. Liu et al. (2013) reported that the number of 
Oct4-GFP+ colonies observed upon sequential addition of the four factors (OK-M-S) 
exceeded those resulting from the more traditional practice of simultaneous 
introduction of factors. Subsequently, the group identified an early epithelial-to-
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mesenchymal transition (EMT) indicated by up-regulation of Slug; an event that 
they suggest boosts reprogramming by giving rise to a more homogeneously 
mesenchymal, and therefore optimal, fibroblast population capable of efficient 
mesenchymal-to-epithelial transition (MET). MET analysis revealed that Snail, a 
core mesenchymal gene, is repressed by Sox2, aiding in the collapse of the 
mesenchymal identity of fibroblasts. Concurrently, the four reprogramming factors 
work in concert to quell the process of EMT by interfering with TGF-β signalling 
pathways. Once these initial barriers to reprogramming have been interrupted, 
expression of E-Cadherin through the action of Klf4 allows cells to gain an epithelial 
identity before acquiring pluripotency. 
Soufi et al. (2012) investigated the initial reprogramming factor binding 
events that take place in the first 48 hours of reprogramming in human fibroblasts 
and made several key conclusions. All four factors were found to co-bind to 
chromatin extensively, across 35% of the genome, upon initial induction of 
reprogramming compared with only 3% in ES cells. Interestingly, even within this 
narrow early window, genes associated with progression of reprogramming 
including GLIS1 and the miR-302/367 were co-targeted by OSKM, in addition to 
pro-apoptosis genes TP53 and p19 being bound by all four factors or c-Myc alone, 
respectively, consistent with previous reports in the mouse (Kawamura et al., 2009). 
A notable finding of this study is that Oct4, Sox2 and Klf4 extensively bind DNaseI 
resistant domains representing closed chromatin and to a much lesser extent c-Myc. 
This is indicative of Oct4, Sox2 and Klf4 acting as pioneer factors during 
reprogramming, allowing subsequent recruitment of other factors to otherwise 
inaccessible chromatin regions and given that most reprogramming promoting 
genes lie within closed chromatin this initial pioneer factor activity is essential for 
progression of cells towards iPSCs. Finally, despite the dynamic activity of pioneer 
factors, many large genomic regions containing late pluripotency genes were found 
to remain unbound by OSKM during the initial stage of reprogramming. The 
authors proposed that this was due to elevated levels of repressive histone mark 
H3K9me3 in these differentially bound regions (DBRs), and this was supported by 
 32 
evidence that siRNA-mediated knock down of histone methyltransferases SUV39H1 
and SUV39H2 increased Oct4 and Sox2 binding within DBRs and enhanced 
reprogramming speed and efficiency. The enhancing effect of SUV39H1 inhibition 
was also reported elsewhere (Onder et al., 2012). 
A temporal requirement for reprogramming factor expression was described 
by Stadtfeld et al. (2008b), using a doxycycline inducible primary reprogramming 
system to reprogram MEFs carrying an Oct4-GFP reporter. Expression of the four 
factors was required for at least 7 days before Oct4-GFP+ colonies could be 
maintained in the absence of doxycycline, with the number of colonies increasing 
with longer doxycycline treatment. Using a secondary reprogramming system, 
Hanna et al. (2009b) used pre-B cells carrying a Nanog-GFP reporter and 
doxycycline inducible reprogramming factors to demonstrate that over time almost 
all (93%) cells underwent reprogramming to activate expression of Nanog-GFP. 
Thus the authors contended that reprogramming is a stochastic process and there is 
merely a temporal requirement for cells to realise their reprogramming potential 
with enough cell divisions. Furthermore, manipulation of pathways that increased 
the rate of cell division/proliferation, for example, knock down of the p53 pathway 
or overexpression of Lin28, resulted in accelerated activation of Nanog-GFP, 
suggesting that the stochastic nature of reprogramming was proliferation 
dependant and susceptible to refinement.  
 
 
1.4.3 Epigenetics of reprogramming 
 
1.4.3.1 Chromatin remodeling and the role of vitamin C during reprogramming 
Chromatin and DNA modifications have been purported to play an 
important role during the reprogramming process. The extent to which epigenetic 
remodelling plays a role during reprogramming is not yet fully determined, 
however, even as early as the pioneering studies it was clear that epigenetic 
reactivation of key pluripotency genes such as Nanog and Oct3/4 was important for 
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generation of fully reprogrammed, high quality germ-line competent iPS cells 
(Takahashi and Yamanaka, 2006; Okita et al., 2007). Whilst the first four factor 
derived iPSCs (iPS-MEF4), using Fbx15 as a reporter, produced cells which were 
morphologically similar to ESCs and contributed to teratomas and mouse 
embryonic development, they did not successfully silence the transgenes or re-
establish the correct DNA methylation marks at the Oct4 and Nanog promoters and 
live chimeric mice could not be generated (Takahashi and Yamanaka, 2006). On the 
other hand, using Nanog as a reporter of reprogramming resulted in iPS cells 
(Nanog iPS 20D17 and 20D18) showing up-regulation of an extensive set of 
pluripotency genes, de-methylation of Oct4 and Nanog promoters (similar to that of 
ESCs) and generation of germ-line competent live chimeras (Okita et al., 2007). In 
addition to DNA modification, chromatin modification has also been perceived to 
play an important role during reprogramming. Chromatin of ESCs is widely 
thought of as being “open” (Orkin and Hochedlinger, 2011); histone acetylation and 
H3K4 trimethylation (H3K4me3) is associated with “open” euchromatin and active 
transcription whereas histone deacetylation and H3K27 trimethylation (H3K27me3) 
is linked to the silent heterochromatin state (Hotta and Ellis, 2008; Maherali et al., 
2007). A significant example of chromatin remodelling during reprogramming is 
reactivation of the inactive X chromosome in female lines, which is thought to 
provide evidence towards a more reprogrammed state.  During iPSC derivation, 
extensive chromatin reformation must be carried out to remove the distinctive 
chromatin modifications that are established on the future inactive X for stable 
silencing (Maherali et al., 2007). The same study carried out genome-wide analysis 
of K4 and K27 trimethylation using chromatin immunoprecipitation (ChIP) 
followed by promoter array analysis and revealed that almost 95% of “signature 
genes” (with differential histone methylation patterns between mouse embryonic 
fibroblasts (MEFs) and ES cells) in iPS cells exhibited nearly identical methylation 
patterns to ES cells (Maherali et al., 2007). This indicates that in vitro reprogramming 
can re-establish the epigenome of a differentiated cell to that of an ES cell. 
Furthermore, microarray gene expression analysis confirmed that iPS cells are 
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transcriptionally highly similar to ES cells. These data highlight the importance of 
epigenetic remodelling for complete reprogramming. 
Small molecules targeting chromatin-modifying enzymes have long been 
known to promote reprogramming (Huangfu et al., 2008a; Mali et al., 2010; Liang et 
al., 2010; Zhang and Wu, 2013). Sodium butyrate, a fatty acid and histone 
deacetylase (HDAC) inhibitor, has been found to be supportive of ESCs from both 
mouse and human cells with butyrate treatment being implicated in down-
regulation of Tcf3, a suppressor of Nanog in mouse ESCs. In addition, butyrate was 
found to directly act on epigenetic modifiers with evidence of induction of H3K9 
acetylation and DNA demethylation of the Dppa5 promoter being reported (Ware 
et al., 2009). Several reports have implicated butyrate as a potent enhancer of 
reprogramming when applied either transiently or at low concentrations with 
observations of histone H3 acetylation, DNA demethylation at gene promoters and 
enhancement of pluripotency gene expression all contributing to improved 
reprogramming (Liang et al., 2010; Mali et al., 2010; Zhang and Wu, 2013). 
Treatment of reprogramming cultures with valproic acid (VPA), another HDAC 
inhibitor, reportedly results in reprogramming efficiencies of almost 2.5% (more 
than 100-fold increase compared with control), and in addition allows for the 
omission of c-Myc in the reprogramming factor cocktail (Huangfu et al., 2008a). 
In human reprogramming, shRNA-mediated knock down of DOT1L, an 
H3K79 histone methyltransferase was found to increase reprogramming, and 
replace KLF4 and MYC. Notably, this resulted in an increase in NANOG and LIN28, 
both of which are known to enhance reprogramming (Onder et al., 2012). The 
authors found that loss of H3K79me2 in somatic cell specific genes occurs early 
during reprogramming and suggested that DOT1L functions to facilitate down-
regulation of this histone mark usually associated with transcriptionally active 
genes.  
Resetting of the epigenetic landscape within reprogramming cells is a crucial 
series of events required for robust and complete acquisition of pluripotency. ES 
cells, which largely contain open, active chromatin, contain bivalent domains that 
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consist of chromatin decorated with both repressive histone3-lysine27 
trimethylation (H3K27me3) and activating histone4-lysine4 trimethylation 
(H3K4me3) marks. Two key protein complexes, Polycomb group (PcG) and 
Trithorax group (trxG) complexes underlie these repressive and activating marks, 
respectively. Early transcriptional events, such as down-regulation of somatic cell 
specific markers and up-regulation of pluripotency genes, are driven by changes in 
the chromatin state at these genes, facilitated by the PcG and trxG complexes. 
Expression of Wdr5, a member of the trxG complex, increases during 
reprogramming and is required during the early stages to initiate changes to the 
epigenetic landscape through interaction with Oct4 (Ang et al., 2011). Utx, an 
H3K27 demethylase also known as Kdm6a, plays a role in regulation of 
pluripotency induction during reprogramming and absence of Utx in somatic cells 
causes failure to reprogram by causing deviant regulation of H3K27me3 
demethylation directly interfering with activation of pluripotency associated genes 
including Sall1, Sall4 and Utf1 (Mansour et al., 2012). 
Histone3-lysine9 methylation (H3K9me) has been implicated as the key 
epigenetic block in pre-iPSCs in culture conditions containing serum. Downstream 
targets of bone morphogenic proteins (BMPs), the H3K9 methyltransferases 
Suv39h1, Suv39h2 and Setdb1 were shown to play a role in maintaining H3K9 
methylation in pre-iPSCs. Induction of H3K9 demethylases belonging to the Kdm 
family, particularly Kdm4b (also known as Jmjd2b), in pre-iPSCs reduced H3K9 
methylation releasing the barrier to reprogramming which was shown to be 
enhanced by vitamin C (Chen et al., 2013). Vitamin C was found to facilitate 
removal of the H3K9me3 mark releasing cells from this intermediate state and 
allowing progression to iPSCs with high levels maintained at key pluripotency 
genes Dppa3, Nanog and Sox2 sustaining a closed chromatin state and preventing 
binding of Oct4 (Chen et al., 2013). BMP driven activation of H3K9 
methytransferases, Suv39h1 and Suv39h2, was found to support this 
heterochromatic state in pre-iPSCs but treatment with vitamin C reduced H3K9me 
through the action of demethylases allowing reprogramming of pre-iPSCs to iPSCs. 
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Setdb1 knock down alleviated the need for vitamin C treatment supporting a role 
for Setdb1 as an inhibitor of reprogramming. Strikingly, the authors also showed 
that knock down of Setdb1 resulted in conversion of almost 100% of pre-iPSCs to 
Oct-GFP+ iPSCs further emphasising the role of epigenetic regulators in 
reprogramming. An earlier report by Esteban et al. (2010) corroborated this showing 
the release of pre-iPSCs to a fully reprogrammed state by addition of vitamin C. 
Vitamin C was first implicated as an enhancer of reprogramming by Esteban 
et al. (2010) where it was identified during investigation of compounds to reduce 
generation of reactive oxygen species (ROS) during reprogramming. Vitamin C was 
found to increase reprogramming efficiency partly through modulation of cell 
proliferation by inhibition of p53 and the downstream target p21. This was thought 
to be a different mechanism by which Silva et al. (2008a) reported conversion of pre-
iPSCs to a fully reprogrammed state by inhibition of Erk signalling in 2i conditions, 
since total and active Erk levels remained unchanged. 
The Jumonji C (JmjC) family of histone demethylases functions in histone 
demethylation at lysine resides in an iron Fe(II) and 2-oxoglutarate (2OG) 
dependent manner and vitamin C functions as an electron donor to reduce iron in 
the absence of substrate, thereby maintaining its catalytic activity (Monfort and 
Wutz, 2013). Vitamin C has also been reported to facilitate reprogramming by 
reducing H3K36me3 and when an siRNA targeting the demethylase Kdm3b was 
used, a reduction was observed in vitamin C–mediated progression of pre-iPSCs to 
a fully reprogrammed state (Chen et al., 2013; Li et al., 2011; Zhu et al., 2010).  
Induction of the H3K36 histone demethylases Jhdm1a and Jhdm1b (also 
known as which Kdm2a and Kdm2b), which are downstream targets of vitamin C, 
have been shown to regulate reprogramming in synergy with Oct4 (Wang et al., 
2011). Overexpression of these histone demethylases during three-factor 
reprogramming with Sox2, Klf4 and Oct4 was shown to enhance reprogramming 
both in the presence and absence of vitamin C in addition to improving 
reprogramming kinetics as characterised by the earlier appearance of Oct-GFP 
colonies (Chen et al., 2013). Strikingly, overexpression of Jhdm1b enabled efficient 
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reprogramming using only Oct4 at rates higher than those previously reported 
(Chen et al., 2011b; Zhu et al., 2010; Li et al., 2011) but Jhdm1b mutants lacking DNA 
binding or histone demethylase function were found to diminish Oct4 
reprogramming, suggesting that the enhancing effect was owing to demethylation 
activity and/or binding to Oct4.  
MEFs stably expressing the H3K36 histone demethylase Jhdm1b restored 
three factor (SKO) reprogramming ability in late passage (P6) fibroblasts, which was 
observed to be completely abolished in control cells due to Ink/Arf induced cellular 
senescence and addition of vitamin C further increased reprogramming efficiency 
(Wang et al., 2011). Ink/Arf silencing in MEFs was previously reported by Tzatsos et 
al. (2009) where Jhdm1b was found to suppress the Ink/Arf locus in MEFs by 
offsetting the senescence-induced down-regulation of polycomb-repressive complex 
(PRC) protein Ezh2, through H3K36 demethylation. This resulted in an increase in 
H3K27me3 at the Ink/Arf locus further driving binding of another PRC component, 
Bmi1, facilitating silencing of p16Arf. Kdm2b promotion of reprogramming was 
similarly reported by Liang et al. (2012) in a proliferation and Ink4a/Arf 
independent manner. Instead it was purported to play a role in activation of early 
genes such as Cdh1, Epcam and Crb3 in collaboration with the reprogramming 
factors, by maintaining low levels of H3K36me2 at the promoters of these genes. 
Strong induction of the ESC specific micro-RNA cluster 302/367 was 
promoted by a combination of Oct4, Jhdm1b and vitamin C. (Wang et al., 2011). The 
authors cloned the miRNA 302/367 promoter to a firefly luciferase reporter and 
found evidence for physical interaction of Oct and Jhdm1b to cooperatively bind the 
miRNA 302/367 promoter leading to activation. Further ChIP-qPCR and co-
immunoprecipitation experiments subsequently verified this interaction, suggesting 
that histone modifications triggered by Jhdm1b are essential to allow Oct4 binding 





1.4.3.2 Resetting of DNA methylation and reprogramming 
Resetting of methylation status occurs late in reprogramming whereas 
bivalent domains are laid down steadily following the first wave of transcriptional 
activity in response to the reprogramming factors (Polo et al., 2012). The 
implications of imprinting status of iPSCs have been widely discussed. Stadtfeld et 
al. (2010) reported that a vast majority of iPSCs derived from varying tissues 
exhibited abnormally low expression of Gtl2 and Rian; maternally expressed 
imprinted genes located in the Dlk1-Dio3 cluster. This silencing in iPSCs was found 
to be the result of hypermethylation in an intergenic differentially methylated 
regions (IG-DMR) located within the Dlk1-Dio3 locus, in which almost all CpGs 
were found to be methylated in “Gtl2off” iPSCs compared with  “Gtl2on” iPSCs or 
ESCs. Furthermore, these Gtl2off iPSCs did not contribute highly to chimeras and 
persistently failed to generate “all-iPSC” mice using the tetraploid complementation 
assay, widely regarded as a gold standard of pluripotency. Administration of 
valproic acid (VPA) was determined to “rescue” Gtl expression in two Gtl2off clones, 
one of which subsequently enabled generation of “all-iPSC” mice, however, the 
pups were deemed non-viable. Another group also reported difficulty in generating 
all-iPSC mice from some iPSC lines as a result of decreased expression of genes in 
the Dlk1-Dio3 region (Liu et al., 2010), lending support that proper epigenetic 
resetting is important during reprogramming to produce high quality iPSCs. Carey 
et al. (2011) later reported contrasting results claiming that regardless of the 
imprinting state at this locus, they found no difference in the potential of “Gtl2-ON” 
or “Gtl2-LOW” iPSCs to contribute to chimeras and so claimed that silencing at this 
imprinted locus was not strictly definitive of reduced pluripotency. Further to this, 
these authors determined reprogramming factor stoichiometry to play a critical role 
in reprogramming, and differences in the expression levels of factors lead to 
significant differences in the quality of iPSCs derived. A comparison was made 
between two highly similar reprogramming systems using doxycycline-inducible 
polycistronic vectors to express the four reprogramming factors, differing only in 
the sequence in which the factors were expressed (OSKM versus OKSM) and the 
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linkers used in the vectors. This resulted in OSKM cells with higher levels of Oct4 
and Klf4 and OKSM cells with higher levels of Sox2 and c-Myc upon administration 
of doxycycline to induce reprogramming. Whilst both cell lines were capable of 
generating iPSCs, the resulting OKSM iPSCs were of poorer quality than those 
generated with OSKM, as determined by aberrant expression of the imprinted gene 
Gtl2. However, this could be rectified by overexpression of additional Oct4 and 
Klf4, and subsequently “all-iPSC” mice could be generated from one of these clones 
In a later report, Stadtfeld et al. (2012) determined that addition of vitamin C 
during reprogramming diminishes aberrant hypermethylation at the IG-DMR of 
Dlk1-Dio3 locus, and subsequently, all-iPSC mice were generated from iPSCs 
derived from B cells for the first time. It was determined that vitamin C functions by 
maintaining histone acetylation and activating histone marks, H3K4me2 and 
H3K4me3, which is lost in the absence of vitamin C during reprogramming. This 




1.4.4 Models of reprogramming 
 
Several reports have identified distinct stages of reprogramming with 
stochastic and deterministic models both being put forward (Yamanaka, 2009; 
Hanna et al., 2009b; Smith et al., 2010; Samavarchi-Tehrani et al., 2010; Buganim et 
al., 2012; Golipour et al., 2012). Early on two models were proposed; the elite, or 
predetermined model, and the stochastic model. The former put forward that only a 
limited number of predetermined cells were capable of becoming iPSCs, and tissue 
stem cells, or undifferentiated precursors, were a good candidate. However, 
evidence that initial reported reprogramming efficiencies could be drastically 
increased (Nakagawa et al., 2008; Huangfu et al., 2008a; Huangfu et al., 2008b) and 
reports of iPSCs derived from tissues such as liver, stomach and pancreas (Aoi et al., 
2008; Stadtfeld et al., 2008a) challenged the idea that only a few ‘elite’ cells were 
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susceptible to reprogramming. The contrasting stochastic model proposes that upon 
reprogramming factor introduction, most or all cells have the potential to become 
iPSCs. The initiation stage of reprogramming is driven by BMP signalling in 
cooperation with reprogramming factor expression, activating the miR-205 and 
miR-200 families of microRNAs which regulate an immediate MET event 
(Samavarchi-Tehrani et al., 2010). Polo et al. (2012) observed that successful 
reprogramming consisted of two “waves” of transcriptional activity with the first 
wave being driven by c-Myc and Klf4 expression followed by the second wave 
driven by Oct4, Sox2 and Klf4 expression. Some cells which only initiated succeeded 
in initiation of the first wave but not the second failed to progress in 
reprogramming. During the later stages of reprogramming, cells are required to 
mature and stabilize in order to become transgene independent and maintain their 
acquired pluripotent state. Golipour et al. (2012) reported that persistent transgene 
expression hindered the later stabilization of cells and that silencing of exogenous 
factor expression was required for complete reprogramming, a feature earlier 
reported by Okita et al. (2007). The maturation and stabilization stages require 
expression of distinct sets of pluripotency genes including Nanog, Sall4, 
endogenous Oct4, Rex1 and Esrrb followed by transgene removal and expression of 
endogenous Sox2, Dppa2 and Pecam1 (Samavarchi-Tehrani et al., 2010; Buganim et 
al., 2012; Golipour et al., 2012). Interestingly, activation of endogenous Sox2 has 
been reported to mark a late phase in reprogramming comprising a predictable, 
step-wise series of gene expression signatures where Sox2 activates successive 
expression of Sall4, Lin28, Fgf4, Fbxo15 and Dnmt3b, representing a hierarchical 
model (Buganim et al., 2012).  
More recently, a review by Buganim et al. (2013) pulled together these 
models, discussing the evidence for a two phase model incorporating an early, long 
lasting, stochastic phase and a later, shorter, hierarchical phase following Sox2 
expression. The stochastic phase is initiated by four factor (OSKM) induction and 
the ensuing dynamics of genome-wide transcriptional regulation, where cells 
expressing OSKM will immediately undergo cellular fate changes either conducive 
 41 
to reprogramming or alternatively down refractory pathways such as apoptosis or 
senescence. The ‘stochastic’ nature of this phase lies in the unpredictable way in 
which OSKM expression induces genome wide transcriptional activation and the 
random probability in which any given cell will experience just the precise genome-
wide changes to impart ‘reprogrammability’. Indeed, the long latency of this initial 
phase supports the notion that there is a stochastic element in play and so it follows 
that time is a key requirement for some cells to lay down the correct gene expression 
networks to become amenable to reprogramming. Reprogrammable cells will then 
undergo several defined changes including morphological changes, increased rates 
of proliferation coupled with transcriptional and metabolic stimulation, 
mesenchymal to epithelial transition (MET), reorganization of histone modifications 
and activation of DNA repair pathways. Progression through reprogramming is 
met by an intermediate stage, which sees activation of early pluripotency markers, 
laying down the foundations of the pluripotency transcriptional network (Buganim 
et al., 2012), temporary expression of developmental regulators (Polo et al., 2012) 
and gradual activation of glycolysis (Hansson et al., 2012). In addition, an unknown 
bottleneck occurs, contributing to the long delay of cells to progress. Perhaps this is 
again due to the requirement for certain early predictive genes of reprogramming 
such as Utf1 and Esrrb to be expressed (Buganim et al., 2012) triggering initiation of 
the final ‘hierarchical’ phase in some cells. This ‘deterministic’ phase progresses in a 
more predictable manner, marked by the activation of endogenous Sox2 (Buganim 
et al., 2012). Finally, stabilization of the core pluripotency network via action of 
Oct4, Sox2 and Nanog allows exogenous factor independence and emergence of 
bona fide iPSCs (Boyer et al., 2005).  
The precise role of each of the reprogramming factors has been widely 
studied, and yet a precise step-wise sequence of events has not been identified that 
fully elucidates the transition from a somatic to a pluripotent cell type. This begs the 
question of whether there is in fact one route to iPS cells, or if the acquisition of 
pluripotency is a result of the events initiated by the introduction of transcription 
factors in concert with some perfectly timed yet stochastic events. The answer is 
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likely to lie somewhere in the middle. It is clear that some very distinct events occur 
during the course of reprogramming; early on down-regulation of genes associated 
with the somatic starting cells occurs, followed by mesenchymal-to-epithelial 
transition (MET) and up-regulation of pluripotency genes, in addition to a whole 
host of well characterized epigenetic changes which ‘reset the genome’. A vast 
amount of knowledge has been generated about the reprogramming process but the 
fact of the matter is that efficiencies of reprogramming are still by and large low. 
Only a few reports of dramatic increases in efficiency have been published, and 
even so many of these claims remain uncorroborated or controversial, highlighting 
the importance of independent reproducibility in published works to eliminate 
potential artefacts of laboratory-to-laboratory variability. 
 
 
1.4.5 Identifying and overcoming barriers to reprogramming 
 
Senescence has been identified as a major barrier to iPSC generation and 
2009 saw a number of reports on the role of p53 and related cell cycle regulating 
tumour suppressor genes during reprogramming. Up-regulation of p53, p16Ink4a and 
p21 is triggered upon exogenous reprogramming factor expression (Banito et al., 
2009; Kawamura et al., 2009). Knock down of these genes during reprogramming 
using shRNAs was shown to significantly increase efficiency of pluripotent colony 
formation demonstrating the importance of cell cycle regulation during 
reprogramming. Another group reported generation of 3 factor iPSCs was achieved 
in p53-null (p53-/-) MEF and this study identified that overexpression of Mdm2, an 
E3 ligase and negative regulator of p53 (Vassilev et al., 2004), replicated the positive 
effect of p53 repression in reprogramming (Hong et al., 2009). When Kawamura et 
al. (2009) reprogrammed MEF from mice derived with a non-degradable mutant of 
a related p53 negative regulator, Mdm4, they observed an almost 7-fold increase in 
Nanog+ colony number providing further evidence for the inhibitory role of p53 in 
reprogramming.  Marion et al. (2009) suggested that this barrier effect caused by p53 
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during reprogramming was a result of genomic integrity being maintained via the 
DNA damage response induced by reprogramming factor expression. The authors 
suggested that whilst depletion of p53 resulted in increased efficiency, that this was 
at the risk of allowing substandard cells to progress towards iPSCs that normally 
would not have been able to for reasons of compromised genomic stability; a sort of 
innate natural selection was being bypassed by abrogation of p53 and related genes. 
Some evidence was presented to support this theory, as p53-deficient iPSCs were 
shown to have increased chromosomal abnormalities compared with wild type 
iPSCs including increased occurrence of chromosomal breaks and end-to-end 
fusions and in addition, depletion of p53 allowed telomerase deficient cells to 
reprogram to iPSCs; cells which were otherwise incapable of acquiring pluripotency 
(Marion et al., 2009). Interestingly, Utikal et al. (2009) showed that p53 -/- cells 
reprogrammed sub-populations of Thy1+ Thy1- and SSEA-1+ cells had similar 
reprogramming potential. 
The Ink4/Arf locus consists of tumour suppressor genes p16Ink4a and p19Arf 
(encoded by Cdkn2a) and p15Ink4b (encoded by Cdkn2b) involved in cell cycle and 
senescence regulation that are known to play a critical role in reprogramming. 
p16Ink4a regulates the Retinoblastoma (Rb) pathway, downstream of p53 (Sage, 2012) 
and p19Arf drives expression of p53 by inhibition of Mdm2 mediated degradation 
(Spike and Wahl, 2011).   These genes are expressed at basal levels in differentiated 
cells and acquire both repressive H3K27me3 and active H3K4me3 marks, known as 
bivalent chromatin, as they undergo silencing during reprogramming to iPSCs 
whilst still retaining the ability for reactivation upon differentiation (Li et al., 2009a).  
p19Arf activation of p53 and p21 in the mouse has been reported as a key roadblock 
of reprogramming (Spike and Wahl, 2011) and aberration of these pathways has 
been proven beneficial to reprogramming, enhancing both the kinetics and 
efficiency of pluripotent colony formation drastically (Li et al., 2009a). Interestingly, 
these authors showed that by contrast in human cells, INK4a seems to be the 
inhibitor of reprogramming with shRNA targeting INK4a exhibiting an enhancing 
effect, whereas ARF shRNA had no effect on iPSC formation. 
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Another clear barrier to reprogramming potential is the capability of cells to 
proliferate. Utikal et al. (2009) reported the observation that MEF progressively lose 
their reprogramming potential following serial passaging; an observation also 
experienced by our group. An increase in passage number of starting MEF 
undergoing reprogramming was accompanied by a decrease in alkaline 
phosphatase (AP) staining associated with pluripotent cells and a concomitant 
increase in senescence related staining with β-galactosidase. This was also 
accompanied by an increase in p16, p19 and p21 in agreement with previous reports 
that these markers obstruct progression towards iPSCs. Furthermore, three 
immortalized cell lines derived from different somatic tissue origins were used to 
demonstrate that senescence and limitations in cell-cycle pathways substantially 
hindered reprogramming capacity of cells, with immortalized cells regularly shown 
to reach upwards of 40% reprogramming efficiency compared to their non-
immortalized counterparts, with near 100% efficiency demonstrated in some cases 
(Utikal et al., 2009). Smith et al. (2010) used a single-cell imaging approach to 
retrospectively trace iPSC colonies to their cell of origin and found that these 
colonies emerged from a subclass of fibroblasts which they termed “fast-dividing”. 
They found that as soon as the first cell division these cells established a higher 
proliferative rate than normal fibroblasts, and within a few days match that seen in 
ES cells. This evidence supports the idea that proliferative potential is a key 
requirement for somatic cells to successfully progress through reprogramming. 
Expression of the four reprogramming factors directly affects a number of 
cluster families of micro-RNAs. p53 regulated miR-34 and miR-145 family members 
play critical roles in the impediment of reprogramming by promotion of cell cycle 
arrest, apoptosis and differentiation. miR-34a/b/c function in part by inhibition of 
key pluripotency genes including Nanog, Lin28, Sox2 and c-Myc and depletion of 
miR-34a has been shown to enhance reprogramming efficiency and kinetics (Yang 
and Rana, 2013). miR-145 has been reported to suppress Oct4, Sox2 and Klf4 during 
differentiation of ESCs although it is repressed by Oct4 in ESCs, suggesting a 
possible mechanism in reprogramming by which miR-145-mediated endogenous 
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repression of OSK is abolished by Oct4 repression. MEF enriched miRNAs miR-21, 
miR-29a and let-7 have been reported as barriers to reprogramming through 
positive regulation of TGF-β and MAPK pathways or negative regulation of 
pluripotency genes. c-Myc, which has been shown to play a critical role early in 
reprogramming, mediates reprogramming initiation in part by repressing these 
MEF associated miRNAs (Yang and Rana, 2013). 
ESC-specific cell cycle (ESCC) miRNAs (Wang et al., 2013c) including miR-
290-295, miR-302a-367 and miR-17-92 are known to influence epigenetic status and 
cell cycle regulation. ESC specific miRNAs, miR-291-3p, miR-294 and miR-295 were 
found to replace c-Myc during reprogramming, although in the presence of c-Myc 
there was no effect observed on four factor reprogramming (Judson et al., 2009). 
This could be explained by the finding that c-Myc binds the promoter of the miR-
290 cluster, suggesting that these miRNAs could be targets and downstream 
effectors of c-Myc, although the exact mechanism remains unclear. A later report 
determined that human orthologues of these miRNAs, hsa-miR-302a and hsa-miR-
372, enhanced reprogramming of both fetal and adult fibroblasts by synergistic 
repression of multiple targets (Subramanyam et al., 2011). These targets were 
identified to play roles in cell cycle and epigenetic regulation, signalling and 
epithelial to mesenchymal transition (EMT), highlighting the fact miRNA-mediated 
regulation of cell processes is extensive and highly complex making it difficult to 
determine the exact mechanism(s) by which promotion of reprogramming is 
conferred. 






1.5 RNAi and reprogramming 
 
Reprogramming of somatic cells to a pluripotent state via the ectopic 
expression of a limited set of transcription factors is now routinely performed by 
countless research groups, and indeed life science and drug companies, around the 
world. However, the question still remains as to the exact regulatory mechanism(s) 
underlying the transition of cells from a specialised, differentiated state to the 
establishment of pluripotency. Recently, the use of RNA interference (RNAi) has 
been reported to be a highly useful tool to identify regulators of the reprogramming 
process, giving some insight in to the mechanism of this inefficient process. 
RNA interference (RNAi) is a naturally occurring biological mechanism in 
cells where gene regulation is controlled by RNA hybridization to target messenger 
RNAs, resulting most commonly in inhibition of gene expression by way of 
destruction of mRNA, consequently causing down-regulation of target genes. This 
innate mechanism is an important part of host-pathogen defence, particularly in 
response to invasion by viruses, and vast research into the field in the early 1980’s 
saw this mechanism identified in an array of organisms including bacteria (Light 
and Molin, 1982; Light and Molin, 1983), dictyostelium (Crowley et al., 1985), 
Xenopus oocytes (Melton, 1985; Harland and Weintraub, 1985), Drosophila 
(Rosenberg et al., 1985) and plants (Ecker and Davis, 1986) where researchers 
noticed that  transcriptional inhibition was caused by application of anti-sense RNA. 
Around this time, similar observations were also reported in the mouse (Izant and 
Weintraub, 1984; Izant and Weintraub, 1985). Since then, the principles and 
mechanism of RNAi have been extensively studied resulting in the capability of 
artificially engineered RNAi expression constructs as a tool to investigate gene 
regulation in vitro. 
There are two main ways in which RNAi is used to knock down gene 
expression in mammalian cells in vitro. Short interfering RNAs (siRNA) are double 
stranded RNA fragments of approximately 21bp in length, first described by 
Elbashir et al. (2001a) which can be designed to target any gene of interest and, 
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conveniently, can now be artificially synthesized by a number of companies. When 
introduced to cells, these siRNAs directly interact with the RISC complex to mediate 
gene repression of a target mRNA containing a complementary sequence to one of 
the two siRNA strands; the effector strand known as the guide strand (Mittal, 2004; 
Matzke and Birchler, 2005). This approach may seem straightforward, however, the 
knock down effect can be weak and/or transient, particularly in rapidly dividing 
cells and may require serial transfections in order to obtain satisfactory knock down. 
Alternatively, an expression vector can be created to stably express a short hairpin 
RNA (shRNA) targeting a gene of interest (Moffat and Sabatini, 2006; Echeverri and 
Perrimon, 2006). In this case, the sequence is designed to introduce a small loop or 
hairpin between the complementary RNA strands upon expression, which 
facilitates endogenous processing of the shRNA in a similar fashion to endogenous 
microRNAs. Exogenously expressed shRNAs are trimmed by Dicer, an 
endoribonuclease, to produce smaller fragments similar to siRNA that is similarly 
incorporated into the RISC complex and involved in gene repression.  
Regardless of which RNAi method is used, when investigating functional 
mechanisms of gene repression, the most important factor to consider is the level of 
gene repression achieved. This is a very important caveat when considering RNAi 
as a tool for knock down of gene expression particularly when knock down of many 
genes is required, for example, in the context of a screen. Extensive studies into 
optimization of RNAi have led to a considerable list of ‘rules’ to take into account 
when designing RNAi sequences or vectors. For example, initial ‘first-generation’ 
designs were superseded by ‘second-generation’ shRNAs that took advantage of a 
micro-RNA (miRNA)-like backbone design, to aid in more efficient endogenous 
processing within cells (Silva et al., 2005; Boudreau et al., 2008). In addition, siRNAs 
should include 2 nucleotide 3’ overhangs, mimicking endogenous Dicer cleavage 
and an increased efficiency of knock down has been reported with UU 3’ overhangs 
although other combinations also work (Elbashir et al., 2001b). Other rules have 
been suggested regarding optimal region of gene targeting, GC content, 
concentration of siRNA, specificity of bases at certain positions within the sense 
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strand as well as many other structural considerations (Semizarov et al., 2003; 
Mittal, 2004; Reynolds et al., 2004) making it clear that RNAi design is deeply 
complicated. Despite extensive guidelines within the literature, a definitive formula 
for designing RNAi sequences that guarantees to achieve robust knock down of a 
target gene is still undetermined. Furthermore, sequence specificity must be well 
considered when using RNAi, as it has been widely reported that even a single 
nucleotide difference in siRNA sequences can drastically abolish gene targeting 
(Elbashir et al., 2001b; Miller et al., 2003). In addition, off-target effects resulting 
from incomplete specificity are a significant problem, with Jackson et al. (2003) the 
first to demonstrate that off-target gene regulation could occur when siRNAs 
exhibited only partial complementarity. In fact, the authors showed that as few as 11 
adjacent complementary nucleotides were enough to elicit an off-target effect in 
contrast to other reports that siRNA was highly specific in its effect (Jackson et al., 
2003; Semizarov et al., 2003; Miller et al., 2003).  
Recently, the mesenchymal genes Snai1 and Snai2 have been identified from 
an RNAi screen to play key opposing roles in reprogramming (Gingold et al., 2014). 
By inducing partial differentiation in a Nanog-GFP reporter line with 
administration of retinoic acid (RA), the authors sought out to identify regulators of 
Nanog expression. Knock down of Snai1 was found to inhibit GFP expression 
whereas knock down of Snai2 was found to have the opposite effect, with increased 
GFP expression observed. Subsequent overexpression of Snai1 and Nanog during 
reprogramming of pre-iPSCs was found to increase the number of fully 
reprogrammed iPSCs more than 2-fold compared with Nanog alone, with Snai2 
overexpression having a negative effect. Additionally, Snai1 was found to facilitate 
binding of Nanog within the promoter and enhancer regions of the miR-209-295 
locus, as well as binding to Lin28, another pluripotency associated gene.  
The use of RNAi has been valuable for functional genomics studies, and 
loss-of-function phenotypes in mammalian cells induced by RNAi screening 
methods have been successfully generated over the years allowing for the 
investigation of gene function in a variety of cell types including BJ human foreskin 
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fibroblasts (Berns et al., 2004), mammary cells (Silva et al., 2008b) and blood cells 
(Bassik et al., 2013). Previously, whole genome RNAi screens were successfully 
employed to elucidate genes that govern mouse and human embryonic stem cell 
identity (Hu et al., 2009; Chia et al., 2010), and siRNA screens have uncovered genes 
involved in Oct4 modulation and ESC identity, including Paf1C which blocks ESC 
differentiation following ectopic expression (Ding et al., 2009), the role of chromatin 
protein complex Tip60-p400 in ESC gene regulation and identity (Fazzio et al., 
2008), and MAP kinase phosphatases involved in regulation of ERK and GSK3 
signalling pathways as promoters of differentiation in ESCs (Yang et al., 2012). More 
recently, similar approaches using shRNA libraries have been applied in both 
mouse and human contexts to identify novel regulators of reprogramming. Yang et 
al. (2014) uncovered specific genes required at each transitional step during 
reprogramming and in addition the authors found that the expression of many 
genes was shown to remain unchanged during reprogramming. Interestingly these 
were purported to play key roles in controlling transitions of cellular identity 
during reprogramming, with some genes found to be required and others 
representing barriers to reprogramming. Qin et al. (2014) generated a global view of 
reprogramming barriers with genes identified from many major cellular pathways 
including transcription, ubiquitination, phosphorylation and dephosphorylation, 
cell adhesion and chromatin regulation emphasising the point that reprogramming 
of somatic cells to pluripotency is a deeply complex process with cell processes 
being infinitely interconnected and interdependent. Another approach employing a 
protein kinase shRNA screen of 734 kinases identified 59 barriers to 
reprogramming, with remodelling of the cytoskeleton being highlighted as an 
important modulator of reprogramming. TESK1 and LIMK2, whose inhibition 
promotes MET, were identified as barriers to this cellular restructuring process and 
consequently knock down promoted reprogramming in both mouse and human 
cells (Sakurai et al., 2014). 
Taken together these studies demonstrate that RNAi is a powerful tool to 
identify key players involved in ESC/iPSC pluripotency and self-renewal and gain 
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1.5.1 CRISPR/Cas9 mediated gene editing 
 
Recently, an exciting new genome editing technology dubbed the ‘CRISPR-
Cas9 system’ has been described, which allows highly efficient gene knock out both 
in vivo and in vitro (Swiech et al., 2015; Maddalo et al., 2014). This system was 
identified in bacteria and archaea as a mechanism of immunity whereby fragments 
of foreign genetic material from invading phage or plasmid DNA were integrated 
into the host genome at so-called clustered regularly interspaced short palindrome 
repeats, or CRISPR, loci (Pourcel et al., 2005; Mojica et al., 2005; Bolotin et al., 2005). 
Subsequently, the Cas9 protein incorporates both processed CRISPR RNAs (crRNA) 
and trans-activating crRNA (tracrRNA) to form a cRNA-tracrRNA-Cas9 complex 
which then mediates double strand break at homologous sequences of the invaders 
(Mali et al., 2013b; Gasiunas et al., 2012). This system has been taken advantage of in 
an in vitro context whereby in vitro-transcribed chimeric RNA known as short guide 
RNA (sgRNA, or guide RNA) takes the place of the crRNA-tracrRNA combination 
(Jinek et al., 2012). Targeting of loci in human and mouse cells was first 
demonstrated in recent years, with two groups reporting simple and robust gene 
targeting of several loci simultaneously using CRISPR-Cas9 systems (Cong et al., 
2013; Mali et al., 2013c). Remarkably, simultaneous mutation of up to five genes in 
mouse ESCs has been demonstrated and in the same study mice were generated 
with mutations in multiple genes through coinjection of zygotes with Cas9 mRNA 
and sgRNAs (Wang et al., 2013b). This multiplexed gene editing approach has since 
had major impact on the accessibility of routine gene editing in laboratories with its 
straightforward and reproducible protocol, rendering difficult and lengthy gene 
targeting approaches redundant.  
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The original Cas9 protein causes a double strand break in the target DNA, 
which can be repaired either by non-homologous end joining (NHEJ) which is error 
prone, or homology directed repair (HDR). This potential drawback was quickly 
overcome by the use of mutant Cas9 which converted the nuclease function of wild 
type Cas9 to a nickase function instead (Cong et al., 2013). Subsequently, a “double 
nicking” system was describe whereby a pair of offset guide RNAs targeting 
opposite DNA strands were expressed with the mutant Cas9, mediating targeted 
double strand breaks. Because the mutant Cas9 is unable to cause double strand 
breaks on its own, this system has increased specificity and fidelity by reducing off-
target activity (Mali et al., 2013a; Ran et al., 2013).  
This gene editing technique has quickly become the front-runner as the go-to 
gene knock out tool, and has already revolutionised reverse genetics investigation 
of both single and multiple genomic loci. At least three groups have employed 
lentiviral-based gRNAs in conjunction with Cas9 (either as part of the same 
construct or using Cas9 constitutively expressing cells) for genome wide targeting in 
the mouse and human (Koike-Yusa et al., 2014; Shalem et al., 2014; Wang et al., 
2014) and researchers have also demonstrated use of the CRISPR system as a 
potential method of gene therapy to treat cystic fibrosis and blood disorders (Xie et 
al., 2014; Schwank et al., 2013). These reports demonstrate the robust and 





 In summary, although a vast amount of knowledge has been gained about 
the reprogramming process in a relatively short period of time since Takahashi and 
Yamanaka (2006) first reported generation of iPSCs, the exact mechanism(s) 
underlying the reprogramming process remains largely elusive. One of the key 
issues that remains to be fully understood is why reprogramming is so consistently 
inefficient regardless of the system used. A number of groups have claimed 
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surprisingly high reprogramming efficiencies, with some reports even declaring 
almost 100% reprogramming efficiency. However, these reports are rarely 
corroborated and offer little in the way of mechanistic insight to the findings. For 
the work presented in this thesis, I used an RNAi screening strategy to identify 
novel regulators of reprogramming with the objective of gaining some mechanistic 





CHAPTER 2 – Materials and Methods 
 
2.1 Mammalian cell culture 
 
2.1.1 Cell culture and reprogramming reagents 
 
ESC and iPSC medium: 
Glasgow Minimal Essential Medium (GMEM, Sigma G5154) supplemented with:  
10% Foetal Calf Serum (FCS, Invitrogen, 10270 Batch 40F0240K) 
Non-essential amino acids (1X NEAA, Gibco 11140-035) 
L-Glutamine (2 mM, Invitrogen, 25030-024) 
Sodium pyruvate (1 mM, Invitrogen, 15140-122) 
2-mercaptoethanol (100 μM, Life Technologies 31350010) 
Leukemia inhibitory factor (LIF, 100 units/ml, homemade human recombinant) 
Penicillin-Streptomycin (P/S, 50 units/ml (P) or 50 μg/ml (S), Sigma, P4333) 
 
MEF medium: 
ESC and iPSC medium 
bFGF/FGF2 (5 ng/ml, Peprotech 100-18-B) 
Heparin (1 ng/mL, Sigma) 
 
Reprogramming medium: 
ESC and iPSC medium 
Ascorbic acid/Vitamin C (10 μg/ml, Sigma A4034) 






Cell freezing medium: 
Dimethysulfoxide (DMSO, 10%, VWR International, 23500.260) 
FCS (90%) 
 
Cell culture selection drugs: 
Blasticidin S hydrochloride (10 ug/ml, Sigma, 15205) 
Puromycin dihydochloride (5 ug/ml, Sigma, P8833) 
 
Transfection reagents: 
Calcium chloride hexahydrate (2 M, Sigma, 442909) 
HBS (2X, made in house by adding 8 g NaCl + 0.2 g Na2HPO4-7H2O + 6.5 g HEPES 
with volume brought up to 500 ml with dH2O and pH adjusted to 7.0) 
Polybrene (10 mg/ml, Merck Millipore, TR-1003-G) 
FuGene HD transfection reagent (Promega, E2311) 
Opti-MEM I Reduced Serum Medium (OptiMEM, Life Technologies, 31985-062) 
 
Miscellaneous cell culture reagents: 
Dulbecco’s Phosphate Buffered Saline (PBS, Sigma D8537) 
Gelatin (0.1% in PBS, Sigma G5154) 
Trypsin (0.25%, Gibco 15090-046) 
Ethylenediaminetetraaceticacid (EDTA, 0.1%, Sigma 03620) 
 
 
2.1.2 Cell lines used in this study 
 
E14 ES cell line 
TNG MKOS ESC line containing a doxycycline-inducible MKOS-ires-mOrange 
transgene and a Nanog-GFP reporter 
MEF primary culture from 129 mice 
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TNG MKOS MEFs derived from chimeric embryos generated with TNG MKOS ESC 
line, (referred to as ‘transgenic MEF’ herein) 
Platinum-E (Plat-E) retroviral packaging cell line 
 
 
2.1.3 ESC culture technique 
 
 ESCs were cultured in ESC medium with trypsin/EDTA passaging every 2-3 
days or when the cells reached approximately 80% confluency. For passaging, cells 
were washed with PBS, incubated with trypsin/EDTA for 2-3 minutes at 37°C, 
harvested in complete GMEM medium then centrifuged at 300g for 3 minutes. The 
cell pellet was resuspended in complete GMEM medium and cells seeded to a new 
gelatin-coated tissue culture vessel as appropriate and incubated in a humidified 
incubator set to 37 °C/7.5% CO2. 
 
 
2.1.4 Generation of chimeric embryos 
 
 ESCs were cultured as above and 48 hours prior to use a doubling dilution 
series was generated from 2x106 cells in 2 ml of complete GMEM medium in a 
gelatin-coated 6-well tissue culture plate. From this, single cells or colonies of an 
appropriate size (5-8 cells) were harvested and aggregated with morulae of C57Bl/6 
mice. All embryo manipulation techniques were carried out by Transgenic Unit staff 







2.1.5 Mouse embryonic fibroblast isolation, cryopreservation and cell culture 
technique 
 
 Mouse embryonic fibroblasts (MEFs) were taken from embryonic day 12.5 
(E12.5) mouse embryos. Pregnant mice were culled and dissected to isolate embryos 
that were decapitated, eviscerated and then dissociated in 0.25% trypsin/0.1% EDTA 
using a 21 gauge needle. Cells from individual embryos were then resuspended in 
10 ml of MEF medium, large pieces allowed to sediment and ~9.5 ml of MEF cell 
suspension plated in a 10 cm2 tissue culture dish then incubated in a humidified 
incubator set to 37 °C/7.5% CO2.  
When cells reached confluency, they were harvested for cryopreservation as 
follows: cells were washed with PBS, harvested by trypsin/EDTA incubation then 
collected and counted prior to centrifugation at 300g for 3 minutes. The cell pellet 
was resuspended in freezing medium at a concentration of 2-5x106 cells/ml and 1 ml 
aliquots cryopreserved with initial storage at -80 °C for 24 hours followed by 
transfer to liquid nitrogen (LN2) for long term storage. 
To recover cryopreserved MEF, vials were briefly thawed in a water bath set 
to 37 °C, resuspended in MEF medium followed by centrifugation at 300 g for 3 
minutes. Cells were resuspended in MEF medium then counted and seeded in 
tissue culture vessels as required. 
 
2.1.5.1 Quantification of transgenic cell contribution 
In this study we used transgenic MEF carrying dox-inducible four 
reprogramming factors with a mOrange reporter. To quantify this, following MEF 
isolation a small aliquot of the MEF (approximately 1/20 of the isolated MEF) were 
plated in a 12-well tissue culture dish in reprogramming medium for 48 hours and 
the total percentage of transgenic cells was determined based on mOrange reporter 




2.1.6 Reprogramming from MEF 
 
In general reprogramming experiments were carried out in a 6-well format, 
with 1x105 MEFs (wild type or transgenic, depending on the experiment) seeded per 
well. MEFs were recovered from cryopreservation approximately 2 days prior to 
seeding for experiments. Cells were either seeded directly from the initial recovered 
culture for experiments (passage 2, P2) or passaged/expanded to a new vessel up to 
one time prior to seeding, with cells only being used up to P3 to maintain good 
proliferation conditions. 
 
2.1.6.1 Transfection of MEF for primary reprogramming experiments 
Wild type MEFs were seeded in gelatinized 6-well plates at a density of 
1x105 cells per well and incubated for 24 hours before transfection. Spent medium 
was replaced with 2 ml of fresh MEF medium without heparin or P/S and the 
following ratio of vectors prepared per transfection in Eppendorf tubes: 0.5 μg PB-
TAP-IRI-2LMKOSimO (O'Malley et al., 2013), 0.5 μg CAG-rtTA, 0.5 μg hyperactive 
piggyBac transposase (hyPBase, Yusa et al. (2011)). Depending on the experiment, 1 
μg of PB-overexpression vector and/or 1 μg of PB-shRNA vector were also added. 
Fugene HD was used at a ratio of 1:4 for total DNA (μg) : Fugene HD reagent, so if 
DNA vectors totaled 3.5 μg in 3.5 μl then 14 μl of Fugene HD was used. A 100 μl 
transfection volume was used per 6 well, so the total volume of DNA and Fugene 
HD reagent was calculated and subtracted from 100 μl and this volume, e.g. 82.5 μl, 
of OptiMEM Medium was added to the DNA mix. The Fugene HD reagent was 
then added carefully below the fluid surface, avoiding contact with the plastic tube. 
The mixture was incubated at room temperature for 5 minutes and then 100 μl of 
the transfection mixture was added drop-wise to each well of MEFs in 2 ml of MEF 
Medium without P/S. After overnight incubation at 37 °C, the spent medium was 
replaced with fresh reprogramming medium to induce reprogramming factor 
expression, and this was taken as day 0 of reprogramming. Nanog-GFP+ colonies 
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were counted around day 10 to quantify any differences observed compared with 
control wells.  
 
2.1.6.2 Preparation of shRNA retrovirus supernatant for reprogramming 
Platinum-E (Plat-E) retrovirus packaging cells were seeded at a density of 
2.5-3x106 cells per 10 cm plate in 10 ml of MEF medium containing blasticidin (10 
ng/μl) and puromycin (2 ng/μl). After 24 hours, with Plat-E reaching confluency of 
around 60%, individual shRNA vectors were transfected by calcium chloride 
transfection: 63 μl of 2 M CaCl2 was added to 15 μg of vector in 437 μl of distilled 
water (dH2O), mixed and added dropwise to 500 ul of 2X HBS in an Eppendorf 
tube. Approximately 950 μl of this transfection solution was added dropwise to a 10 
cm plate of Plat-E cells in 10 ml of MEF medium while swirling the plate to ensure 
even distribution, then incubated overnight at 37 °C. This process was repeated for 
each shRNA transfection. The following day, the transfection medium was replaced 
with fresh MEF medium and incubated for 24 hours at 32 °C to maintain stability of 
the virus. The following day, the virus supernatant was removed from the cells and 
filtered using a 0.45μm filter and syringe in to a 50 ml tube, and polybrene was 
added at a final concentration of 6-8 μg/ml. 2 ml per 6-well was distributed on to the 
MEF cultures replacing the MEF medium, as required. Viral titre was not calculated 
and a pMXs-DsRed vector was used as a transfection/infection control.  
 
2.1.6.3 Reprogramming transgenic MEF with shRNAs 
For all reprogramming experiments involving “topping up” with shRNA, 
MEFs were seeded at a density of 1x105 MEFs per 6 well in MEF medium, 
constituting 3% transgenic MEFs (based on mOrange expression quantification 
outlined above) diluted with 97% wild type 129 MEFs. The following day after MEF 
plating, cells were infected with virus as detailed above and the cultures were 
incubated at 32 °C for 4 hours and then transferred to 37 °C incubation overnight. 24 
hours later, virus supernatant was replaced by reprogramming medium and this 
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was counted as day 0 for all reprogramming experiments. Medium was replenished 
every 2 days. 
 
2.1.6.4 Primary reprogramming with shRNAs  
For primary reprogramming with shRNAs, 1x105 wild type MEFs were 
seeded in 6 wells and transfected with a polycistronic vector containing the four 
reprogramming factors MKOS with a mOrange reporter (PB-TAP-
attP2LMKOSimO) using Fugene HD transfection reagent as per the manufacturers 
instruction (see below section). The day after transfection, virus supernatant was 
applied to cells as above and 24 hours later this was replaced with reprogramming 
medium (d0). Efficiency of transfection could be estimated by eye after 48 hours by 
observation of mOrange reporter expression. 
Where other factors were introduced that were not shRNAs but were 
contained in virus vectors, the virus supernatant was produced and applied in 
exactly the same way as for the shRNA vectors above. 
 
2.1.6.5 Colony counting experiments 
For end-point analysis, Nanog-GFP+ colonies were counted at various time 
points either manually by eye using a fluorescent microscope, or for later 
experiments using the Celigo cell cytometer instrument. 
 
2.1.6.6 Time course analysis 
For time-course analysis by flow cytometry, whole 6-well reprogramming 
cultures were harvested by trypsin/EDTA at each required time point, cells counted 
and centrifuged at 300 g then re-suspended in PBS at a concentration of 
approximately 1x106 cells/ml. The cell suspension was then aliquoted into round 





2.1.6.4 Transgenic MEF reprogramming for Q-PCR analysis 
To determine changes in gene expression in cells undergoing 
reprogramming, >94% transgenic MEFs were reprogrammed and samples taken at 
various time points, as required. For these experiments, >94% transgenic MEFs were 
seeded in gelatinized 6-well plates at a density of 2.5x104 cells per well in MEF 
medium. The following day, the medium was replaced with reprogramming 
medium, and this was used as day 0 of reprogramming. For each time point, whole 
well samples were harvested with trypsin/EDTA and RNA extraction and cDNA 
synthesis were carried out (see Sections 2.2.2 and 2.2.3), followed by Q-PCR analysis 






















2.2 Molecular Biology Techniques 
 
2.2.1 Plasmid vectors used in this study 
 
pENTR-2B2 Entry vector for cloning of gene(s) of interest (GOI) 
with Gateway recombination sites, enabling easy 
cloning of DNA into compatible vectors. Kanamycin 
resistant. 
 
pMXs-gw Destination vector for pMXs-GOI plasmids. Contains 
Gateway recombination sites flanked by retrovirus 
LTRs. Ampicillin resistant. 
 
pBabe-dual Retroviral vector containing dual converging U6 and 
H1 RNA polymerase III promoters, published by Li et 
al. (2006) and available on Addgene. Ampicillin 
resistant. 
 
pRetroSuper-Hyg Plasmid containing a multiple cloning site (MCS) 
flanked by retrovirus long terminal repeats (LTR) and 
pUC origin of replication. Ampicillin resistant. 
 
CAG-rtTA Plasmid constitutively expressing reverse tetracycline 
transactivator (rtTA), a protein that binds the TetO 
operator sequence when bound by doxycycline. 
Required for activation of doxycycline inducible 
vectors. 
 
pCMV-hyPBase Plasmid encoding a hyperactive piggyBac transposase, 
which catalyzes the integration and excision of 
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piggyBac transposons into DNA, under control of a 
CMV promoter. Ampicillin resistant. 
 
PB-TAP-attP2LMKOSimO Plasmid vector expressing doxycycline inducible 
piggyBac transposon encoding four reprogramming 
factors c-Myc, Klf4, Oct4 and Sox2 with mOrange 
reporter. Ampicillin resistant. 
 
pMXs-Dmrtc2 Retroviral vector containing the open reading frame 
(ORF) of Dmrtc2 (note this vector is lacking the 3’-
UTR). Ampicillin resistant. Used for overexpression 
experiment. 
 
pMXs-hCD2 As above but containing the  human CD2 ORF. 
Ampicillin resistant. Used in overexpression 
experiment. 
 
pRS-Hyg-U6H1-shRNA Modified pRetroSuper-Hyg vector containing dual 
converging RNA Polymerase III promoters U6 and  
H1. All shRNA expression vectors created using this 
plasmid by ligating shRNA oligos in to BbsI site. 
 
 
2.2.2 RNA isolation 
 
 Cells in culture were washed with PBS and 1 ml of TRIzol reagent (Life 
Technologies, 15596-026) applied directly to cells per 6 well and processed 
according to manufacturer instruction. Briefly, cells in TRIzol were homogenized to 
ensure complete lysis then transferred to a 1.5 ml Eppendorf tube and incubated at 
room temperature for 5-10 minutes. 200 μl of chloroform was added and the tube 
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vigorously shaken then samples were centrifuged for 15 minutes at 12,000 g. The 
colourless upper aqueous phase was transferred to a new 1.5 ml Eppendorf tube 
(approximately 400 μl) then 400 μl of 100% isopropanol was added and mixed well. 
After incubation at room temperature for 10 minutes, centrifugation at 12,000 g was 
repeated for 10 minutes and the supernatant was removed leaving the RNA pellet 
behind. The pellet was washed with 1 ml of 75% ethanol, vortexed briefly then 
centrifuged at 12,000 g again for 5 minutes. The supernatant was removed and 
pellet dried at room temperature for 5-10 minutes then resuspended in nuclease free 
water. The RNA was either used immediately or stored at -80 °C. All centrifugation 
steps were carried out at 4 °C. 
 
 
2.2.3 cDNA synthesis 
 
 MML-V reverse transcriptase (Life Technologies, 28025-013) was used for 
cDNA synthesis according to manufacturer instruction but briefly 20 μl reactions 
were prepared in 2 steps. Firstly 1 μg of total RNA was added to a nuclease-free 
microcentrifuge tube with oligo dT (100 μM, T24) and 100 mM of each of four 
deoxyribonucelotides dATP, dTTP, dCTP and dGTP (Life Technologies, 10297-018) 
totaling 10 μl. This was incubated at 65 °C for 5 minutes then placed on ice. Next, a 
mastermix of 5X First-Strand Buffer, 0.1 M DTT, MML-V reverse transcriptase (Life 
Technologies, 28025-013) and RNaseIN (NEB, M03141) was made and 10 μl added 
to the initial reaction mixture. Samples were then incubated for 1 hour at 37 °C, 10 
minutes at 90 °C then cooled and stored at 4 °C until use. If not being immediately 







2.2.4 Quantitative PCR analysis 
 
 Quantitative real time PCR (Q-PCR) was carried out using the Roche 
Universal Probe Library (UPL) hydrolysis probe-based system with a Roche 
LightCycler® 480 Real-Time PCR instrument. An 8 μl Q-PCR reaction was carried 
out as follows: a master mix was made up containing 4 μl of 2X Probes master mix, 
0.08 μl of UPL probe and 1.92 μl of 20 μM forward and reverse primers for each 
reaction, and this was loaded on to a 384-well LightCycler® 480 Real-Time PCR 
plate. cDNA made from 1 μg of total RNA was diluted 1:10 with nuclease-free 
water and 2 μl of this was loaded in to each reaction. The plate was centrifuged at 
300 g for 1 minute to collect the reactions at the bottom of the wells and the plate 
loaded into the LightCycler® 480 instrument using the UPL program recommended 
by the manufacturer. A standard curve was included in the reactions to allow for 
relative quantification to be calculated by the LightCycler® 480 software. Q-PCR 




2.2.5 Bacterial transformation and plasmid DNA preparation 
 
 DH5α E. coli bacteria were routinely transformed to generate plasmid DNA 
stocks for standard high copy plasmids. Typically <10 ng of stock plasmid, or 5-10 
μl of ligation reaction was used per transformation as follows: 50-100 μl frozen 
aliquots of bacteria were removed from -80 °C storage and thawed on ice. DNA was 
added to the bacteria, in an appropriate concentration/volume, and the mixture was 
incubated on ice for 5 minutes followed by heat shock at 42 °C for 30 seconds then 
immediate transfer back on to ice for 2 minutes. 500 μl of LB broth was added to the 
tube and incubated at 37 °C for 1 hour. 10-500 μl of the mixture was spread on to LB 
agar plates, with antibiotics as appropriate, and plates were incubated for 16-24 
hours at 37 °C. Individual colonies were picked from plates into 5ml of LB broth, 
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containing antibiotics as appropriate, after being stabbed on to new LB agar plates 
as a master plate. This plate was again incubated for 16-24 hours at 37 °C while the 
inoculated broth was incubated with 250 rpm agitation at 37 °C for 16-18 hours. 
Following incubation, the bacterial broth was centrifuged at 4000 g for 10 minutes 
and the supernatant removed. Plasmid DNA was purified from the bacterial cell 
pellet using the QIAprep Spin Miniprep kit (Qiagen, 27106). This scale of plasmid 
preparation was usually used for initial ligation reaction validation, and once 
confirmed, larger stocks were generated by inoculation of 50-100 ml of LB broth, 
using the QIAprep Spin Midiprep kit (Qiagen, 12243) for plasmid DNA purification. 
 
 
2.2.6 Restriction enzyme digestion and purification of DNA fragments 
 
 Restriction enzyme digestion was primarily used either during the course of 
cloning new plasmid vectors or for confirmation of correct plasmids following 
ligation reactions, for example. For cloning new vectors, the amount of DNA 
digested varied but was typically >1 μg and for confirmation of plasmid vectors 
typically 100-200 ng was digested. All restriction enzymes and buffers were 
supplied by NEB with the specific quantities/concentrations used according to 
manufacturer instruction. Digestion reactions were carried out in 20 μl reactions 
and incubated for 1 hour at 37 °C unless otherwise recommended. After DNA 
digestion an OrangeG loading buffer (NEB, made up with 40% sucrose) was added 
to samples and reactions were loaded onto a 0.8-2% (w/v) agarose gel for 
electrophoresis separation of DNA fragments. A 1Kb Plus DNA ladder (Life 
Technologies, 10787-018) was loaded alongside samples and gels were run at 100-
120 V for ~45 minutes. GelRed nucleic acid stain (Cambridge BioScience) was 
incorporated into gels to visualize DNA bands with UV illumination. DNA 
fragments of the correct size were extracted from gels using a scalpel and DNA was 
purified using the Zymoclean Gel DNA Recovery kit (Zymo Research) according to 
manufacturer instruction, with DNA eluted in 6-8 μl of sterile water. 
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2.2.7 shRNA expression vector construction 
 
21 bp shRNA sequences for candidate genes were determined using the Life 
Technolgies online tool BLOCK-iT™ RNAi Designer. For vector construction, BbsI 
restriction sites were included at either end of the oligo duplex and a loop sequence 
was inserted between the sense and antisense sequences resulting in a 55-nucleotide 
oligo. An example is shown below, where red indicates the sequence for insertion 









The sequences are orientated in the 5’ to 3’ direction with the first black sequence 
representing the ‘sense’ shRNA sequence and the ‘antisense’ shRNA sequence 
following the blue loop sequence – it is the antisense sequence which we expect to 
be employed as the guide strand of each shRNA. Note the red ‘G’ in the forward 
oligo is due to the preference of the U6 promoter to initiate transcription at a ‘G’ 
nucleotide (Ma et al., 2014a). Three shRNAs were designed for each candidate gene 
of interest and the vectors constructed as follows: 9 μl of 100 μM forward and 
reverse oligos were added to 2 μl of 10X T4 DNA ligase buffer. Annealing of the 
oligos was carried out in a PCR machine set to 98°C and programmed to reduce the 
temperature slowly to 20 °C. The annealed oligos were diluted to 100 nM and 4 μl 
added to 50 ng of purified pRS-Hyg-U6H1 digested with BbsI, 10X T4 DNA ligase 
buffer and 1 μl of T4 DNA ligase (NEB, M0202L). The samples were made up to 10 
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μl with dH2O and incubated at room temperature for 1.5-2 hours, then transformed 



























2.3 Flow cytometry  
 
2.3.1 Flow cytometry materials 
 
All flow cytometry analyses were carried out using the BD LSR Fortessa cell 
analyzer instrument with harvested cells resuspended in flow cytometry buffer (FB, 
2% FBS in PBS) for antibody staining in 96-well U bottom plates, then aliquoted into 
FACS tubes (BD Falcon, 3520) for analysis. 
 
 













Anti-Mouse                 
CD54 (ICAM-1)           
Biotin 
YN1/1.7.4 




Anti-Human/Mouse                                               
CD44                          
APC 
IM7 




Streptavidin                   
PE-Cy7 
- - 1/1500 25-4317 
Anti-Human/Mouse                                
SSEA-1                      
647 
eBioMc 
Mouse                
IgM 
1/50 51-8813 
Anti Mouse/Rat       
CD90.1 (Thy1.1)                   
APC 
HIS51 




Anti-CD324                      
(E-cadherin)                       
Biotin 
DECMA-1 




2.3.3 Antibody staining technique for flow cytometry analysis 
 
Harvested cells were counted then centrifuged at 300g and 
resuspended in FB at a concentration of 1x106 cells/ml. Primary antibodies 
were added and samples were incubated on ice for 15-30 minutes. Cells were 
centrifuged, primary antibodies aspirated and cells washed in FB. After 
centrifugation, the wash step was repeated and cells were resuspended in 
FB. Secondary antibodies were then added and samples incubated on ice for 
5-10 minutes. The wash steps were repeated as before and cells were finally 
resuspended in FB at a concentration of 2x106 cells/ml and transferred to 
FACS tubes on ice, ready for analysis using the BD LSR Fortessa analyzer. 
 
 







Flow Cytometry with BD 
LSR Fortessa 
Laser excitation line 
488 nm 561 nm 640 nm 
Band pass 
(BP) filter 
530 ± 30 GFP     
582 ± 15   mOrange   
780  ± 60   PE-Cy7   
670 ± 30     APC 
Table 2.1 BD LSR Fortessa instrument settings for flow cytometry analyses. The laser 
excitation line indicates the operational wavelength of each laser and the band pass filter 
indicates the range of wavelength of light detected by the instrument. 
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2.3.5 Flow cytometry gating and data analysis strategies 
 
 Gating strategy used for flow cytometry analyses is detailed in O'Malley et 
al. (2013), specifically Supplementary Figure 4, but briefly described here. Cells 
were initially gated according to forward- and side-scatter (FSC, SSC), broadly 
correlating with cells size and granularity, respectively, to enrich for ‘live’ cells 
while disregarding dead/dying cells and debris. Early in time course experiments 
this gating was broad, in line with the heterogeneous nature of reprogramming 
cultures containing a mixture of both large fibroblast-like cells and progressively 
smaller reprograming cells. Transgenic cells could be identified from mOrange 
expression originating from the four-factor polycistronic vector, thus indicating cells 
specifically undergoing reprograming. In addition to the antibody-specific gene 
expression profile of interest, depending on the experiment, these cells could also be 
gated for Nanog-GFP+ or GFP- expression. Correction of any overlap between 
fluorophores used in these experiments during acquisition (also known as 
compensation) and data analysis was carried out using Diva or FlowJo software, 















2.3 Genome-wide gene expression analysis 
 
2.3.1 Microarray analysis 
 
 Reprogramming samples retrovirally infected with shLacZ, MUT 1, MUT 5 
and shDmrtc2 for microarray were collected and RNA isolated as per Section 2.2.2. 
The samples were then processed using the Illumina® TotalPrep RNA 
Amplification Kit (Life Technologies, AMIL1791) to produce biotinylated cRNA. 
The quality of the samples was determined using an Agilent Bioanalyzer, and the 
samples were subsequently used for microarray analysis using the Illumina 
MouseWG-6 Gene Expression BeadChip. Microarray analysis was carried out by 
Louise Evenden at the Wellcome Trust Clinical Research Facility located at the 
Western General Hospital in Edinburgh. 
 Data analyses for the microarray was carried out separately by Rafal 
Gumienny and Alexander Kanitz from Mihaela Zavolan’s lab at the University of 




2.3.2 RNA-sequencing analysis 
 
 Samples of MEF infected with shLacZ, MUT 9, MUT 11 and shDmrtc2 were 
harvested with trypsin/EDTA and aliquoted 25% and 75% into separate Eppendorf 
tubes. The tubes were centrifuged at 300 g for 3 minutes, supernatant removed and 
pellets were snap frozen in liquid nitrogen. These samples were shipped to Afzal 
Syed in Mihaela Zavolan’s lab at the University of Basel for RNA-sequencing (RNA-
seq) and Northern Blot analyses. Briefly, the RNA-seq technique involved mRNA 
isolation directly from frozen cell pellets using the Dynabeads® mRNA DIRECT™ 
Kit (Life Technologies, 610.11). 100 ng of mRNA was fragmented with alkaline 
hydrolysis buffer and then cleaned up using the RNeasy MinElute Cleanup Kit 
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(Qiagen, 74204). The mRNA ends were repaired by dephosphorylation then 
phosphorylation and the clean up step was repeated. 3’- sequencing adapter ligation 
was carried out overnight, clean up step repeated followed by 5’- sequencing 
adaptor ligation overnight. A final clean up step was performed and cDNA 
prepared. A pilot PCR was carried out followed by the final PCR, and the PCR 
products from this were cleaned up using the Agencourt AMPure XP kit (Beckman 
Coulter, A63880). The samples then forwarded to the sequencing facility. RNA-seq 
analysis was carried out by R. Gumienny using a biophysical modeling approach, 
MIRZA, to predict putative shDmrtc2 target sites (Khorshid et al., 2013; Gumienny 
and Zavolan, 2015). 
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The use of reverse genetics to disrupt genes and determine the phenotype 
has been long used in biology. In the context of stem cell biology, several groups 
have reported the use of RNA interference (RNAi) to identify genes involved in 
stem cell self-renewal, pluripotency regulation, chromatin modulation and signaling 
pathways required to maintain ESC identity (Hu et al., 2009; Chia et al., 2010; Ding 
et al., 2009; Fazzio et al., 2008). In addition genome-wide and custom knock down 
screens have been used as a tool to dissect the reprogramming process and 
distinguish genes and associated pathways that are important during each stage of 
the transition of somatic cells to pluripotent iPSCs (Yang et al., 2014; Qin et al., 2014; 
Samavarchi-Tehrani et al., 2010; Sakurai et al., 2014). However, the complex and 
dynamic nature of reprogramming has made it difficult to pinpoint the exact 
determinants and sequence of cellular events for a somatic cell to successfully 
become an iPSC and the low efficiency at which the majority of reprogramming 
systems operate has hindered this further.  
The foundation of the work within this thesis stemmed from the published 
work of another member of our lab, James O’Malley, who identified two cell surface 
markers, ICAM1 and CD44, that could be used to track the movement of cells 
undergoing reprogramming using flow cytometry. Using a secondary 
reprogramming system with transgenic fibroblasts which carried the four 
reprogramming factors containing a mOrange reporter and a Nanog-GFP reporter 
under control of the endogenous Nanog promoter, O'Malley et al. (2013) developed 
a novel high-resolution system allowing for reprogramming cells to be visualized at 
a single cell level during reprogramming by following their expression of ICAM1 
and CD44. They determined that fibroblasts prior to reprogramming expressed 
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broad levels of ICAM1 and high expression of CD44. As reprogramming was 
initiated ICAM1 repression was followed by downregulation of CD44 with iPSCs 
emerging from the low CD44 population with up-regulation of ICAM1. By sorting 6 
different cell populations at day 10 of reprogramming, based on the distinct series of 
population changes that occurs as determined by ICAM1/CD44 and Nanog-GFP 
expression, the authors were able to determine global gene expression profiles 
concurrent with the changing populations during reprogramming, using RNA-
sequencing. From the gene expression analysis, five distinct patterns of gene 
expression were identified (O'Malley et al. (2013), Figure 3A, Groups A to E) and it 
is clear from a number of other published data sets that distinct gene expression 
patterns occur during reprogramming (Samavarchi-Tehrani et al., 2010; Sridharan et 
al., 2009). Group B, that is genes that displayed low expression in fibroblasts and 
iPSCs with transient up-regulation during reprogramming, was the focus at the 
foundation of this thesis. This group of genes was particularly interesting as we 
hypothesized that the transient up-regulation of gene expression that was observed 
was either required for cells to successfully progress through reprogramming to 
iPSCs (and therefore overexpression would enhance reprogramming), or this was 
an aberrant transient up-regulation that hindered efficient reprogramming (and 
therefore using shRNA to knock down/suppress gene expression would enhance 
reprogramming). By designing shRNAs targeting the group B genes, those that had 
a positive or detrimental effect on reprogramming could be easily identified by 
using the flow cytometry technique described by O'Malley et al. (2013) in addition 
to simpler assays such as colony counting based on Nanog-GFP expression. Using 
this strategy I sought to identify novel genes that play a role in the reprogramming 
process in an attempt to further dissect the mechanism(s) and pathways underlying 






3.1.1. Aims of this chapter 
 
The aims of this chapter are threefold. Firstly, I analysed RNA-seq and 
microarray data generated both within our lab and others to compile a list of 
candidate genes for targeted knock down. Secondly, in parallel, I established an 
efficient and effective RNA interference (RNAi) system to knock down target genes 
during reprogramming. Finally, I tested the effect of knock down of candidate genes 
during reprogramming and identified shRNAs targeting candidate genes that gave 

























3.2.1. Candidate gene selection for RNAi screening 
 
The starting point for this study was established from earlier work in our lab 
performed and published by James O’Malley. Detailed in the O’Malley et al. (2013) 
publication, RNA-sequencing data was generated using samples of cells that were 
at early, intermediate and late phases of reprogramming based on cell sorting using 
novel cell surface markers ICAM1 and CD44 together with a pluripotency marker 
Nanog-GFP.  J. O’Malley identified five groups of genes based on distinct patterns 
of gene expression during reprogramming. One of these groups, “group B”, 
contained genes that exhibited low levels of expression in MEF, transiently up-
regulated then down-regulated expression when cells reached an iPSC stage. This 
group of genes we termed “UP-DOWN” genes (Figure 3.1a and b) and this data was 
the main basis for candidate gene selection for this project. It was unknown as to 
whether this transient up-regulation was required for reprogramming to progress 
or simply aberrant up-regulation triggered by strong induction of the four 
reprogramming factors. We hypothesized that some of these genes may represent 
the former situation and if so knocking down gene expression early in 
reprogramming, thereby preventing transient (aberrant) up-regulation, may 
enhance reprogramming by abolishing this barrier. On the other hand, knock down 
of genes that are required to transiently up-regulate during reprogramming would 
result in loss of reprogramming potential. Thus this approach has the potential to 
identify both barrier and essential genes for reprogramming. A principal 
component analysis generated from the RNA-sequencing data (Figure 3.1c) 
indicated that the cells take a detour to reach a pluripotent state (red arrow), instead 
of taking the shortest route towards iPSCs (blue arrow). I aimed to make a ‘shortcut’ 
by inhibiting transient up-regulation of inhibitory genes.  
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Figure 3.1. Gene expression profile of cells undergoing reprogramming. Five distinct 
mRNA expression profiles were determined for cells at early, intermediate and late stages of 
reprogramming (a). An “UP-DOWN” group of genes was identified as having low expression 
in MEF and iPSCs/ESCs with transient up-regulation occurring during reprogramming (a, b). 
Principal component analysis demonstrates the usual route of reprogramming MEF to iPSCs 






The UP-DOWN group contained 706 genes, many more genes than could be 
screened manually as was intended for this project rather than using a high-
throughput approach. As a means to narrow down the candidate list to a more 
practical number, an additional data set published by Samavarchi-Tehrani et al. 
(2010) was considered in conjunction with the UP-DOWN gene list. Briefly, the 
authors used an RNAi screening approach using short interfering RNA (siRNA) 
targeting over 4000 genes in order to identify regulators of the early initiation phase 
of reprogramming. After 5 days of reprogramming, alkaline phosphatase (AP) 
staining was used as a read out of reprogramming cells and the area of AP staining 
was calculated for each well. By putting these results in order of AP staining area I 
was able to narrow down my candidates based on the genes which had a higher AP 
staining value than p53 on the siRNA list since it is well documented that knocking 
down p53 during reprogramming leads to enhanced reprogramming efficiency 
(Banito et al., 2009; Kawamura et al., 2009; Hong et al., 2009). This approach 
identified 47 “barrier” candidate genes and I reasoned that knock down of these 
genes during reprogramming might enhance reprogramming as well as or better 
than knock down of p53. Similarly, 15 “essential” candidate genes were identified as 
having lower AP staining values than Oct4, which has been reported to decrease 
reprogramming efficiency when knocked down (Heng et al., 2010; Samavarchi-
Tehrani et al., 2010), and I reasoned that if knock down of one of these genes 
impeded reprogramming more than Oct4 then expression of that gene may be 
required during reprogramming. This could subsequently be tested with 
overexpression during reprogramming. In addition to siRNA data, the Samavarchi-
Tehrani study also included a microarray time course analysis of gene expression 
during reprogramming. This data set was analyzed in conjunction with the 
O’Malley RNA-seq data resulting in elimination of 8 and 6 genes from the “barrier” 
and “essential” candidate lists, respectively, as they only exhibited the UP-DOWN 
pattern in one data set. Thus, from this approach 39 potential “barrier” gene 
candidates and 4 potential “essential” gene candidates were determined. 
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In addition to these 43 candidates, I made use of unpublished microarray 
data that I generated during previous work investigating a highly stable iPSC line, 
C7s2.11, which had lost the capacity to differentiate after it was established from 
reprogramming of MEF. I reasoned that genes which were strongly up-regulated or 
down-regulated in this cell line compared with ESCs might represent genes that 
play an important role in the acquisition and/or maintenance of pluripotency and 
consequently it would be interesting to including them in my knock down 
screening. This strategy gave rise to 11 additional candidates. In total, an initial 
candidate gene list of 54 genes was determined for testing in an RNAi knock down 





9930023K05Rik (Rik) Mxi1 Taf1b 
Adrb2 Nagk Tcfap2a 
Asprv1 Nfe2l3 Tlx2 
Bhmt2 Ovol Fosb 
Bmp8b Peg3 Foxj2 
Cldn4 Perp Jun 
Dmkn Phox2a Nfatc2 
Dmrtc2 Phox2b Aldh3a1 
Drp2 Plcd3 Dkkl1 
Elf4 Prx Ephx1 
Elf5 Rapgef4 Fetub 
Hand1 Rhox6 Hmgn3 
Hat1 Rhox9 Pnpla3 
Krtdap Scel Rac3 
Lgals7 Sfn Tgm2 
Map3k6 Smyd1 Dclk2 
Map3k8 Spink2 Dok2 
Mid1 Stk19 Emp2 
Table 3.1. List of candidate genes identified from published and unpublished data 
sets. Candidate genes identified from the O'Malley et al. (2013) and Samavarchi-Tehrani et 
al. (2010) data sets are grouped according to identification as UP-DOWN genes >AP+ than 
p53 siRNA genes (orange) or UP-DOWN genes <AP+ than Oct4 siRNA genes (blue). 
Genes identified from unpublished microarray data are grouped according to identification 
as highly expressed in C7s2.11 iPSCs compared with ESCs (green) or highly expressed in 
ESCs compared with C7s2.11 iPSCs (yellow). 
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3.2.2. A retrovirus-based shRNA expression vector for efficient knock down of 
target genes 
 
Reprogramming is a notoriously inefficient and slow process. In addition, 
using transient siRNA transfection for knocking down genes during 
reprogramming can also be ineffective at reducing gene expression to a suitable 
level. With these drawbacks in mind it was important to design a highly efficient 
and practically straightforward system for screening the knock down of candidate 
genes during reprogramming. In order to do this, several points were considered: 
 
(1) Reprogramming is inefficient and typically less than 1% of cells become 
iPSCs. 
 
(2) Reprogramming is highly heterogeneous and many factors influence the 
success of reprogramming including the reprogramming system used, 
specific reagents used, the condition of starting cells etc. and this can make 
interpretation of reprogramming data difficult from one experiment to the 
next. 
 
(3) For this screening, cells must contain all four reprogramming factors in 
addition to the knock down vector; both induction of reprogramming and 
stable transfection of shRNA must be efficient. 
 
(4) RNAi knock down systems are complicated and can be ineffective at 
reducing gene expression to a sufficient level to induce a phenotype and 
additionally different genes require different levels of knock down to have 
an effect. 
 
We use a robust and reproducible reprogramming system taking advantage 
of transgenic MEF carrying a polycistronic cassette encoding the four 
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reprogramming factors, c-Myc, Klf4, Oct4 and Sox2, under control of a tetO 
doxycycline-inducible promoter, and constitutively expressed reverse tetracycline 
transactivator (rtTA) (Figure 3.2). The four factors are separated with self-cleaving 
2A-peptides and followed by ires-mOrange, allowing clear visualisation of 
expression of the transgene cassette. In addition the MEFs harbour a GFP reporter 
under control of the endogenous Nanog promoter, a gene that is expressed towards 
the end of reprogramming when cells acquire pluripotency. We use the expression 
of Nanog-GFP as a read out of reprogrammed cells/colonies (referred to as ‘colony 
counting’ herein). This system limits some of the heterogeneity of reprogramming 
by ensuring all transgenic cells, at least in theory, have equal capacity to express the 
four factors at similar levels (this reprogramming system will be referred to as 





Figure 3.2. Generation of transgenic MEFs for reprogramming. A doxycycline-inducible 
vector containing MKOS and mOrange reporter was targeted in ESCs containing a Nanog-
GFP reporter. These cells were used to generate chimeric mice from which transgenic 
MEFs were isolated. Expression of MKOS was induced with administration of dox and 
visualized with mOrange expression and Nanog-GFP+ iPSCs were generated. 
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To knock down my candidate genes, I designed a retrovirus based short 
hairpin RNA (shRNA) expression vector, building on the pRetroSuper plasmid 
backbone, containing dual converging RNA polymerase III promoters, U6 and H1. 
This dual promoter system enabled the shRNA to be expressed in both directions 
thereby ensuring high expression of shRNA could be achieved from a single vector 
(Zheng et al., 2004; Chen et al., 2005). In addition, a BbsI restriction enzyme site was 
introduced between the two promoters, enabling highly efficient cloning of any 
shRNA sequence of interest. A virus packaging cell line, PlatE, was transfected with 
each shRNA vector to produce virus supernatant containing retrovirus-carrying 
shRNAs. This supernatant was then used to infect our transgenic MEFs for 24 hours 
and replaced with dox containing medium to initiate reprogramming. The 
reprogramming cultures were monitored every day for appearance of iPSC colonies 
and Nanog-GFP+ colonies were counted from day 10 onwards (Figure 3.3). 
One of the main drawbacks of using an shRNA knock down system is that 
designing oligos targeting your gene of interest is based on computational 
algorithms following a set of ‘guideline rules’. The sequences are not experimentally 
validated and as such are not guaranteed to efficiently target a gene resulting in 
knock down. Although it is possible to scan the literature to find sequences that 
have been reported to efficiently knock down specific genes, this is not feasible for a 
larger scale screen, particularly involving genes that have not been widely studied 
or well characterized. Consequently, it is advised to test more than one shRNA 
sequence for each gene of interest in order to increase the likelihood that knock 
down can be achieved. For this reason, I chose to design three shRNAs per gene of 
interest (denoted P1, P2 or P3), resulting in construction of over 150 vectors 
representing the candidate genes. For an unknown reason, cloning of some of the 
shRNAs was difficult and could not be completed for all shRNAs targeting each of 
the 54 candidate genes as persistent mutations occurred. As a result, shRNA vectors 
were generated for only 44 of the 54 original candidate genes, with some candidates 
represented by less than 3 vectors, in addition to control vectors targeting LacZ. A 
retroviral vector expressing DsRed (pMXs-DsRed) was used as a virus infection 
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control and by FACS analysis I could reproducibly achieve 50-75% infection 











Figure 3.3. Schematic of shRNA knock down of candidate genes during 
reprogramming. pRetroSuper shRNA vectors were cloned for each candidate gene and 
used to make virus supernatant with which transgenic MEF carrying doxycycline-inducible 
four reprogramming factors were infected. Dox was administered to initiate reprogramming 
and Nanog-GFP+ colonies were counted from day 10 onwards. 
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3.2.3 A custom shRNA screening to identify novel regulators of reprogramming 
 
Five initial rounds of reprogramming with individual shRNAs were carried 
out as a first pass screening. Approximately 24 to 38 shRNAs were tested in each 
experiment with all shRNAs representing any given gene tested together within the 
same experiment to enable side-by-side comparison. However, it is important to 
note that since viral titre was not determined for each shRNA in any of the 
experiments, and only DsRed was used as an infection control, it is highly likely 
that the viral titre produced for each shRNA differed. As such, these preliminary 
experiments were being used to determine several things; 1) To confirm that 
method of shRNA vector transfection could successfully produce viral supernatant, 
2) To confirm that any virus supernatant produced could successfully infect MEF, 3) 
To determine whether the transgenic MEF could still undergo reprogramming upon 
retroviral infection and finally 4) To determine if the addition of any of the 
candidate shRNAs to reprogramming cells enhances or hindered the generation of 
Nanog-GFP+ iPSCs, when compared with the control. From experience of using this 
reprogramming system within our lab, we know that Nanog-GFP+ colonies 
typically establish by around day 10 and therefore Nanog-GFP+ colonies were 
counted on days 10, 13 and 15 for this preliminary screen (Figure 3.4). 
For all experiments 5% transgenic MEFs were plated in 6 wells, with wild 
type MEF used to dilute the cells to the appropriate ratio. This equates to 
approximately 5000 transgenic cells per well that are capable of reactivating the 
reprogramming factors upon dox treatment and undergoing reprogramming. With 
this in mind, it should be noted that our Tg reprogramming system is highly 
efficient, as can be seen from the experiments where uninfected MEF were 
reprogrammed (Figure 3.3). In these experiments, the reprogramming efficiency 
varied between 2-7%. An initial observation found that infection of MEF with 
retroviral shRNAs significantly hindered reprogramming of transgenic cells, as 
evident from a substantial decrease in Nanog-GFP+ colony number in DsRed and 
shLacZ conditions when compared with uninfected reprogramming conditions. It 
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seems that viral infection and/or expression of exogenous shRNA is somewhat toxic 
to the cells. Despite this, even with reduced efficiency the control shLacZ condition 
continued to display reprogramming efficiencies of typically 1-3%, which is higher 
than many reported reprogramming systems. 
When shRNAs targeting candidate genes were tested, several generated an 
increased number of Nanog-GFP+ colonies when compared to shLacZ control on 
day 15, and a few shRNAs even generated more colonies than the uninfected 
condition including shRNAs targeting Aldh3a1, Rac3, Emp3, Nagk and Dmrtc2. 
Interestingly even as early as day 10 many shRNAs were found to give several fold 
increase in Nanog-GFP+ colonies, indicating that knock down of these genes might 
enhance reprogramming kinetics in addition to enhanced efficiency. The most 
significant of these included shRNAs targeting Rhox9, Hand1, Mxi1, Nfe2l3, 
Phox2a, Phox2b, Prx, Rapgef4, Aldh3a1, Dkkl1, Rac3, Emp2, Elf4 and Dmrtc2. 
Notably, an shRNA targeting Dmrtc2 (shDmrtc2 P3) was determined as a 











Figure 3.4. Effect of candidate shRNAs during reprogramming. Five initial 
reprogramming experiments reveal shRNAs that enhance or inhibit generation of Nanog-
GFP+ colonies during reprogramming of transgenic MEF. Bars represent the average 
number of Nanog-GFP+ colonies counted from 2 independent wells for each shRNA. 
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A number of shRNAs also resulted in a decrease in colony number, 
representing a number of potential “essential” gene candidates for reprogramming. 
These included shRNAs targeting Ovol1, Sfn, Fosb and Tgm2. Interestingly, Ovol1 
has been implicated in driving MET in cancer (Roca et al., 2013), Sfn (also known as 
14-3-3σ) plays a role in proliferation of ESCs through binding of GSK-3β (Chang et 
al., 2012), Fosb has been identified as a reprogramming factor for generating 
induced haematopoietic stem cells from HUVECs (Lucas and Frenette, 2014) and 
Tgm2 is an enzyme that has been implicated with diverse roles in cell adhesion, 
proliferation and apoptosis depending on it’s locality within the cell (Nadalutti et 
al., 2011). Thus, some of these genes might feasibly play a role as positive regulators 
or enhancers of reprogramming, although the specific knock down of these genes 
was not validated. The effect of these shRNAs during reprogramming was not 
followed up with overexpression experiments to see if expression of their cDNA 
together with Yamanaka factors could enhance reprogramming. This was because 
reduction of reprogramming efficiency can be caused many reasons and even 
control shRNA vector infection causes reduced reprogramming efficiency compared 
to a non-infection control. Less iPSC colonies by an shRNA may be due to higher 
off-target toxicity of the shRNA. Moreover, this initial screen already identified 
several potential ‘barrier’ candidates. We imagined an enhanced reprograming 
phenotype was less likely to be caused by off-target effects.   Nonetheless, further 
investigation of the “essential” candidates mentioned above is a potential avenue of 
further study. 
Going forward, 20 shRNAs representing 17 genes were chosen for further 
validation during further rounds of reprogramming. This second round of 
screening enabled exclusion of many candidates as there was no significant 
difference compared with control in the number of Nanog-GFP+ colonies at day 10 
or later. However, several shRNAs gave rise to a 5 to 10-fold increase in the number 
of Nanog-GFP+ colonies at day 10, compared with control. These included shRNAs 
targeting Emp2, Rac3, Rhox9, Dkkl1 and Elf4 (Figure 3.5). Additionally, this 
experiment confirmed the earlier observation that one shDmrtc2 P3 in particular 
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induced a significantly enhanced reprogramming phenotype. Remarkably, at day 10 
around a 45-fold increase in Nanog-GFP+ colony number was observed and by day 
14 a 10-fold increase was maintained when this shRNA was expressed. This is at a 
time point when we know that most colonies have become iPSCs and express 
Nanog-GFP. This finding indicated that not only did shDmrtc2 P3 enhance 
reprogramming efficiency in terms of the total number of colonies obtained at the 
end of reprogramming, but also accelerated reprogramming kinetics as 





































































































































































































































Figure 3.5. Further validation of candidate shRNAs during reprogramming. Most 
shRNAs could be excluded from these results for further testing as no significant difference 
in Nanog-GFP+ colony number was observed when compared with control. However, 
several shRNAs were identified as enhancers of reprogramming, including those targeting 
Emp2, Rac3, Rhox9, Dkkl1, Elf4 and most significantly Dmrtc2.   
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In addition to assessing the number of Nanog-GFP+ colonies during 
reprogramming I also took advantage of a technique developed in our lab using 
fluorescence activated cell sorting (FACS) analysis to track cells as they undergo 
reprogramming using novel cell surface markers ICAM1 and CD44 (O'Malley et al., 
2013). During reprogramming, cells express ICAM1 heterogeneously and are 
positive for CD44 expression. As reprogramming progresses, ICAM1 is down-
regulated followed by down-regulation of CD44 and finally, as cells become iPSCs 
they once again express high levels of ICAM1. This ICAM1+/CD44- position is 
where iPSCs and ESCs are found (Figure 3.6a). This technique allows for changes in 
the ‘normal’ or ‘typical’ FACS profile to be easily identified, for example if the cells 
move through the ‘reprogramming route’ at a faster rate, and thus is an ideal tool to 
identify if an added factor has a positive effect on reprogramming kinetics. This 
analysis also takes advantage of the Nanog-GFP reporter carried by the cells, 
enabling the percentage of reprogramming (transgenic) cells that express Nanog-
GFP to be determined at any time point throughout the experiment. Again, this can 
be used as further validation if an added factor has a positive effect on 
reprogramming.  
I chose to perform FACS analysis for three top shRNAs based on the 
preliminary Nanog-GFP+ colony count data; shDmrtc2 P3, shDkkl1 P3 and shEmp2 
P2. I predicted that if any of these shRNAs did indeed enhance reprogramming 
efficiency then I would observe an increase in the percentage of Nanog-GFP+ cells 
and if there was a positive effect on the timing or kinetics of reprogramming then I 
would observe the cells moving through the ICAM1/CD44 profile faster and/or 
expressing Nanog-GFP earlier. Indeed this is what I observed; as expected, the 
shLacZ control and uninfected samples exhibited similar FACS profiles throughout 
the time course as reported by O'Malley et al. (2013). Albeit there were more Nanog-
GFP+ cells in the uninfected sample (28%) compared with shLacZ (2%) at day 10 
(Figure 3.6b). This is unsurprising given that infection with retrovirus of the 
shRNAs seems to be somewhat toxic as mentioned previously, however, by day 13 
both conditions give rise to a similar proportion of Nanog-GFP+ cells. In contrast, all 
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three shRNAs had a positive effect on reprogramming. shDkkl1 P3 gave rise to 56% 
Nanog-GFP+ cells at day 13 compared with 36% for shLacZ. In addition, the 
appearance of Nanog-GFP+ cells was already evident around day 7 of 
reprogramming compared with day 10 for shLacZ. Even more strikingly, shEmp2 
P2 gave rise to 69% Nanog-GFP+ cells at day 13 and by day 10 had already matched 
the percentage observed in the uninfected condition. The most pronounced result, 
however, was observed for shDmrtc2 P3. By day 10, 58% of cells were already 
positive for the pluripotency marker Nanog-GFP, increasing to 77% by day 13. Even 
more remarkably, there was a clear acceleration in the rate of reprogramming 
observed with most cells already having down-regulated CD44 and many up-
regulating ICAM1 by day 7. This is consistent with two to three day acceleration in 
the rate of reprogramming compared to control. This striking result led me to focus 

































Figure 3.6. FACS analysis of ICAM1, CD44 and Nanog-GFP expression in cells 
undergoing reprogramming. (a) Cells undergoing reprogramming follow a specific “route to 
iPSCs” determined by ICAM1 and CD44 expression (adapted from O'Malley et al. (2013)). (b) 
Addition of shDkkl1 P3, shEmp2 P2 and shDmrtc2 P3 give rise to enhanced reprogramming 
efficiency with shDmrtc2 P3 showing significantly faster ICAM1/CD44 kinetics as early as day 






3.3.1 shRNA is a powerful tool to identify novel regulators of reprogramming 
 
These initial experiments have provided evidence to support published 
studies that shRNA can be a powerful tool to knock down gene expression, and in 
this case to successfully uncover novel roles for genes during reprogramming. 
shRNA expression vectors containing dual RNA Polymerase III promoters, U6 and 
H1, were used in this study over the option to purchase synthetic siRNA for several 
reasons. Firstly, siRNA can be a costly option, particularly when many siRNAs are 
required to knock down many genes, for example in the case of an siRNA library 
with prices usually upwards of several thousands of pounds. In contrast, the 
shRNA vectors used in this study were constructed at a low cost, facilitated by the 
fact that the pRetroSuper backbone was able to be propagated indefinitely, and the 
shRNA cloning technique was highly efficient resulting in quick and easy 
validation. In addition, contrary to the transient nature of siRNA, shRNA 
expression vectors allowed for persistent and high expression of shRNAs within the 
reprogramming cells, alleviating the requirement for serial transfection as is 
required with siRNA which is depleted in cells over time unless replenished by 
further transfections. The fact that reprogramming cells form colonies may even 
hinder or abolish the possibility of efficiency repeated siRNA transfection during 
reprogramming. Furthermore, since I had devised a relatively small candidate list, 
the screen was practically simple and specific shRNAs targeting the genes of 
interest could be tested individually, abrogating the need to carry out pooled 
shRNA experiments which can make interpretation and validation of results more 
complicated and time consuming. In other words, positive or negative hits could be 
easily traced to specific genes without the need for further screening to link a 
phenotype to one of many pooled shRNAs. One potential drawback of both siRNA 
and shRNA-mediated knock down in vitro has been identified in reports that 
overload of ectopic si/shRNAs can compete with endogenous miRNAs for 
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processing machinery and lead to toxicity as a result (Grimm et al., 2006). However, 
designing Ago-2 specific RNAi is one way to alleviate this miRNA perturbation (Ma 
et al., 2014b). It seems that the shRNA expression vectors used in this study were 
somewhat toxic to cells when compared with an uninfected control and it was 
unknown whether this was due to virus infection of cells or shRNA expression 
itself. However, infection of cells with a pMXs-DsRed vector gave rise to similar 
results as shLacZ infection, suggesting that it was virus infection in general rather 
than shRNA expression that is toxic. Since several shRNAs in our screening gave 
rise to enhanced reprogramming even when compared with the uninfected control, 
this phenomenon didn’t seem to be a major factor in this context. In fact comparison 
of candidate shRNAs to the uninfected control ensured that only shRNAs that gave 
rise to a greatly enhanced reprogramming phenotype were taken forward in the 
study as these were predicted to be the most likely to have reproducible and robust 
effect. 
Another point for consideration is our use of a dual promoter vector using 
converging U6 and H1 promoters to express shRNAs from both strands of the same 
DNA template. Having had limited experience or expertise within our lab of using 
RNAi at the start of this study, we theorized that a dual promoter system would be 
more likely to ensure high expression of shRNA than a single promoter system. 
Indeed it has been widely reported that a U6/H1 dual promoter RNAi expression 
vector can mediate efficient gene knock down (Kaykas and Moon, 2004; Zheng et 
al., 2004; Chen et al., 2005). Early experiments comparing single U6 promoter 
vectors with dual U6/H1 converging promoter vectors in our hands gave 
inconclusive results as to whether one system was more efficient than the other (not 
shown), and as such we opted to proceed with the dual promoter vector with the 
reasoning that it had the potential to produce a higher level of shRNA expression. 
As already briefly mentioned, the reprogramming system we use in our lab 
is generally robust and highly efficient. However, as can be seen clearly in the data 
presented within this chapter, the number of iPSC colonies generated during each 
reprogramming experiment is greatly variable, even for the same batch of 
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transgenic cells reprogrammed in the same way. Another difficulty comes with 
additional layers required for reprogramming experiments, for example, the 
necessity for virus infection in these experiments provides a further source of 
variability to the results. Nonetheless, results were easily reproducible in terms of 
the phenotype observed, however, consideration must be made to take into account 
the interpretation and presentation of these data.  
When these considerations are taken together, this shRNA screening proved 
to be a powerful tool to identify several novel regulators of reprogramming, with 




3.3.2. FACS analysis of ICAM1 and CD44 is a useful tool for studying 
reprogramming kinetics  
 
 It is commonplace in the reprogramming field to quantify reprogramming 
efficiency as the number iPSC-like colonies generated from an initial number of 
reprogramming cells at a certain arbitrary time point. Furthermore, although many 
studies have identified factors or small molecules as enhancers of reprogramming 
efficiency, few studies have reported drastic or reproducible improvement in the 
kinetics, or timing, or reprogramming. And since reprogramming is widely known 
to be a slow and inefficient process, the identification of shDmrtc2 P3 as both an 
enhancer of reprogramming efficiency and kinetics is an exciting prospect. In 
conjunction, the ICAM1/CD44 FACS analysis technique developed in our lab has 
provided a unique tool with which investigation of reprogramming kinetics is easy 
and clear. We can determine, literally at a glance, whether any 
condition/factor/small molecule has a significant effect on reprogramming using 
this method, and when used in conjunction with additional markers such as Nanog-
GFP, a more complete picture of the route by which any given cells undergo 
reprogramming can be produced. In addition to enhancement, aberrations or 
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barriers can also be easily identified, and when investigating several factors (in this 
case several different shRNAs), a meaningful comparison can be made and robust 
conclusions drawn since single cells are analysed and visualised, as opposed to 
using somewhat arbitrary or subjective methods such as colony counting to 
determine reprogramming efficiency. 
 
 
3.3.3. The importance of experimental controls 
 
Since these reprogramming experiments were carried out in conjunction 
with retroviral transduction (to express the shRNA vectors), it was important to 
determine what impact, if any, viral transduction would have on reprogramming 
efficiency and furthermore to choose an appropriate shRNA control for which to 
compare all candidate gene shRNAs with. Notably, it was clear that viral 
transduction had a detrimental effect on reprogramming, as several fold fewer 
Nanog-GFP+ colonies were observed when cells were transduced either with a 
retroviral shRNA or non-shRNA control vector. When initially designing control 
shRNA vectors, a number of vectors were tested side by side and shLacZ was 
determined at the time to be the most appropriate shRNA control for a number of 
reasons. Firstly, an shRNA targeting LacZ was thought to have few or no off-targets 
since LacZ is not a gene expressed in the mouse, and therefore it was reasoned that 
this vector should produce shRNA without a target (and therefore have little or no 
effect on reprogramming). Secondly, when tested alongside a non-shRNA retroviral 
vector (pMXs-DsRed), a consistently similar number of Nanog-GFP iPSC colonies 
were observed in experiments. This suggested that the decrease in reprogramming 
efficiency when compared with the uninfected control was probably due to viral 
transduction rather than toxicity of shRNA production. Thirdly, another shRNA 
targeting a different sequence of LacZ (shLacZ P2) was also tested, however, this 
gave rise to a similar number of Nanog-GFP+ colonies as the uninfected control. 
One reason for this could be that viral production/infection was inefficient with this 
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vector so it was excluded as a reliable control. Based on these observations it was 
determined that shLacZ would be an appropriate control vector. In hindsight, it 
would have been useful to have a positive shRNA control, for example targeting 
p53. Knock down of p53 is well reported to enhance reprogramming efficiency and 
this could have been a useful control to determine the extent of any positive effects 
observed with transduction of group B candidate gene shRNAs on reprogramming. 
Although I am confident that I have identified several shRNAs that enhance 
reprogramming efficiency and kinetics in this chapter, by including an shRNA that 





CHAPTER 4 - Investigation of shDmrtc2 as a novel positive 




 Dmrtc2, also known as Dmrt7, is a protein-coding gene belonging to the 
doublesex and mab-3-related transcription factor (Dmrt) family. This family of 
genes contains a characteristic cysteine-rich DNA binding motif known as the DM 
domain. This facilitates DNA binding through a highly intertwined structure that 
chelates zinc, allowing binding to the major groove of DNA. Outside of this DM 
domain, the genes have very little sequence similarity. Interestingly, Dmrt7 and 
Dmrt8 are only found in mammals and no other vertebrate species, suggesting they 
are mammalian specific Dmrt genes (Hong et al., 2007). Dmrtc2 is expressed in 
embryonic gonadal tissue, specifically the ovary or testes with higher abundance 
found in the female rather than male gonads. However, Dmrtc2 becomes expressed 
in a male-specific manner postnatally and is required for spermatogenesis. Dmrt7 
knock out mice have been generated by gene targeting and were found to be 
developmentally indistinguishable from littermates and could grow into adulthood 
suggesting Dmrt7 is dispensable for embryonic development. However mutant 
mice were infertile and no sperm could be detected in the epididymis of Dmrt7-/- 
males (Kawamata and Nishimori, 2006). This is reportedly due to an arrest of 
spermatogenesis at the pachytene stage of meiosis (Kim et al., 2007). Interestingly, 
there has been very little reported on this gene in recent years. 
RNAi can be a very useful but imperfect system for knock down of gene 
expression. Since RNAi systems utilize endogenous machinery to process si/shRNA, 
there are a number of factors that must be considered and validated when using 
such systems to ensure not only robust knock down of genes of interest but also to 
ensure confidence that the results obtained are a direct consequence of specific 
knock down of a gene and not some other secondary cause or effect which can be a 
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common problem with RNAi strategies (Singh et al., 2011; Jackson et al., 2003; 
Echeverri et al., 2006). Indeed, published studies usually provide functional 
validation of genes identified through RNAi screens (Yang et al., 2014; Qin et al., 
2014). At the very least, a hit obtained through RNAi studies should be validated by 
further RNAi targeting the proposed gene, and where possible, a rescue experiment 
should be carried out to confirm that overexpression of the gene, in a form that 
cannot be targeted by the RNAi, abolishes the phenotype observed with knock 
down (Kittler et al., 2005). 
 
 
4.1.1. Aims of this chapter 
 
In the previous chapter an shRNA targeting Dmrtc2 was identified to 
significantly enhance Nanog-GFP+ colony number and kinetics when applied 
during reprogramming of transgenic MEF. Following on from this the aims of this 
chapter are to characterize further the effect of shDmrtc2 during reprogramming, to 
validate that shDmrtc2 does target Dmrtc2 causing knock down of this gene at an 
mRNA level as expected and to further validate whether it is the knock down of 
Dmrtc2 that is responsible for the positive phenotype observed during 














4.2.1. Validation of shDmrtc2 as an enhancer of reprogramming efficiency and 
kinetics 
 
Following on from identification of shDmrtc2 as a positive regulator of 
reprogramming, several repeat experiments were conducted with shDmrtc2 in 
order to confirm that the strong positive phenotype observed was in fact true and 
reproducible. This was particularly important because of the variability of 
reprogramming which can make consistency in reprogramming data difficult, not 
least between labs but even within the same hands. To overcome this, I carried out 
several additional experiments to be certain that the phenotype observed using 
shDmrtc2 during reprogramming was reproducible. 
Firstly I confirmed that the increased reprogramming efficiency conferred by 
shDmrtc2 during reprogramming could be replicated. Indeed, upon repeating 
several more colony counting experiments, I could faithfully reproduce my 
previous results; addition of shDmrtc2 to reprogramming resulted in over 40-fold 
increase in Nanog-GFP+ colonies compared to shLacZ  (Figure 4.1a). Although the 
total colony number varied between experiments I consistently observed increased 
relative colony numbers in the shDmrtc2 sample compared with both the 
uninfected and shLacZ samples indicating that this is a real phenotype due to the 
shDmrtc2 vector (Figure 4.1b). 
Since addition of shDmrtc2 in reprogramming resulted in many Nanog-
GFP+ colonies appearing by day 10 and FACS analysis indicated the presence of 
Nanog-GFP+ cells as early as day 7 I sought to determine the earliest time point at 
which Nanog-GFP+ colonies emerged during reprogramming with shDmrtc2. To do 
this I monitored the appearance of colonies during reprogramming and tracked 
individual colonies throughout their progression to iPSCs (Figure 4.2). Within only 
a few days of reprogramming induction, a change of cell morphology was clearly 
evident in the shDmrtc2 condition, with cells becoming more compact and rounded 
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in shape, and clear formation of small foci in the cultures. Strikingly, I observed the 
appearance of bright green Nanog-GFP+ colonies as early as day 5 of 
reprogramming with shDmrtc2. By comparison, the first faint green colonies 
appeared on day 7 in the shLacZ control condition (Figure 4.2). This confirmed that 
the addition of shDmrtc2 to reprogramming resulted in at least a 2 to 3 day 
acceleration of the appearance of Nanog-GFP+ colonies compared with control. 
Given that reprogramming is a notoriously slow process, this was a particularly 



































































































Figure 4.1 Validation of shDmrtc2 
during reprogramming. Addition of 
shDmrtc2 during reprogramming 
reproducibly enhances the number of 
Nanog-GFP+ colonies by day 10 
compared with control, represented as 
fold-change relative to shLacZ (a) or 
absolute colony number from 3 















































Figure 4.2. Colony tracking reveals accelerated appearance of Nanog-GFP+ colonies 
with shDmrtc2 during reprogramming. Bright green Nanog-GFP+ colonies appeared as 
early as day 5 of reprogramming with shDmrtc2. By comparison, there was a 2 to 3 day 
delay in the appearance of Nanog-GFP+ colonies with shLacZ control. 
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Small molecule inhibition of Tgfβ receptor Alk5 (Alki) has been reported to 
enhance reprogramming and this has been confirmed in our lab (Li et al., 2009b; 
Maherali and Hochedlinger, 2009). The addition of Alki and vitamin C to 
reprogramming cultures is routinely used within our lab as a ‘best condition’ for 
reprogramming. That is, the most efficient reprogramming system in our hands. As 
such, we sought to find a novel factor that enhances reprogramming even further in 
these conditions and tested shDmrtc2 as a potential candidate. When Alki was 
added to the shRNA reprogramming cultures, an increased number of Nanog-GFP+ 
colonies were observed in the control conditions on day 9, as expected (Figure 4.3). 
Strikingly, in this enhanced condition shDmrtc2 resulted in a 5 to 8-fold increase in 
Nanog-GFP+ colonies in the uninfected and shLacZ controls, respectively. When 
reprogramming in the absence of Alki was carried out in parallel, Alki was 
surprisingly found to have a negative effect on reprogramming with shDmrtc2. In 
fact, in the absence of Alki, shDmrtc2 gave rise to approximately 14 to 100-fold more 
colonies than in both control conditions. Therefore, shDmrtc2 was found to greatly 





































Figure 4.3. The effect of Alki on 
reprogramming with shDmrtc2. 
Addition of Alki enhanced 
reprogramming efficiency in the 
uninfected and shLacZ control 
conditions but hindered 
reprogramming with shDmrtc2. 
Despite this, shDmrtc2 generated 
many fold more Nanog-GFP+ 
colonies than controls in all 
conditions.  
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After successfully confirming the phenotype in our transgenic 
reprogramming system, it was important to replicate this experiment using a 
different system to be confident that this result was not simply an anomaly of the 
reprogramming system used. Accordingly, I used a primary reprogramming system 
(see Chapter 2 – Materials and Methods) to test shDmrtc2. Briefly, to carry out 
primary reprogramming we use piggyBac transposon to deliver a polycistronic 
cassette carrying the four factors by co-transfection with piggyBac transposase into 
MEF constitutively expressing rtTA from the Rosa 26 locus (Rosa rtTA), and 
carrying a Nanog-GFP reporter. Again, four factor induction could be monitored by 
mOrange expression and Nanog-GFP+ colonies are counted from day 10. shDmrtc2 
was delivered by retrovirus infection as before, after transfection of the four factor 
cassette. Using this primary reprogramming approach I was able to successfully 
replicate the enhanced reprogramming phenotype (Figure 4.4), with over 30-fold 
more Nanog-GFP+ colonies counted with shDmrtc2 compared with shLacZ control, 
providing evidence that this phenotype is a robust and true result of addition of 














































Figure 4.4. Enhanced 
reprogramming with shDmrtc2 is 
reproducible in a piggyBac-
mediated primary reprogramming 
system. When shDmrtc2 was 
applied to primary reprogramming, a 
30-fold increase in Nanog-GFP+ 
colonies was observed on day 10, 
compared with shLacZ control. 
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Furthermore, consistent with previous data, when individual colonies were 
monitored, I could observe a 4 day acceleration in the appearance of Nanog-GFP+ 
colonies with shDmrtc2 compared with shLacZ in the primary reprogramming 
context (Figure 4.5). Bright green colonies were evident by day 10 during 
reprogramming with shDmrtc2 with the equivalent type of colony appearing in the 
control condition by day 14. Notably these time points are several days later than 
those observed in the secondary reprogramming system but this is likely due to the 
more efficient nature of secondary reprogramming compared with primary 





Figure 4.5. The shDmrtc2 effect on reprogramming is conserved between 
reprogramming systems. Addition of shDmrtc2 during primary reprogramming results in 
accelerated appearance of Nanog-GFP+ colonies by approximately 4 days when compared 
with control, supporting the data obtained in the secondary reprogramming context. 
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Following on from these results, I wanted to take advantage of the presence 
of a puromycin selection cassette contained within the Nanog-GFP reporter, 
allowing for Nanog expressing cells to be maintained in the presence of puromycin. 
I theorized that since shDmrtc2 accelerated the appearance of Nanog-GFP+ colonies 
during reprogramming, cells in this condition could be more amenable to surviving 
puromycin selection through earlier activation of Nanog and if so, I was interested 
to know how soon after administration of dox that puromycin selection could be 
applied while still enabling Nanog-GFP+ colonies to emerge during 
reprogramming. I carried out these experiments using our transgenic 
reprogramming system, plating approximately 2.5x104 transgenic cells (94% 
transgenic) per 6-well with dox remaining in the culture medium throughout. 
Remarkably, when 1 μg/ml of puromycin (puro) was administered as early as 1 day 
after initiation of reprogramming with shDmrtc2 and subsequently cultured for an 
additional 9 days in the presence of puro and dox, more than 450 puro resistant 
colonies survived demonstrating Nanog-GFP+ expression, compared with less than 
30 Nanog-GFP+ colonies with shLacZ,. This was more than a 16-fold increase 
suggesting that shDmrtc2 induces accelerated activation of Nanog (Figure 4.6). 
Furthermore, if puro was added 3 or more days after the start of reprogramming, 












































Figure 4.6. Accelerated activation of 
Nanog-GFP by shDmrtc2 confirmed 
by puromycin selection.  shDmrtc2 
enabled puromycin selection as early 
as 1 day after initiation of 
reprogramming demonstrating 
accelerated Nanog activation 
compared with control. Nanog-GFP+ 
colonies were counted on day 10 of 
reprogramming. 
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It should be clarified that these data provide evidence that cells become puromycin 
resistant before obtaining detectable GFP expression (cells were not GFP+ at day 1), 
while both transgenes connected by ires were expressed under the control of the 
endogenous Nanog promoter.  It is probably because different numbers of 
molecules are required for the detection of GFP and puromycin resistance. In other 
words fewer numbers of molecules may be required by cells to confer puromycin 
resistance than the molecules required for detection of GFP, hence the cells appear 
to be puromycin resistant at an earlier time point than when Nanog-GFP+ cells are 
detected. Nonetheless, these data demonstrate a significant difference in the ability 
of reprogramming cells to acquire puromycin resistance with shDmrtc2 compared 
with control, which is consistent with the observation that Nanog-GFP+ colonies are 
detected days earlier with shDmrtc2. Since dox was administered throughout these 
experiments to day 15, we don’t know if shDmrtc2 enables cells to become dox-
independent (and therefore transgene independent) at an earlier time point. This 
would be an interesting experiment, and I predict that shDmrtc2 would accelerate 
transgene independence of reprogramming cells. 
 
 
4.2.2. shDmrtc2 knocks down Dmrtc2 expression at an mRNA level 
 
The most important experimental validation required when using RNAi is to 
determine whether the shRNA does in fact target the gene of interest, in this case 
Dmrtc2. To do this I used quantitative RT-PCR (Q-PCR) to assess the expression 
level of Dmrtc2 in the knock down condition compared with control. As a reminder, 
Dmrtc2 expression is low in MEF, is up-regulated during the first days of 
reprogramming and subsequently down-regulated where it remains low in 
iPSCs/ESCs. Because of this transient up-regulation during reprogramming it was 
important to check expression levels for several time points to ensure that gene 
expression was being knocked down even at the time points when endogenous 
levels usually increased. I chose to analyze Dmrtc2 expression every day for the first 
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10 days of reprogramming for two reasons; 1) to confirm the UP-DOWN pattern of 
expression observed in the initial published data by O'Malley et al. (2013) and 
determine at what time point expression levels peaked and 2) to determine if 
Dmrtc2 expression levels were knocked down throughout reprogramming or for 
only a certain period. 
Since Q-PCR determines mRNA expression from a bulk sample, rather than 
single cells, it was important to use samples in which all or most of the cells were 
undergoing reprogramming. Therefore, I chose to carry out reprogramming using 
high contribution transgenic MEFs where >94% of cells were found to activate 
mOrange expression when dox was administered. Using these cells, I could initiate 
reprogramming with dox and use bulk reprogramming cultures at each time point 
for Q-PCR, negating the need for further manipulation of cells by flow cytometry. 
Samples were taken every day for 10 days of reprogramming for Q-PCR analysis to 
provide a high-resolution picture of Dmrtc2 expression during reprogramming with 
or without shDmrtc2. 
 I confirmed that shDmrtc2 expression was transiently up-regulated during 
reprogramming, as reported, and peaked at around day 4 followed by gradual 
down-regulation to the level found in iPSCs/ESCs by day 10 (Figure 4.7). 
Furthermore, shDmrtc2 was found to knock down expression of Dmrtc2 at an 
mRNA level as expected by approximately 60-80% compared with shLacZ and this 
knock down was maintained throughout the first 10 days of reprogramming (Figure 
4.6b). Interestingly, all time points with the exception of d1 exhibited knock down; 
given that the cells are infected with the shRNA viral supernatant 24 hours before 
reprogramming is induced, this result suggests that it took approximately 48-72 
hours for the shRNA to exert an effect. This is particularly notable since the first 
Nanog-GFP+ colonies in the shDmrtc2 condition could be detected by day 5, 
highlighting that the effect of shDmrtc2 is likely occurring within a very short time 




    




4.2.3. Additional shRNAs targeting Dmrtc2 do not replicate the phenotype 
 
Following confirmation of Dmrtc2 knock down by shDmrtc2, it was 
important to test further shRNAs targeting Dmrtc2. This was to determine if the 
phenotype could be replicated by knock down of Dmrtc2 by additional shRNAs 
targeting different sequences of Dmrtc2 mRNA, validating that the phenotype was 
specific to Dmrtc2 knock down and not resulting from non-specific knock down of 
another gene. I designed and tested 5 additional shRNAs (P1, P2, P4, P5 and P6) 
targeting independent sequences within Dmrtc2. As before, reprogramming was 









d1 d2 d3 d4 d5 d6 d7 d8 d9 d10 d1 d2 d3 d4 d5 d6 d7 d8 d9 d10



















































































Figure 4.7. Dmrtc2 expression during 
reprogramming. Transient up-regulation of Dmrtc2 
is observed during reprogramming (top panel, left). 
This is knocked down by shDmrtc2 (top panel, right 
and bottom panel). Bars represent the average of 2 
independent samples treated with the same shRNA 
virus supernatant batch, and are representative 
and consistent with Dmrtc2 expression observed in 
other experiments using different virus supernatant 
batches. 
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colony numbers were counted at different time points. Additionally, the extent of 
Dmrtc2 knock down in the presence of each new shDmrtc2 shRNA was determined.  
Interestingly, none of the additional shRNAs enhanced reprogramming 
efficiency or kinetics based on Nanog-GFP+ colonies counted. Addition of P1, P5 
and P6 in reprogramming gave rise to a moderate 2-fold increase of Nanog-GFP+ 
colonies at day 12 compared with control, however, this was not comparable to the 
6 to 7-fold increase demonstrated by P3 (Figure 4.8a). Furthermore, none of the 
additional shRNAs gave rise to a significant number of early appearing Nanog-
GFP+ colonies by day 8, as observed with P3. Surprisingly, when the expression 
level of Dmrtc2 for each condition was checked by Q-PCR, three out of the five 
additional shRNAs knocked down expression comparable to P3 (Figure 4.8b). P1 
and P5 resulted in no knock down even though both of these shRNAs induced a 
moderate increase in Nanog-GFP+ colonies by day 12. P2, P4 and P6 on the other 
hand reduced mRNA levels by approximately 50%, (similar to P3) but despite this, 
none of these shRNAs gave rise to the increased efficiency or kinetics demonstrated 
by P3. This unexpected result gave an indication that knock down of Dmrtc2 may 
not in fact be responsible for the phenotype observed by addition of shDmrtc2 P3 














4.2.4 Overexpression of Dmrtc2 does not rescue the phenotype 
 
A rescue experiment was carried out following these unexpected results, 
with a view to gain clarification of the suspicion that an off-target effect may be 
underlying the phenotype. If knock down of Dmrtc2 mediated by shDmrtc2 P3 was 
responsible for the enhanced reprogramming then I expect that overexpression of 
Dmrtc2 (which lacks target sequence of shDmrtc2 P3) would compensate for the 
effect of the knock down and ‘rescue’ or reverse the positive phenotype. In other 
words I would anticipate no effect on reprogramming in this context if knock down 
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Figure 4.8. Additional shRNAs do not replicate the reprogramming phenotype 
observed with shDmrtc2 P3. No enhancement of reprogramming is observed with addition 
any alternative shRNA targeting Dmrtc2 (a), however shRNAs P2, P4 and P6 knock down 




validation experiment within the RNAi field (Kumar et al., 2006). To induce ectopic 
overexpression of Dmrtc2 in reprogramming cells, I created a retrovirus 
overexpression vector encoding the cDNA of Dmrtc2 (pMXs-Dmrtc2) and co-
transfected this with shDmrtc2 P3 during reprogramming. It is important to note 
here that the targeting sequence of shDmrtc2 is complementary to a region within 
the 3’-UTR of the Dmrtc2 mRNA. pMXs-Dmrtc2 was constructed using the Dmrtc2 
cDNA, which does not include the 3’ UTR, and so it is refractory to targeting by 
shDmrtc2. Therefore, only endogenously expressed Dmrtc2 should be knocked 
down, with the overexpression vector compensating for this. A human CD2 
overexpression vector (pMXs-hCD2) was used as a control for the Dmrtc2 
overexpression vector and Nanog-GFP+ colonies were counted on day 9 of 
reprogramming. The control conditions (shLacZ with either pMXs-hCD2 or pMXs-
Dmrtc2) gave rise to similar numbers of colonies and perhaps unsurprisingly, 
shDmrtc2 with either pMXs-hCD2 or pMXs-Dmrtc2 gave approximately 3 to 6-fold 
more Nanog-GFP+ colonies than the controls (Figure 4.9), indicating that 
overexpression of Dmrtc2 did not abolish the enhanced phenotype bestowed during 
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Figure 4.9. Overexpression of Dmrtc2 does not rescue the enhanced reprogramming 
phenotype induced by shDmrtc2. Despite overexpression of Dmrtc2, an increased colony 
number was still observed in the presence of shDmrtc2 P3 during reprogramming.  
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In parallel, the mRNA level of Dmrtc2 was checked by Q-PCR to ensure that 
overexpression by pMXs-Dmrtc2 was in fact occurring. In the context of 
overexpression by pMXs-Dmrtc2 in conjunction with knock down by shDmrtc2 
during reprogramming, Dmrtc2 expression levels were found to be at least 10 to 
100-fold higher compared with the control shLacZ condition, including at day 4 







Taken together, these data further supported the notion that regulation of 
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Figure 4.10. Q-PCR analysis of Dmrtc2 mRNA levels during reprogramming in control 
and overexpression conditions. Overexpression (OE) of Dmrtc2 with pMXs-Dmrtc2 in the 
presence of shDmrtc2 knock down (KD) shRNA confirms elevated expression of Dmrtc2, 





4.3.1 The importance of knock down validation when using RNAi 
 
 As demonstrated in this chapter, it is not enough to simply determine that a 
gene is specifically knocked down to have confidence that this is the cause of any 
phenotype observed. In addition to this basic validation, the phenotype should be 
replicated by knocking down the same gene with additional shRNAs targeting 
different sequences of the gene. In this study, 5 additional shRNAs targeting various 
regions of the Dmrtc2 gene were tested. When using RNAi for knock down 
experiments, it is typically advised that 3 to 6 si/shRNAs are tested for each gene of 
interest in order to reasonably expect at least one of them to faithfully reduce gene 
expression. Indeed, this was demonstrated here since I observed knock down of 
Dmrtc2 to similar levels in 4 out of the 6 shRNAs. As a result, I could be reasonably 
confident that the effect of shDmrtc2 was not due to repression of Dmrtc2, since all 
of the additional shRNAs tested failed to reproduce either the enhanced efficiency 
or acceleration of reprogramming observed with shDmrtc2, even moderately. 
Further to this, a rescue experiment showed that even in the presence of excessively 
high levels of exogenous Dmrtc2, the phenotype exerted by shDmrtc2 was able to 
persist, providing support that knock down of Dmrtc2 was not the mechanism by 
which reprogramming efficiency and kinetics was enhanced. Taken together, these 
validation results gave me confidence that an off-target event was the causal link 
between the addition of shDmrtc2 and positive effect on reprogramming. 
 
 
4.3.2 Gene specific knock down can be achieved with shRNA 
 
 The basic validation following discovery of a phenotype during 
reprogramming involved firstly confirming by Q-PCR that shRNAs used in this 
study knocked down genes in a specific manner (Josefsen and Lee, 2011). Q-PCR 
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data representing mRNA expression levels for Dmrtc2 confirmed that when 
compared with the normal levels of Dmrtc2 observed throughout reprogramming 
(in this case in the shLacZ condition), the addition of shDmrtc2 resulted in a knock 
down of Dmrtc2 mRNA by up to nearly 80%. Even at the time points at which 
Dmrtc2 was maximally up-regulated in the control, a 60% knock down was 
achieved.  
Knock down efficiencies vary greatly between RNAi systems used and in 
addition it is not difficult to imagine that different genes potentially require 
different levels of knock down to result in a phenotypic change (Mantei et al., 2008; 
Yang et al., 2014; Qin et al., 2014; Gingold et al., 2014; Berns et al., 2004; Paddison et 
al., 2002; Chen et al., 2005). Furthermore, validation by Q-PCR to assess knock down 
at the transcript level is not exhaustive. Since it is more often proteins and not 
mRNA that are the “end-point” functional effectors within cells, it is good practice 
to determine whether any knock down at mRNA level is reflected in a knock down 
at the protein level by Western Blot analysis. This can provide useful information, 
particularly in a case where knock down is seen at the mRNA level, but no 
phenotype results. In this case, investigation of the protein output for the gene of 
interest may indicate that there is no reduction of protein levels, as may be the case 
for particularly stable or long lasting proteins, and hence no phenotype has resulted 
from mRNA knock down. It has been suggested that for some genes, a knock down 
of more than 95% at the transcript level is required before changes in the protein 
product can be seen (Moffat and Sabatini, 2006) so it is important in some cases to 
verify a reduction in protein levels in addition to Q-PCR validation. With 
substantial ongoing research into the mechanisms of RNAi, more and more is being 
discovered about RNAi processing machinery and the importance of RNAi design 
to facilitate increasing knock down efficiencies (Schwarz et al., 2003). However, with 
new gene editing technologies such as CRISPR and TALEN becoming more 
accessible (Bogdanove and Voytas, 2011; Shalem et al., 2014; Wang et al., 2014; 
Wang et al., 2013a), with which gene knock out can easily be achieved, it is likely 
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that the use of RNAi will become less commonplace as a championed gene 
interference technology. 
In addition to variance in knock down efficiency, it is important to make a 
point here about the variability of reprogramming and the subsequent implications 
on data. A good example of this can be seen in the colony counting experiments for 
shDmrtc2; although I could very faithfully reproduce the phenotype inferred by 
shDmrtc2, and thus I am confident that it is a true result, the variable nature of 
reprogramming very often results in wildly different numbers of colonies being 
produced between experiments, despite the fact that the same materials and 
reagents are used for each experiment. This is exemplified in Figure 4.1b; the results 
for three independent reprogramming experiments are shown and although they all 
confirm that shDmrtc2 gives rise to several fold more colonies than control, the 
absolute numbers of colonies in each experiment are drastically varied. This is also 
evident in the original screening experiments carried out in Chapter 3, Figures 3.3 
and 3.4. This can make representing data difficult; if I wanted to represent the data 
using absolute numbers of colonies then the standard deviation and subsequently 
error bars would be large. In order to circumvent this issue, I have represented the 
data as a fold-change value comparing shDmrtc2 to shLacZ (Figure 4.1a). 
 
 
4.3.3 Off-target effects are a potential consequence of RNAi 
 
 One of the main drawbacks of using RNAi in gene knock down studies is 
the phenomenon of off-target effects. That is, the unspecific action of an si/shRNA 
on an unintended target causing an unwanted effect (Jackson and Linsley, 2010). 
Off-target effects are a well-known side effect of using RNAi, and have been found 
to increase with increasing concentration of siRNA and sequence specificity 
(Jackson et al., 2003; Jackson et al., 2006). Off-target silencing can create problems for 
interpretation of data, particularly if several off-target events occur (see Chapter 6 – 
Discussion for more on this topic). As a general rule, off target silencing is an 
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unwanted phenomenon, but in the case of this study it appears that there is a 
significant and reproducible positive effect on reprogramming as a result of an off-
target. As such, my investigation of this reprogramming phenotype continues with 
a view to determine the off-target gene, to enable further characterization and 
functional importance in the context of reprogramming. 
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CHAPTER 5 – An off-target effect of shDmrtc2 underlies 




There has been much research on the topic of off-target effects of RNAi and 
with a multitude of sources being reported as potential causes of this unintended 
silencing, pinpointing the exact root is often complex and difficult. Indeed in some 
cases there may be a combination of factors in play. There is always the possibility 
of the guide strand finding imperfect pairing with some region of the 3’-UTR of an 
off-target mRNA, causing either cleavage or inhibition of translation which is 
known as miRNA-like off-targeting, since miRNAs primarily target 3’-UTRs for 
gene regulation. In particular, off-target effects of this type are commonly mediated 
by sequence complementarity of the 3’-UTRs of unintended targets to the si/shRNA 
seed region (Jackson et al., 2006). Interestingly, it was found that base mismatches in 
the seed region abolished silencing of some off-targets, but these were simply 
replaced with silencing of new unintended targets with complementarity to the 
resulting seed sequence (Jackson et al., 2003). Another unintended effect of ectopic 
shRNA expression is the competition with endogenous miRNAs for RNAi 
processing machinery. For example, it has been shown that overexpression of 
shRNA can saturate Exportin-5 (Exp5), a mediator of nuclear export required by 
shRNAs and pre-miRNAs, which comes at the expense of endogenous miRNA 
processing. This could be rescued with overexpression of Exp5 (Yi et al., 2003; Yi et 
al., 2005). It has also been reported that in the case of shRNAs, the positioning of the 
loop structure is crucial for correct Dicer cleavage into subsequent siRNA, and a 
deviant cleavage site can result in increased off-target effects due to promiscuous 
Dicer cleavage and incorrect shRNA processing (Gu et al., 2012). Thus, off-target 
effects are a common occurrence and it is unlikely that a perfect si/shRNA can be 
designed to completely abolish this phenomenon. The most that can be hoped for is 
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that any resulting off-target effects do not interfere with the ultimate goal of the 
RNAi being used, and that any phenotypes observed are true of the specific on-
target.  
During the previous chapter I provided evidence to suggest that the positive 
effect on reprogramming observed by the addition of shDmrtc2 was due to an off-
target effect of the RNAi; that is, shDmrtc2 acting on an unknown and unintended 
target caused the phenotype. Since the effect on reprogramming was substantial, I 
chose to move forward with my investigation of shDmrtc2 with a view to 




5.1.1 Aims of this chapter 
 
The aim of this chapter is to use single and double nucleotide mutants of 
shDmrtc2 to identify shRNAs that can or cannot replicate the phenotype observed 
with shDmrtc2 in reprogramming. Subsequently these vectors will be used to carry 
out genome-wide microarray and mRNA-sequencing analysis with the aim of 
identifying candidates that exhibit differential gene expression between shDmrtc2 
and its mutants. Through validation of these candidates, the aim is to identify the 













5.2.1. Strategy to identify off-target candidates of shDmrtc2 
 
It is clear that the efficiency of knock down by RNAi is highly dependent on 
sequence specificity between the target mRNA and antisense siRNA sequences. 
Even as little as a single nucleotide substitution in a si/shRNA sequence has been 
shown to be sufficient to abolish the resulting knock down of a target gene (Jackson 
et al., 2003; Elbashir et al., 2001b; Martinez et al., 2002). With this in mind, I sought 
to generate mutants of shDmrtc2 with double or single nucleotide substitutions, 
with a view to identify vectors which could either abolish the reprogramming 
phenotype observed with shDmrtc2, or enhance reprogramming similarly to 
shDmrtc2 (so called “negative mutant” or “positive mutant”, respectively). I 
reasoned that a negative mutant would be a useful control to investigate off-target 
knock down, particularly if it maintained Dmrtc2 knock down, since the sequence 
would be almost identical to that of shDmrtc2 but have no effect on reprogramming. 
On the other hand, a positive mutant would be advantageous as an additional 
positive control allowing for candidates to be refined based on the differential 
expression of negative controls (shLacZ and negative mutant) and positive samples 








































Enhanced Yes Yes Yes 
Original shDmrtc2 
vector 
No effect No Yes Yes Negative control 
Enhanced Yes No Yes Positive control 
No effect No No Yes/No 
No siRNA production 
or knock down of 
targets with no role in 
reprogramming? 
Figure 5.1. Strategy to determine causal off-target gene promoting enhanced 
reprogramming phenotype. (a) By comparing differential gene expression during 
reprogramming between samples that enhance (yellow) or have no effect (blue, and shLacZ 
control) on reprogramming I sought to identify the off-target gene (green) underlying the 
enhanced reprogramming phenotype. (b) Expected reprogramming result of negative or 
positive shDmrtc2 mutants based on Nanog-GFP+ colony counting. Arrows represent the 
expected gene expression of off-target gene ‘X’ responsible for the enhanced 
reprogramming phenotype caused by shDmrtc2 in each sample: high expression in shLacZ 
control and negative mutant samples (up arrow) or low expression/knock down in shDmrtc2 











































5.2.2. Mutants of shDmrtc2 can abolish or maintain the phenotype 
  
Mutant vectors were created in two sets; initially, 6 mutant vectors were 
created containing identical shRNA sequences to shDmrtc2 with the exception of 
two individual nucleotide substitutions (Figure 5.2a, MUT 1-6). Mutants 1 to 4 
contained substitutions of nucleotides within the seed region, whereas mutants 5 
and 6 contained one substitution within the seed region and one substitution out 
with the seed region. Although reports suggested that a single nucleotide 
substitution is enough to affect knock down efficiency of RNAi (Jackson et al., 2003), 
I chose to include two nucleotide substitutions in these initial vectors to optimize 
the chance of finding a vector that would abolish the phenotype.  
Reprogramming was carried out with the addition of mutants 1 to 6 to 
determine the effect, if any, of the double nucleotide mutations on the phenotype 
observed using shDmrtc2. Strikingly, all six mutant vectors abolished the positive 
phenotype observed with shDmrtc2, giving rise to fewer Nanog-GFP+ colonies at a 
number similar to shLacZ (Figure 5.2b). In order to validate these results, it was 
important to determine the levels of Dmrtc2 transcript in the presence of each 
mutant during reprogramming. Interestingly, despite all of these mutants having 
little or no effect on reprogramming compared with shLacZ, mutants 1 and 5 were 
determined to knock down expression of Dmrtc2 at a level similar to that observed 
with shDmrtc2 (Figure 5.2c). This gave further evidence that the positive phenotype 
conferred by shDmrtc2 during reprogramming was not due to the knock down of 
Dmrtc2 and must be the result of some off target effect. From these data I proposed 
that when considering global gene expression I would expect the gene or genes 
responsible for the positive reprogramming phenotype resulting from shDmrtc2 
would exhibit lowered gene expression in shDmrtc2 when compared with shLacZ, 
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Figure 5.2. shDmrtc2 double nucleotide mutants during reprogramming. (a) The 21bp 
sequence of shDmrtc2 is antisense, or complementary, to a sequence within the Dmrtc2 3’-
UTR region (top line). 6 mutants with double nucleotide mutations were generated. Seed 
region is shown in orange and mutations are shown in purple. (b) The effect of shDmrtc2 
double nucleotide mutants on reprogramming was quantified by Nanog-GFP+ colony count 
on day 12. (c) Q-PCR of Dmrtc2 expression was carried out for samples on days 2 to 6 of 
reprogramming. MUT 1 and MUT 5 knocked down Dmrtc2 expression to similar levels as 

































When flow cytometry analysis for ICAM1/CD44 was carried out on samples 
reprogrammed with MUT 1 and MUT 5, these gave similar profiles to that of 
shLacZ with cells in the shDmrtc2 sample clearly advancing at an earlier time point, 





Figure 5.3. ICAM1/CD44 FACS of shDmrtc2 double nucleotide mutants 1 and 5. MUT 1 and MUT 5, which did not increase Nanog-GFP+ iPSC 
colony numbers, also failed to accelerate reprogramming kinetics observed in shDmrtc2 samples (days 6 and 7, highlighted in red box).  
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Flow cytometry analysis was carried out for three markers commonly used 
to characterize the progression of cells undergoing reprogramming; Thy1, E-
cadherin and SSEA-1 (Figure 5.4). During reprogramming, expression of a MEF 
related marker, Thy1, decreases and expression of E-cadherin, a cell-adhesion 
molecule that is required for the maintenance of pluripotency, increases. These 
changes in gene expression are characteristic of a mesenchymal to epithelial 
transition (MET) during reprogramming. It was interesting to determine whether 
the positive phenotype exhibited by shDmrtc2 was concurrent with advanced 
timing of MET. When these two markers were analysed by flow cytometry 
shDmrtc2 exhibited acceleration of Thy1 down-regulation and E-cadherin up-
regulation on days 3 and 4. However, analysis of a pluripotency marker, stage-
specific embryonic antigen 1 (SSEA-1), demonstrated no marked difference in the 
shDmrtc2 sample compared with controls suggesting that there is no acceleration of 
acquisition of this intermediate pluripotency marker with shDmrtc2. SSEA-1 is 
commonly used as a marker of pluripotency but we see no earlier expression of this 
marker in the shDmrtc2 sample as expected given the enhanced reprogramming 
phenotype. In addition, these flow cytometry data demonstrate that Nanog-GFP+ 
cells can reside within both the SSEA-1 positive and negative populations and so 



























Figure 5.4. Flow cytometry analysis for markers Thy-1, E-cadherin and SSEA-1. The flow cytometry profiles generated from all conditions 
demonstrated no remarkable differences in the gene expression profiles for these markers between shDmrtc2, control and mutants. 
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5.2.3 Microarray analysis reveals off target candidates of shDmrtc2 
 
A robust and reproducible difference both in the colony number and timing 
of Nanog-GFP+ colonies between shDmrtc2 and shLacZ was abolished by only two 
mutations in the sequence of shDmrtc2 in MUT 1 and MUT 5. Despite this, both 
mutant shRNAs could knock down Dmrtc2 transcript levels indicating efficient 
production of siRNA but altered off-targets. To identify an essential off-target knock 
down by shDmrtc2 that enhances reprogramming I took shDmrtc2, shLacZ, MUT 1 
and MUT 5 samples forward for microarray analysis using the Illumina MouseWG-
6 v2 BeadChip. In total, six samples of cells undergoing reprogramming from days 0 
to 5 were taken for six conditions consisting of one each of shLacZ and MUT 1 and 
two replicates each of shDmrtc2 and MUT 5 (R1, R2), totalling 36 samples for 
analysis. If knockdown of off-target gene X is the cause of the phenotype by 
shDmrtc2, I expected the expression pattern of X to be like Figure 5.5 (top graph). 
The results from this microarray approach were somewhat unclear and 
careful analysis was carried out in order to draw some conclusions. Firstly, when 
expression of Dmrtc2 was checked, all shRNA conditions (shDmrtc2, MUT 1 and 
MUT 5) were expected to indicate a down-regulation of Dmrtc2 compared with 
shLacZ, as determined from experiment previously described in Section 5.2.2. 
However, this was only clearly the case for MUT 1 and shDmrtc2 (R1). Both 
replicates of MUT 5 and shDmrtc2 REP2 showed little or no knock down of Dmrtc2. 
This was a first indication that the microarray approach might not be sensitive 
enough to detect off target candidates, unless they were strongly repressed by 
shDmrtc2. However, despite this potential drawback, at first glance several 
candidate genes could be identified from the microarray as having lower expression 
in the shDmrtc2 replicates compared with controls, with the clearest candidates 
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Figure 5.5. Microarray analysis identifies genes with differential expression with 
shDmrtc2 during reprogramming. The expected expression of off-target gene ‘X’ is shown 
(top panel). Top hits of genes with differential gene expression comparing shDmrtc2 
samples with shLacZ or negative mutant samples MUT1 and MUT 5 were Herpud1, Bnip3l, 
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Notably, of the genes that did exhibit differential gene expression between 
shDmrtc2 and controls, a maximal knock down of up to 50% was observed at some 
time points for some candidates, with many genes reaching a knock down of 40% or 
less. Although it cannot be known for any given gene the required extent of knock 
down to elicit a phenotype, it is probably unlikely that a 40-50% decrease in 
transcript level would result in such a striking phenotype as induced by shDmrtc2.  
 In order to approach the data analysis in a more systematic way, we worked 
in collaboration with the lab of Dr. Mihaela Zavolan. R. Gumienny used 
bioinformatics approaches including sequence target prediction and seed region 
count prediction to identify candidates that were predicted to be direct targets of 
shDmrtc2. That is, targets which had some degree of complementary sequence 
specificity to the antisense sequence of shDmrtc2. A biophysical model designed to 
identify miRNA targets and published by the Zavolan lab, called MIRZA, was used 
to determine direct target candidate genes (Khorshid et al., 2013). We hypothesized 
that a miRNA target prediction model can be applied to identify siRNA off-target 
since siRNAs act like miRNAs when a target does not have 100% complimentarity. 
This model takes into account several parameters underlying the miRNA-mRNA 
interaction facilitated by the Argonaute protein including sequence specific 
position-dependent energy parameters that may impose constraints on this 
interaction. In simpler terms, a MIRZA score can be calculated giving an indication 
of the likelihood that a specific sequence (in this case the sequence of shDmrtc2, 
particularly the 7 base pair seed region) can target and interact with any given 
(gene) sequence based on the sequence complementarity and other parameters 
outlined in the MIRZA model. The higher the MIRZA score, the more likely an 
interaction. When this model was applied for shDmrtc2, a list of genes was 











The first thing to note is that Dmrtc2 has a score of 390817. This reaffirms 
that shDmrtc2 should indeed target Dmrtc2. Surprisingly the gene with the closest 
MIRZA score to this was Rrm2b with a score of 1275; two orders of magnitude 
lower than that of Dmrtc2. Indeed, most of the candidate genes had much lower 
scores than this, indicating that no genes were an obvious off target from which to 
start further analyses based on the MIRZA score alone. In addition to the MIRZA 
score, several additional annotations were made in order to narrow down a 
candidate list from which functional validation experiments could be carried out. 
This included a ‘count of seeds’ score (either 1 or 2) illustrating the number of times 
a sequence was found within the 3’-UTR of a given candidate gene that was 
complementary to the seed region of shDmrtc2 (as highlighted in red in Figure 5.6). 
Surprisingly, when I manually searched for sequence matches within candidate 
gene sequences I discovered that for many of the candidates there were several 
sequences that maintained sequence complementarity to at least 5 consecutive bases 
within the seed region of shDmrtc2, and further complementary bases within the 
surrounding 21bp region. In fact, 3 of these candidate genes (Prpf19, Dpysl2 and 
Celf2) had as much as 15/21 nucleotide complementarity in at least one region of the 
Figure 5.6. Computational and MIRZA analysis of microarray data in conjunction with 
analysis of gene expression profiles of reprogramming samples determines shDmrtc2 
candidates. Candidate genes were determined based on MIRZA analysis and the number of 
seed counts identified (green = 1, orange = 2) by our collaborators in the Zavolan lab. 
Annotation of these genes included identification of sequences anywhere within the transcript 
of candidate genes with complementarity to at least 5 consecutive nucleotides in the shDmrtc2 
seed region (red). The total number of nucleotides within the adjacent 21bp region of this 
sequence that matched the shDmrtc2 sequence was determined (number on the right). 
Candidates are listed (from top, left to bottom, right) in order of top hits based on transcript 
knock down from microarray data. Candidates highlighted in blue represent the genes 
containing a sequence with the highest number of complementary nucleotides to shDmrtc2 
(15/21). Dmrtc2 is highlighted in purple. 
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transcript, which I hypothesized could reasonably be the most likely off-target 
candidates as it has been reported that as few as 11 to 14 base pairs can induce gene 
silencing (Dorsett and Tuschl, 2004). Interestingly, a few of the candidate genes that 
demonstrated some level of reduction in gene expression from the microarray were 
not denoted MIRZA scores but this down-regulation could be due to a 
secondary/indirect effect of shDmrtc2. Since the MIRZA score is calculated from 
several parameters, including seed region and whole 21bp sequence 
complementarity as well as nucleotide position dependent energy parameters 
between the shRNA and target gene, not all candidate genes generated a MIRZA 
score. In addition, there were some apparent inconsistencies with genes having a 
MIRZA score but no apparent sequence homology (Acox3 or Cd99l2 for example), 
however, this was put down to differences in specific transcripts used in the various 
analyses carried out on these data. This work was analyzed using early versions of 
prediction tools developed by our collaborators, which have recently published 
following optimization of the system (Gumienny and Zavolan, 2015). 
 With a candidate gene list generated I worked through validating some of 
these candidates by Q-PCR, as described previously, in shLacZ and shDmrtc2 
conditions (Figure 5.7). Firstly, I confirmed the knock down of Dmrtc2 with 
shDmrtc2 by approximately 60-70%, which was consistent with previous data. 
Subsequently, I was able to confirm knock down by at least 50% of the majority of 
candidate genes in the shDmrtc2 reprogramming compared with shLacZ. Several of 
these genes including Qdpr, Herpud1, Rbms1, Nupr1, Bnip3l and Pak3 were 
consistently down-regulated over the time course, whereas others including Dpysl, 
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Dpysl2
Figure 5.7. Q-PCR validation of candidate genes. Data represented as gene 
expression in shDmrtc2 sample relative to shLacZ sample. 
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This led us to wonder whether the microarray technique was sensitive enough to 
determine differential expression of the elusive off-target gene. In addition, there 
was no way to determine whether any observed down-regulation of genes was due 
to knock down by shDmrtc2 or if it was simply a consequence of reprogramming, 
particularly in the cases where down-regulation during reprogramming was the 
usual expression profile observed for a gene as is the case for Herpud1, Pak3 and 
Bnip3l among others (data not shown). 
 
 
5.2.4 mRNA-sequencing reveals direct and indirect target candidates of shDmrtc2 
 
Following investigation of the double nucleotide mutants, I sought to 
determine if single nucleotide mutants had any effect on reprogramming. A further 
9 mutant vectors were created containing single nucleotide substitutions at different 
positions throughout the length of the shRNA sequence (Figure 5.8a, MUT 7-15). I 
was particularly interested to know if any of these mutants were able to recapitulate 
the phenotype observed in shDmrtc2. When added during reprogramming, 
mutants 9, 10, 12 and 15 had little or no effect on Nanog-GFP+ colony numbers. 
Mutants 7, 8, 13 and 14 gave rise to a moderate increase in the number of Nanog-
GFP+ colonies observed compared with control, but strikingly, mutant 11 generated 
over 14-fold more Nanog-GFP+ colonies than shLacZ, almost fully reproducing the 
result observed with shDmrtc2. Therefore, I successfully identified a mutant of 
shDmrtc2 that promoted reprogramming in a similar way. I was surprised to find 
that out of the 15 double or single mutants that I tested in total only a single mutant, 
with only a single nucleotide difference, enhanced reprogramming to a similar 
extent as shDmrtc2. However, this supports the notion that shRNA is highly specific 





















As a more sensitive approach to determining differential gene expression 
between samples we decided to use mRNA-sequencing (RNA-seq) to further the 
investigation. Additionally, instead of using reprogramming samples with shRNAs, 
we thought that MEFs infected with shRNAs would give us a clearer idea of genes 
that are down-regulated as a direct result of the shRNAs, rather than the 



























Figure 5.8. shDmrtc2 single nucleotide mutants during reprogramming. (a) 9 mutants 
with single nucleotide mutations were generated. Seed region is shown in orange and 
mutations are shown in purple.  (b) Mutant vectors were added during reprogramming 
and Nanog-GFP+ colonies were counted on day 14. Mutant 11 gave rise to a similar 
number of Nanog-GFP+ colonies as shDmrtc2, while all other mutant vectors had little or 




to a double infection of viral supernatant containing shRNAs for 24 hours each. 
Samples were collected 3 days after initial infection for RNA-seq analysis. Afzal 
Syed, from the Zavolan lab, carried out RNA-sequencing sample preparation 
following Northern Blot analysis. Initially, in addition to shLacZ and shDmrtc2, 
several samples were considered based on the results from the single nucleotide 
mutant experiment.  A. Syed carried out Northern Blot analysis for these samples to 
determine whether small RNAs, i.e. shRNAs, could be detected (Figure 5.9). A 
probe against miR-199a was used as a positive control in wild type MEF and the 
shLacZ condition, as this is highly expressed in MEF. Indeed a band could be 





Interestingly, while shDmrtc2 expressed small RNA well, MUT 11 did not. Given 
that MUT 11 replicates the enhanced reprogramming phenotype similarly to 
shDmrtc2 this was very surprising. Moreover, MUT 9, which was found to have 
little or no effect on reprogramming efficiency, expressed the shRNA well, with a 
Figure 5.9. Northern Blot of samples for RNA-sequencing. U3 snoRNA was used as a 
loading control and miR-199a was used as a positive control (highly expressed in MEF). 
Bottom panel represents resulting blot with altered brightness/contrast. Northern Blot was 
performed by A. Syed. 
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faint signal visible for MUT 10 also. However, when the image brightness/contrast 
was enhanced, a faint signal could be detected for all shRNAs. 
In addition to the Northern Blot analysis, reprogramming was carried out 
using the same viral supernatant as used to infect the MEFs for the Northern Blot 
and RNA-seq samples. This was to ensure that the enhanced reprogramming 
phenotype was confirmed using the same virus/shRNAs. Indeed, as expected 
shDmrtc2 and MUT 11 gave rise to significantly more Nanog-GFP+ colonies than all 






Following these results, the samples for RNA-seq were chosen; MUT 9 was used as 
an additional “negative” control with shLacZ and MUT 11 was chosen as an 
additional “positive” control with shDmrtc2. With these samples we theorized that 
the off-target gene would be more highly expressed in shLacZ and MUT 9 than in 
both shDmrtc2 and MUT 11 samples. However, this is with the caveat that the same 
off-target gene is responsible for the phenotype observed in shDmrtc2 and MUT 11. 
If a different mechanism were operating in these two conditions, the off-target gene 




























Figure 5.10. Confirmation of 
enhanced reprogramming 
phenotype using RNA-seq 
shRNA virus supernatant. 
Nanog-GFP+ colonies were 
counted on day 14 of 
reprogramming. 
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A. Syed performed the RNA-seq and R. Gumienny performed 
computational data analysis from which P-values and target prediction scores were 
generated for genes when the two negative controls (shLacZ, MUT 9) were 
compared with the two positive conditions (shDmrtc2, MUT 11). By sorting the 
genes in order of p-value, candidate genes were determined by assessing the target 
prediction score and expression across all samples. The target prediction score was 
calculated from a combination of parameters based on a match to the 7-nucleotide 
seed region and the probability that this is a functional site, scaled to a threshold. 
For the top hits, the differential expression was considered for the positive samples 
compared with the controls and 10 direct targets were determined. In addition, we 
considered if an indirect target could be identified that may act downstream of the 
direct off-target by analyzing all differentially expressed genes, as opposed to only 
those with a predicted target score. Top hits that were the most differentially 
expressed between controls and positive samples were identified and interestingly, 
when a known and predicted protein interaction tool called STRING was used, 5 of 
these were suggested to interact each other (Figure 5.11). These were taken forward 




Figure 5.11. Indirect shRNA off-target candidate interaction identified by STRING tool. 
Putative protein-protein interactions were identified between five genes Cnn1, Acta1, Ctgf, 
Mmp13 and Tnfrsf11b using online tool STRING. (Image taken from website string-db.org, 
version 9.1, entering the gene names in the ‘search multiple names’ function. Interactions 
were identified by STRING from experimental or text mining data). 
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A workflow for the bioinformatics and candidate target selection is shown in 
Figure 5.12 and the 15 direct and indirect candidates with associated RNA-seq data 
analysis are summarized in Table 5.1. It was reasoned that the best way to analyze 
the RNA-seq data would be to first list genes based on their target prediction score 
(denoted by our collaborators using bioinformatics tools).  This would give rise to 
the top hits for which putative targeting by shDmrtc2 was predicted. These targets 
were further narrowed by identifying those with a low P-value in combination with 
the most significant differential expression when comparing the positive and 
negative samples. In this way, the top 10 candidate targets that were putative direct 
targets of shDmrtc2 were determined. In addition, it was reasoned that including 
potential indirect targets would also be useful in determining potential pathways 
involved in the enhanced reprogramming phenotype induced with shDmrtc2. To 
this end, in order to determine potential indirect target candidates the entire data set 
was listed in order of genes that exhibited the most significant differential 
expression when negative and positive samples were compared irrespective of any 
other consideration. This gave rise to a vast list of genes, and in order to choose a 
number of genes to put forward for validation it was reasoned that genes which 
were involved in the same pathway or could be identified as having some 
functional link would be the best candidates to take forward. Indeed, 5 genes were 

































2 negative samples (shLacZ & MUT 9) 
2 positive samples (shDmrtc2 & MUT 11) 
Colony counting assay/screen to 
determine positive control (Figure 5.8) 
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RNA-sequencing 
Bioinformatics analyses: 2 approaches 
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Validation of 15 candidate genes: 
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2. shRNAs targeting each candidate generated 
3. Effect of shRNA tested during reprogramming 
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3 0.00095 NM_199476 Rrm2b 0.87981 385 419 267 219 0.69259 0.63566 0.56783 0.52116 
2 0.00043 NM_153098 Cd109 0.83315 8782 9011 6959 6092 0.79236 0.77229 0.69365 0.67608 
1 0.00057 NM_013822 Jag1 0.63948 2291 2469 1819 1666 0.79400 0.73683 0.72719 0.67484 
1 0.01996 NM_024236 Qdpr 0.49665 483 477 325 327 0.67244 0.68059 0.67745 0.68566 
2 0.07047 NM_029766 Dtl 0.45635 556 543 394 397 0.70784 0.72437 0.71392 0.73059 
1 0.00052 NM_181070 Rab18 0.32939 4472 4506 3497 3197 0.78193 0.77602 0.71492 0.70952 
1 0.00588 NM_008301 Hspa2 0.31192 547 618 393 395 0.71774 0.63488 0.72196 0.63861 
1 0.00052 NM_144731 Galnt7 0.30063 762 805 501 533 0.65758 0.62233 0.70002 0.66250 
1 0.00095 NM_021451 Pmaip1 0.25696 3041 3202 2423 2120 0.79690 0.75667 0.69725 0.66205 
1 0.05838 NM_008800 Pde1b 0.18584 249 231 163 134 0.65612 0.70743 0.53815 0.58024 
                            




NM_008607 Mmp13 0.29984 225 303 169 169 0.75021 0.55606 0.75128 0.55685 
NM_008764 Tnfrsf11b NaN 4425 5120 3467 3021 0.78358 0.67728 0.68261 0.59001 
NM_009606 Acta1 NaN 6462 6672 5343 4778 0.82680 0.80076 0.73932 0.71603 
NM_010217 Ctgf NaN 49917 54863 41651 38704 0.83441 0.75918 0.77536 0.70546 
NM_009922 Cnn1 NaN 18069 18662 15282 13333 0.84573 0.81887 0.73786 0.71442 
Table 5.1. Direct and indirect candidates from RNA-sequencing analysis. Candidates are listed in order of their prediction score. nreads = total 
number of reads assigned to the gene, count of seeds = number of shDmrtc2 seed sequences detected within the gene sequence. 
 146 
5.2.5 Validation of direct and indirect target candidates of shDmrtc2 
 
 Following on from candidate selection from RNA-seq analysis, I sought to 
functionally test whether shRNAs targeting these genes had any effect on 
reprogramming. Although RNA-seq technology is more sensitive than microarray 
in terms of transcript detection, it was clear that none of the candidate genes were 
strongly knocked down with shDmrtc2 or MUT 11 (Figure 5.13). A maximum of 40-
50% knock down was observed for a few of the candidates compared with the 
controls, including Rrm2b, Qdpr and Galnt7, however, a majority of the candidates 
only demonstrated a knock down of approximately 20-30%. Nonetheless, these 
candidates represented the top hits from the RNA-seq data analysis, and shRNAs 
were once again designed to test targeted knock down of these genes during 
reprogramming. As before, 3 shRNAs were designed and cloned for each of the 15 
candidate genes. However some of the vectors were not cloned successfully during 
the first round of vector construction, and due to time limitations only the shRNAs 
















      



























































































































Figure 5.13. RNA-seq results 
for direct and indirect 
candidates. The number of 
total reads assigned per gene 
is represented (Y-axis) for 
each candidate gene. Direct 
candidates (first and second 
rows) and indirect candidates 
(bottom row) are shown. Dark 
blue bars indicate controls 
(shLacZ, MUT 9) and light blue 
bars indicate enhanced 
reprogramming samples 
(shDmrtc2, MUT 11). 
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 Transgenic MEF were infected with retrovirus supernatant carrying the 
candidate shRNAs, and reprogramming was induced by addition of dox and 
Nanog-GFP+ colonies were imaged and counted on day 14 using the Celigo cell 
cytometer instrument. Appearance of Nanog-GFP+ colonies was observed in the 
shLacZ and MUT 9 control conditions and as expected shDmrtc2 and MUT 11 gave 
rise to an abundance of bright green colonies by this time point (Figure 5.14). 
Unfortunately, no acceleration of reprogramming or increased efficiency was 
observed with the addition of any shRNA targeting any of the candidate genes 
(Figure 5.14). In parallel, samples of shRNA-infected MEF were taken to assess the 
knock down efficiency of the candidate shRNAs. Firstly, shDmrtc2 and MUT 11 
conditions were analysed to determine whether expression of candidate genes was 
reduced compared with controls, as determined by the RNA-seq. Surprisingly, 
knock down of most of the candidates was not observed in shDmrtc2 and MUT 11 
conditions. Galnt7, Pde1b and Ctgf were knocked down comparably to the levels 
observed from RNA-seq data, however, even this knock down was modest. The 
remaining candidates showed no difference in expression between controls and 
“positive” samples despite accelerated reprogramming being maintained in 
shDmrtc2 and MUT 11. This gave a hint that down-regulation of the candidate 
genes was not responsible for the phenotype. In addition, many of the shRNAs did 
not appear to knock down their reciprocal candidate gene, which suggest difficulty 
in designing efficient shRNAs. However, one or more shRNAs induced reasonable 
(>50%) knock down of some genes but resulted in no enhanced reprogramming 
phenotype providing some clue that these candidates may not be the off-target. 
These included Dtl (P2, P3), Galnt7 (P1, P3), Pde1b (P3), Pmaip1 (P3), Rrm2b (P2, 
P3) and Tnfrsf11b (P1). Nonetheless, even for these shRNAs there was not strong 
enough knock down to confidently rule out any of these candidates as the off-target. 
This further highlighted the difficulty of the shRNA system. Note that of the 
original 15 candidates, Qdpr was omitted from this analysis and Mmp13 knock 
down was not analysed. This is due to unsuccessful cloning of Qdpr shRNAs, and 
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failure of Mmp13 primers during for Q-PCR. As such, only reprogramming data 




      
       
shLacZ Uninfecte
d 
shDmrtc2 MUT 11 
Figure 5.14. Whole well Nanog-GFP imaging of reprogramming with shRNA. The 
Celigo system was used to image whole 6 wells on day 14 of cells undergoing 
reprogramming with shRNAs targeting candidate genes. shLacZ and MUT 9 were used as 
controls and shDmrtc2 and MUT 11 demonstrate significantly enhanced Nanog-GFP+ 
colony number by comparison. Knock down of gene expression is shown with fold change 
of Nanog-GFP+ colonies represented relative to shLacZ. 
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 In addition to acquisition of whole well images, the Celigo instrument was 
used to quantify the number of Nanog-GFP+ colonies generated in each 
reprogramming well (Figure 5.15). These data confirmed the above observation that 
no shRNAs enhanced reprogramming to the level of shDmrtc2 or MUT 11. A few 
shRNAs induced a small increase in Nanog-GFP+ colony number compared with 
shLacZ including Cd109 P1, Pmaip1 P3 and Rrm2b P1, however with only an 
approximate 2-fold change, this is well within the realms of normal variation 
observed during reprogramming. These initial experiments suggest that the 
candidate genes analyzed are likely not the off-target underlying the enhanced 
reprogramming phenotype observed with shDmrtc2. There was no significant 
knock down observed for any of the candidate genes in the enhanced conditions 
(shDmrt2, MUT 11) by Q-PCR, and for several of the candidates, moderate knock 
down was achieved with at least one shRNA with no consequential effect on 
reprogramming observed.  Nonetheless, more efficient shRNAs are required, which 
induce a more robust knock down before any confident conclusions can be drawn 










































Figure 5.15. Quantification of Nanog-GFP+ colony number from Celigo whole well images. Images of reprogramming wells depicted in 
Figure 5.14 were quantified using Celigo software and fold-change of Nanog-GFP+ colony number relative to shLacZ was calculated for 
shRNAs targeting direct (purple) and indirect (grey) candidates. 
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At this time, the off-target effector of shDmrtc2 remains elusive, although 
given the striking phenotype of not only enhanced efficiency but perhaps even more 
importantly acceleration of reprogramming kinetics, it remains a worthy avenue for 
investigation. Determining the underlying cause of this phenomenon could lend 
some insight into the mechanism of reprogramming somatic cells to pluripotency, 




























The experiments and data discussed in this chapter give some indication that 
the candidate genes investigated are not likely to be the reprogramming enhancing 
off-target of shDmrtc2 that we sought to determine. However, no definite 
conclusion can be drawn due to the unclear results obtained from some of the 
experiments, some of which are discussed here. 
 Northern Blot analysis is an important validation of shRNA generation 
when using RNAi expression vectors as opposed to direct transfection of siRNA to 
cells to ensure that the exogenous expression system is working in concert with 
endogenous machinery to mediate RNAi production and subsequent gene silencing. 
In this study, a significant positive effect on reprogramming was identified with the 
addition of an shDmrtc2, and generation of small RNA was confirmed for this 
vector. However, another shRNA, MUT 11, which also promoted reprogramming 
was found not to produce small RNA well. The little shRNA expression detected 
with MUT 11 could be potentially explained in a few ways. Firstly, DNA probes 
with the sequence of shDmrtc2 were used for RNA hybridization in the Northern 
Blot analysis. Given that this already introduces a U-T mismatch, it may be possible 
that the additional single nucleotide changes in the mutants were enough to inhibit 
hybridization, and thus little or no signal could be obtained. In the case of MUT 11, 
it is interesting to note that there is an A to T mutation change compared with 
shDmrtc2, so it is plausible that this additional U-T mismatch with the probe caused 
robust hybridization inhibition. Another potential explanation is that the enhanced 
reprogramming phenotype observed with shDmrtc2 and MUT 11 is caused by 
different underlying mechanisms. Since a reasonable signal is detected in the 
Northern Blot analysis of shDmrtc2, it is likely that the phenotype is a result of 
expression of the shRNA. However, since little siRNA expression signal was 
detected with MUT 11, it is possible that a siRNA-independent mechanism might be 
promoting reprogramming in this context. For example, expression of the MUT 11 
vector (which may or may not be producing mature siRNA) might be abolishing 
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some barrier to reprogramming by interfering with endogenous miRNA 
machinery/processing before export from the nucleus (since it seems no mature 
siRNA is detected from this vector), resulting in enhanced reprogramming. This 
may also explain the lack of candidates determined from the genome-wide 
expression analyses found to be significantly down-regulated in both shDmrtc2 and 
MUT 11 conditions. Although it is a possibility, I think it is unlikely that shRNAs 
with sequences that differ by only 1 nucleotide and promote reprogramming to a 
very similar degree would be functioning via different mechanisms. Repeating the 
Northern Blot analysis with a MUT 11 specific probe and using an RNA rather than 
a DNA probe will determine more conclusively whether MUT 11 is producing small 
RNA. Another possibility for the enhanced reprogramming phenotype observed 
with MUT 11 is that virus production with this vector may not be as robust as other 
vectors. If this is true, the observed increase in Nanog-GFP+ colonies could simply 
be a result of reduced viral/shRNA toxicity, resulting in a similar number of Nanog-
GFP+ colonies being generated with MUT 11 as is observed in reprogramming with 
no viral infection. This could be clarified by determining viral titer for MUT 11 to 
confirm that virus is being produced with this vector. Taken together these 
experiments could give some insight as to whether the effect of this shRNA is likely 
to be one and the same as that observed with shDmrtc2. 
Another drawback is the lack of knock down observed for many of the 
candidates by their reciprocal shRNAs or in the shDmrtc2 or MUT 11 samples by Q-
PCR. One potential explanation for this is that retrovirus requires proliferating cells 
for high infection efficiency. Since MEFs have limited capacity for proliferation and 
the shRNAs are delivered by retroviral infection, it could be that the MEFs were not 
infected well enough due to slow/low proliferation rates and/or senescence. For the 
Q-PCR experiments, MEFs were plated in 6 wells and subsequently infected with 
shRNA-carrying virus and the cultures collected 3 days after infection. Since the 
infection efficiency was typically found to be approximately 50-75%, measured by 
pMXs-DsRed expression (not shown), and the cells were not sorted for shRNA 
incorporation prior to Q-PCR, it is possible that infection efficiency was not high 
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enough and/or proliferation of non-infected MEFs may have skewed the knock 
down results. However, although knock down of Dmrtc2 was not included as a 
positive control (since Dmrtc2 is not expressed in MEFs), Northern Blot analysis of 
MEF samples provided evidence that shDmrtc2 was robustly producing small RNA 
in this context, and furthermore the enhanced reprogramming phenotype was 
consistently maintained in every experiment suggesting that the shRNA expression 
vector system was working reliably. For these reasons I am confident that there 
should have been high enough expression of the shRNAs for knock down to be 
detected by Q-PCR, although sorting shRNA + MEFs samples prior to Q-PCR 
analysis would clarify this. Furthermore, it is unlikely that low infection efficiency 
was the reason for lack of knock down observed since all shRNA vectors were 
identical with the exception of the 21 bp shRNA sequence which varied from one 
vector to the next and knock down was observed for some shRNAs. Finally, the 
level of knock down for these candidate genes determined by RNA-seq was not 
exceptional with a maximum knock down of 40-50% observed. Since only a single 
sample of each condition was submitted for RNA-seq analysis, it is possible that the 
differences observed between controls and positive samples could be the result of 
normal variance in experimental samples.  This would need to be clarified by 
submitting multiple replicates for each condition to determine a statistically 
significant difference in expression between controls and positive samples. 
However, it is probable that if the enhanced reprogramming phenotype is due to an 
off-target gene directly knocked down by shDmrtc2 then the down-regulation of 
this gene or genes would be fairly obvious between microarray and RNA-seq 
analysis. The fact that few genes have been determined through these two genome-
wide analyses suggests to me that another mechanism may be in play. For example, 
given reports of shRNA expression vectors causing saturation of endogenous 
processing machinery, one possibility is that expression of shDmrtc2 is interfering 
with endogenous miRNAs or other regulatory non-coding RNAs (ncRNA) either 
through disruption of the RNAi processing pathway, or through partial 
complementarity resulting in off-target silencing. However, given the specificity of 
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shDmrtc2 expression correlating with enhanced reprogramming, I am certain that 
there is still some sequence specificity required for the phenotype rather than 
shRNA expression using this system simply being enough to overload and disrupt 
the endogenous process in a positive manner. Interestingly, a BLAST search of the 
shRNA sequence of shDmrtc2 results in several predicted ncRNAs coming up as the 
top hits after Dmrtc2 itself, based on sequence homology. In fact, one of these 
predicted genes, Gm31744, has 16 out of 21 contiguous homologous bases. In 
addition, a similar search for miRNA sequence homology using online tool miRBase 
(www.mirbase.org) identified some homology to mouse mir-221, which has been 
implicated in cell proliferation during angiogenesis (Nicoli et al., 2012; Santhekadur 
et al., 2012). Taken together, it is not unreasonable to suppose that shDmrtc2 may be 
exerting its effect through regulation of some factor or mechanism that is not 




CHAPTER 6 - Discussion 
 
3.1 Knockdown of transient up-regulated genes during reprogramming 
 
 In the work presented in this thesis, I used retroviral based shRNA 
expression vectors to target candidate genes that were identified from RNA-
sequencing data generated within our lab as exhibiting transient up-regulation 
during reprogramming. I hypothesized that the transient up-regulation could be 
aberrant or required for reprogramming and thus acting as either a barrier or 
essential function of reprogramming, respectively. In the former case, I theorized 
that knock down of these “UP-DOWN” genes could lead to a “short cut” during 
reprogramming by abolishing aberrant transient up-regulation and consequently 
reprogramming efficiency and/or kinetics would be enhanced. On the other hand, if 
transient up-regulation was essential then knock down would have a negative effect 
on reprogramming, and therefore overexpression could be tested to determine 
whether high expression of a gene resulted in enhanced reprogramming. My results 
concluded that knock down of several of the original candidate genes gave rise to 
enhanced reprogramming efficiency and/or kinetics and one of these, shDmrtc2, 
was further investigated to determine the role in reprogramming as it significantly, 
and reproducibly, enhanced reprogramming. To validate this result, I tested several 
alternative shRNAs targeting Dmrtc2 to try to replicate the phenotype, in addition 
to overexpression experiments to ‘rescue’ the enhancement of reprogramming. 
However, I could not replicate nor rescue the phenotype with these experiments 
and I concluded that although shDmrtc2 knocked down expression of Dmrtc2, this 
was not responsible for the enhanced reprogramming phenotype observed. Instead, 
I surmised that an off-target effect of shDmrtc2 caused the phenotype. I 
subsequently sought to identify the off-target causal gene by employing microarray 
and RNA-sequencing global gene expression analyses to determine candidate genes 
that had differential expression between shDmrtc2 and control samples. I carried 
out functional validation of candidate genes, using the same retroviral shRNA 
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expression vector system to knock down candidate gene expression during 
reprogramming but did not observe enhanced reprogramming with any candidate 
shRNA. Thus the causal gene responsible for the enhanced reprogramming 
phenotype imparted by shDmrtc2 remains elusive. 
 Expression of the Yamanaka factors during reprogramming causes massive 
global genome changes as cells transition from a somatic to a pluripotent state. In 
this work I investigated the role of transiently up-regulated genes in an endeavor to 
gain insight in to the role of such genes. One possibility is that expression could be 
essential for reprogramming, in which case their transient up-regulation may be a 
required step for progression of cells to an iPSC state and subsequently, 
overexpression of these genes could enhance reprogramming (if high levels are 
required). However, since expression is subsequently down-regulated and remains 
low or not detected in iPSCs and ESCs it is possible that only a short burst of 
expression is required and overexpression could hinder reprogramming. For 
example if downstream gene expression is tightly regulated, then overexpression of 
the primary gene could cause fatal disruption. On the other hand, transient up-
regulation could represent a roadblock to reprogramming by aberrant activation of 
barrier genes, in which case knock down could promote reprogramming. Equally, it 
is possible that many of the genes within this UP-DOWN group have no function or 
impact on reprogramming and therefore alternative modulation would have no 
effect. 
 High reprogramming factor expression is the most obvious reason 
underlying massive dynamic changes in global gene expression during the first 
days of reprogramming. Nonetheless, other contributing factors are also notable. 
For example, somatic cell populations used for reprogramming are almost always 
highly heterogeneous. One of the most commonly used cells types for 
reprogramming – MEFs – are derived in a crude way involving basic and unrefined 
dissection of mouse embryos from which cells from various tissue types of a 
developing mouse are isolated. The resulting heterogeneous starting population 
likely gives rise to a predisposition for some cells more than others to be more 
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amenable to the reprogramming process depending on “starting” global gene 
expression status, contributed to by transiently up-regulated gene expression. 
Consequently, this heterogeneity is likely a contributing factor to the low 
reprogramming efficiency observed with most reprogramming systems. Transient 
up-regulation of genes is not limited to our reprogramming system and has been 
reported by others. Transient up-regulation of Foxd1 has been reported as a 
predictor of iPSC potential (Koga et al., 2014) and Bar-Nur et al. (2014) found that 
transiently up-regulated genes maintained high expression in response to defined 
media conditions, which promoted synchronous reprogramming of cells. This 
suggests that at least for some transiently up-regulated genes, high expression 
facilitates reprogramming and therefore subsequent down-regulation may 
contribute to a delayed and/or asynchronous reprogramming population. Takahashi 
et al. (2014) reported transient up-regulation of mesendodermal genes during 
reprogramming of human fibroblasts, suggesting that cells transitioned through a 
primitive streak like phase. This highlights the question of whether cells are 
becoming a different cell type on the route to iPSCs. These studies demonstrate that 
transient expression of genes can often be critical in cell processes and fate 
determination and there is a correlation between this pattern of gene expression and 
transdifferentiation. A prime example of this is reprogramming of somatic cells to 
iPSCs via transient expression of the four reprogramming factors in a variety of cell 
types. Transient up-regulation of genes, in combination with optimal culture 
conditions is also reported for transdifferentiation of fibroblasts or hepatocytes to 
neurons (Vierbuchen et al., 2010; Marro et al., 2011; Ambasudhan et al., 2011; Yoo et 
al., 2011). In the latter case, the authors used transient expression of exogenous 
Ascl1, Brn2 and Myt1l to induce neuronal fate while endogenous expression of 
these genes was up-regulated. A number of different cell types have been used in 
transdifferentiation studies, where transient up-regulation of transcription factors 
and/or miRNAs have been used to convert cells from one fate to another including 
fibroblasts to cardiomyocytes, blood progenitors or hepatocytes (Ieda et al., 2010; 
Szabo et al., 2010; Sekiya and Suzuki, 2011; Huang et al., 2011) and pancreatic 
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exocrine cells to β-cells (Zhou et al., 2008). These studies highlight the functional 
importance of transiently expressed genes in the context of cellular processes and 
fate determination, further compounding our interest in the role of the “UP-DOWN” 
group of transiently up-regulated genes during reprogramming in our system. 
 
 
3.1 Caveats of this work 
 
In this work, I found an shRNA vector designed against Dmrtc2 significantly 
accelerated kinetics and increased efficiency of reprogramming when delivered 
together with the Yamanaka factors. However, it turned out that the positive effect 
on reprogramming was due to off-target effects, rather than knockdown of Dmrtc2. 
Therefore, I aimed to identify the causal gene of the phenotype creating mutant 
shRNA vectors that maintain or abolish the reprograming enhancement activity and 
analyzing gene expression changes caused by the shRNAs. An important caveat of 
my work was that I took this approach based on a hypothesis that the enhanced 
reprogramming phenotype was caused by decreased mRNA levels of the causal 
gene via off-target effects of shDmrtc2. When shRNA is expressed, the RISC 
complex incorporates the processed siRNA to identify target mRNA for subsequent 
degradation. This is usually the case when there is perfect pairing between the 
siRNA and target RNA (as observed with knock down of Dmrtc2 mRNA by this 
shDmrtc2) usually occurring within the open reading frame sequence (Zeng et al., 
2003; Agami, 2002). However, there is another major pathway by which RNAi can 
induce gene repression and that is by translational inhibition. This pathway is 
predominantly triggered when there is imperfect pairing between siRNA and the 
target (Agami, 2002; Saxena et al., 2003; Doench et al., 2003), and therefore is most 
commonly observed in a miRNA-mediated manner since miRNAs mainly act by 
mismatched targeting of 3’-UTRs in target genes (Zeng et al., 2003; Chu and Rana, 
2006; Doench et al., 2003; Valencia-Sanchez et al., 2006). In fact, since we expect that 
an off-target would have imperfect complementarity to shDmrtc2, it is indeed 
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feasible and arguably likely that the off-target could be functioning in this manner. 
A way to determine whether translational inhibition is occurring is to measure the 
protein level of a gene.  If there is a drop in the detected protein level but no 
difference in mRNA expression then this may suggest that translational inhibition is 
the mechanism in play (Gu and Kay, 2010; Chu and Rana, 2006). In other words, as 
opposed to siRNA mediated cleavage occurring, the mRNA persists but translation 
is inhibited and protein production is reduced resulting in a phenotypic change. 
Given that significant repression by shDmrtc2 of any gene could not be detected by 
the genome-wide analyses carried out, this could be an avenue for exploration 
going forward. However, for the RNA-sequencing analysis we used MEFs with 
shRNA expression without reprogramming factor expression, making the 
assumption that the off-target was a gene that was expressed in MEFs. It is possible 
that it may have not been expressed in MEFs but was rapidly up-regulated during 
reprogramming (as with Dmrtc2), in which case I would miss it in the RNA-
sequencing results. Nonetheless, I expected that any significant differential gene 
expression between shDmrtc2 and controls during reprogramming would be picked 
up as hits in the microarray analysis. siRNA pathways have also been implicated in 
chromatin regulation in plants, yeast and multicellular organisms such as C. elegans 
and similar mechanisms of RNAi regulation have been shown in animals including 
D. melanogaster, though to a lesser extent (Moazed, 2009). In addition thousands of 
longer noncoding RNAs are well characterized in eukaryotes including Xist and 
HOTAIR, which modulate chromatin state. The possibility of shDmrtc2 operating 
by way of chromatin regulation was not probed in the scope of this study, however, 
non-coding RNAs should be accounted for with RNA-seq as far as those that 
contain a polyA tail, however, no such hits came up in the analyses. Finally, a 
drawback to the methods of global gene expression analyses undertaken in this 
work is that neither the microarray nor conventional RNA-seq would detect miRNA 
expression, and thus the potential that shDmrtc2 exerts its effect through 
modulation of miRNAs to mediate enhanced reprogramming remains a possibility.  
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3.2 Future directions 
 
An alternative approach to global gene expression analysis for determining 
the off-target of shDmrtc2 is to use Argonaute cross-linking immunoprecipitation 
followed by sequencing (Ago CLIP-seq). Briefly, this technique involves in vivo 
cross-linking of protein-RNA complexes by UV light then subsequent 
immunoprecipitation of the protein of interest (in this case, the RISC component 
Ago2). A 3’ radiolabelled linker is attached to RNAs allowing for visualisation of 
Ago2-RNA complexes following SDS-PAGE separation. After RNA extraction a 5’ 
adaptor is ligated allowing for subsequent sequencing. This technique is widely 
used in studies of miRNAs and their interactions with both processing complexes 
and mRNAs (Clark et al., 2014; Wen et al., 2011; Chi et al., 2009). Computational 
analysis enables identification of putative mi/siRNA targets based on sequence 
match and thus is a useful tool could be a useful tool in determining the off-target of 
shDmrtc2 (Chou et al., 2013). A preliminary Ago CLIP-seq experiment was carried 
out by the Zavolan lab during the final stages of this work but no conclusions could 
be drawn from the data. Partly because the experiment was only performed once, 
and partly because no further validation was carried out due to time limitations, 
however, some observations could be made. It has been reported that during the 
CLIP protocol miRNA-target hybrids can get ligated and when such hybrids were 
determined for shDmrtc2, a list of putative target candidates was collated. Only 
reads that were supported by a significant number of independent CLIP reads (i.e. 
not hybridized) were included in this list and although this is not as quantitative as 
differential expression data, it may give some additional information or clues as to 
the putative off-target. Notably none of the 15 final candidates determined from the 
RNA-seq were among the top hits from the hybrid CLIP data, yet some genes that 
came up during earlier analyses (not shown), including Trp53inp1, Wisp1, Emp2 
and Lpp were observed. Interestingly, the top hit in this analysis was 
B230219D22Rik, an uncharacterised putative protein-coding gene, highlighting the 
possibility that the off-target candidate could be some unknown and 
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uncharacterised gene. These observations are speculative at this point, but closer 
inspection of the results following replication of the CLIP-seq experiment in 
conjunction with the previous global gene expression analyses could give some 
further clues as to the mechanism underlying enhanced reprogramming with 
shDmrtc2. 
 Whilst shRNA can be a very useful tool in which to observe the effects of 
gene knock down in a relatively efficient manner, it may not the best tool now 
available when investigation of several genes is required, as in this study. A 
plausible alternative would be to employ CRISPR/Cas9 mediated gene editing, as 
described in Section 1.5.1. In the context of my shDmrtc2 work this approach could 
be employed as an alternative to shRNA in the validation of candidate genes, 
although with the proviso that a knock out phenotype can differ from a knock down 
phenotype. By using CRISPR-Cas9 technology to completely knock out rather than 
attempt to knock down expression of candidate genes, it could be reliably deduced 
whether there was an effect in the context of reprogramming that recapitulated that 
of shDmrtc2. Ideally, if this technology were available at the time of the original 
screening stage of UP-DOWN genes, it would have been the preferred method of 
screening. Given that there were several other shRNAs in addition to shDmrtc2 that 
enhanced reprogramming efficiency, it could be worth targeting these genes using a 
CRISPR-Cas9 system to validate the data generated using shRNA. If the phenotype 
observed was found to be due to specific targeting of the corresponding gene then 
these would be novel regulators of reprogramming not previously described. 
In the context of this study whereby the targeting of unwanted genes by 
shDmrtc2 resulted in significant enhancement of reprogramming, positive controls 
are acknowledged to be of particular importance upon reflection of the work. 
Several so-called negative mutants were derived, that is shRNAs similar in 
sequence to shDmrtc2 that did not replicate the positive phenotype, and it was 
hypothesized that these would contribute to delineating the correct target that gave 
rise to increased reprogramming efficiency and kinetics upon comparison to 
shDmrtc2. However upon reflection it is clear that with each of these negative 
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mutants came additional off-targets, and thus the global gene expression for each 
mutant shRNA likely widened rather than narrowed the effector candidate gene 
list. Furthermore it is possible, if not probable, that since differential gene 
expression was being analyzed with this strategy that the natural variation of gene 
expression on a global scale in addition to the method of bulk population analysis 
used, obscured the resolution we sought and the answer was obviously not clear-
cut.  
In hindsight, a more effective strategy may have been to pursue screening of 
shDmrtc2 mutants, with single or double nucleotide substitutions, in order to 
determine several more positive control mutant shRNAs (in addition to MUT 11). 
By using a wider panel of positive control mutants for examination and comparison 
of global gene expression with one another and shDmrtc2 to determine genes that 
showed similar rather than differential expression between the panel of positive 
controls and shDmrtc2 it is likely that a smaller list of genes would be derived, and 
that the target gene may be more easily identified by this method. Using samples of 
cells for the gene expression analyses that have been sorted for the expression of 
reprogramming factors (mOrange) and shRNA (if fused to a reporter or tag) would 
further strengthen the resolution of results acquired. Importantly, this is assuming 
that any positive reprogramming phenotype garnered by each of the positive 
mutants is due to targeting of the same effector gene. 
 Given the striking enhanced phenotype imparted by shDmrtc2 on 
reprogramming there is of course a certain level of frustration with being unable to 
identify the cause or causes underlying this effect. The vast and complex dynamic 
changes which cells sustain during reprogramming have made the dissection 
process particularly difficult and the broad known and potentially unknown off-
target effects of sh/siRNAs has only added to the complications. Technologies such 
as CLIP-seq and CRISPR-Cas9 could play meaningful roles in facilitating these 
investigations, though it could equally result in a never-ending chase. It is also 
possible that the phenotype caused by shDmrtc2 was due to knockdown of multiple 
genes, instead of one single gene. An alternative approach to understand how the 
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reprograming enhancement occurs would be focusing on the global gene expression 
changes resulting from shDmrtc2 during reprogramming in order to determine 
differential pathways or factors activated in this condition in comparison to 
conventional reprogramming with slow kinetics. In this way, investigation of 
indirect, rather than direct, targets of shDmrtc2 may lead to some novel insight of 
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Summary 
Generation of iPSCs is inefficient and the molecular mechanisms underlying reprogramming are not 
well understood. While several studies have demonstrated that reprogramming is not entirely a 
random process and contains predictable step-wise changes, varying degrees of cellular 
heterogeneity that arise in different reprogramming systems can obscure the process. Among 
several reprogramming systems available, delivery of polycistronic reprogramming factor 
expression cassettes with piggyBac transposon into mouse embryonic fibroblasts (MEFs) is one of 
the simplest and most robust reprogramming approaches that provides a low background of 
partially reprogrammed cells. Using two novel cell surface markers, ICAM1 and CD44, clear cell 
population changes undergoing reprogramming can be observed over a time course upon induction 
of the reprogramming factors.  Consequently, this technique allows for easy identification of factors 
that enhance or delay reprogramming, and can be a useful strategy in elucidating key mechanisms 
for efficient generation of iPSCs. 
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1. Introduction 
piggyBac (PB) transposon is the most active and widely used DNA transposon for efficient gene 
delivery. It can be handled as conventional plasmids without safety cabinets and shows high 
integration efficiency when co-transfected together with PB transferase which catalyses the 
integration of PB transposon[1]. Among several strategies to introduce Yamanaka reprogramming 
factors, piggyBac (PB) transposon is one of the easiest and safest tools to generate iPS cells 
(iPSCs)[2-4]. Particularly, in combination with polycistronic cassettes of reprogramming factors 
taking advantage of self-cleaving 2A-peptides, generation of iPSCs is robust and highly 
reproducible from mouse embryonic fibroblasts, which are most commonly used to study molecular 
mechanisms of reprogramming. Recently we reported a PB reprogramming system using cells 
expressing all 4 reprogramming factors, Oct4, Sox2, Klf4 and c-Myc, as visualized by 
ires-mOrange. We demonstrated that almost all colonies expressing mOrange can activate a 
pluripotency marker, Nanog-GFP[5], indicating minimal background of partially reprogrammed 
cells[6]. Using this system we have also demonstrated stepwise progression of reprogramming 




































































This approach allows detailed analysis of reprogramming kinetics, or the effect of factors of interest, 
which can be added or removed from the standard reprogramming conditions, providing a strong 
tool to investigate molecular mechanisms of reprogramming. In this protocol, we describe how to 
reprogram MEFs with PB transposon and analyse the marker expression changes during 
reprogramming with flow cytometry.     
 
2. Materials 
2.1 Reprogramming materials 
1. Mouse embryonic fibroblasts (MEFs). We use MEFs from E12.5 embryos with 
Nanog-GFP reporter to identify iPSC colonies live[5].  While Oct4-GFP reporter is 
commonly used to identify iPSC colonies, we found up-regulation of endogenous Oct4 
occurs much earlier than many other pluripotency genes in the following protocol as also 
shown in other systems[6-8]. Reporter system and/or markers for iPSC need to be chosen 
with great care. Reprogramming efficiency with the following method is largely affected by 
passage number/proliferation rate of MEFs. We usually use MEFs less than passage 3 for 
reprogramming experiments. We recommend culturing MEFs in the presence of Fgf2 and 
heparin (MEF medium as below) for propagation to delay senescence.  
2. Basic medium consists of 500 ml of GMEM (Sigma, G5154) supplemented with 51 ml foetal 




































































non-essential amino acids (100X, Invitrogen, 11140-036), 1140 μl 50 mM 2-mercaptoethanol 
(Life Technologies, 31350010), 550 μl LIF (100,000 units/ml, homemade), 2.5 ml 
penicillin/streptomycin (10,000 U/ml Penicillin, 10,000 μg/ml Streptomycin, Invitrogen, 
15140-122), 5.5 ml 100 mM sodium pyruvate (Invitrogen 11360-039), and 5.5 ml 200 mM 
l-glutamine (Invitrogen, 25030-024). 
3.  MEF medium is supplemented with 10ng/ml Fgf2 (Peprotec 100-18-B) and 1 g/ml 
heparin (Sigma, H3149) to the basic medium before use. Fgf2 10,000x stock (100 g/ml), 
heparin 1000x stock (1 mg/ml) are stored at -80 C for long term, and at 4C for less than 1 
month. Do not repeat freeze and thaw. 
4. Transfection medium is MEF medium without penicillin/streptomycin and heparin. 
5. Reprogramming medium is supplemented with 500 nM Alk4/5/7 inhibitor (Alki, A83-01, 
TOCRIS Bioscience, 2939), 10 μg/ml vitamin C (VitC, Sigma, 1000731348) and 1 μg/ml 
Doxycycline (Dox, Sigma, D9891-1G) (see Note 2, 3). Alki 10,000x stock (5 mM), VitC 
5,000x stock (50 mg/ml), Dox 1,000x stock (1 mg/ml) are stored at -80C for long term, and 
at -20C for less than 1 month. 
6. Dulbecco’s phosphate buffered saline (PBS, Sigma, D8537) 
7. Trypsin EDTA (Invitrogen, 15090-046) 
8. Fugene HD (Promega, E2311) 




































































PB-TAP IRI attP 2LMKOSimO (piggyBac (PB) transposon for Dox-inducible expression of 
2A peptide linked Myc, Klf4, Oct4, Sox2 reprogramming factors followed by ires-mOrange) 
Available upon request to keisuke.kaji@ed.ac.uk. PB-CAG-rtTA (PB transposon for 
constitutive rtTA expression vector), pCMV-hyPBase (constitutive piggyback transposase 
(PBase) expression vector). PB-CAG-rtTA and pCMV-hyPBase are available from 
Wellcome Trust Sanger Institute 
(http://www.sanger.ac.uk/form/-WcLcvb-BStKQEt0xeg5MjA).  
10.  Opti-MEM  (Life Technologies, 31985062) 
 
2.2 FACS analysis materials 
1. Anti-mouse CD54 (ICAM1) biotin, eBioscience, 13-0541-82. 
2. Anti-Human/Mouse CD44 APC, eBioscience, 17-0441-82. 
3. Streptavidin PE-Cy7, eBioscience, 25-431-82. 
4. FACS buffer (2% FCS in PBS). 







































































3.1 Reprogramming of MEF with PB transposon 
1. Day -2; Seed 1.5x105 MEF per well of a 6 well plate in 2.5 ml transfection medium. 
Penicillin/streptomycin and heparin can decrease cell viability when Fugene/DNA mix is 
added, therefore we use transfection medium from this point. 
2. Day -1; Prepare the following DNA mix in an Eppendorf tube per well; PB-TAP IRI attP 
2LMKOSimO 0.5 g, PB-CAG-rtTA 0.5 g, pCMV-hyPBase 0.5 g (total 1.5 g DNA), 
and add 100 l of  Opti-MEM (A). In another tube, prepare 100 l of Opti-MEM and add 6 
ul of Fugene HD (B). Mix A and B, and add to MEFs immediately. It is not necessary to 
incubate the DNA Fugene mix at room temperature, or change medium.    
3. Day 0; Change medium to reprogramming medium. Toxicity of transfection with Fugene 
HD is minimal and the wells should be 70-80% confluent by this time. 
4. mOrange expression should be visible 24 hours after changing medium with a fluorescence 
microscope. Transfection efficiency at day 2 is usually about 10% by flow cytemetry. 
Change medium every 2 days (see Note 4). Clusters of mOrange
+
 ESC-like cells should 
appear by day 5, and we start observing Nanog-GFP reporter
+
 colonies at around day 8. 
Most colonies have Nanog-GFP
+
 cells by day 14. If MEFs with pluripotency gene reporter 
are not available, immunofluorescence against Nanog (eBiosciences, 14-5761-80) or Dppa4 
Cosmo Bio, CAC-TMD-PB-DP4) around day 12-14 is recommended to evaluate number of 





































































3.2 Harvesting samples for FACS time course analysis 
The above Fugene transfection protocol gives 30-100 iPSC colonies depending on condition of 
MEFs. mOrange
+
 cell number is low at the early time points of reprogramming, and gradually 
increase since cells undergoing reprogramming proliferate faster. To analyse the cell surface marker 
changes during reprogramming taking a time course, we recommend preparation of at least the 
following well numbers for each time point; day 2 x10, day 4, x8, day 6 x5, day 8 x3, day 10 and 
onwards x1 each (see Note 5).  
1. Remove media and wash cells in PBS then aspirate. 
2. Lift the cells with 500 μl of trypsin EDTA per 6 well. Incubate for 1-3 minutes at 37°C then 
pipette to dissociate cells to single cells (see Note 6). 
3. Quench with 2.5-5 ml of media into a universal tube and count cells (see Note 7). 
4. Centrifuge at 1300 rpm for 3 minutes. 
5. Aspirate supernatant and resuspend cell pellet in 100 μl FACS buffer per staining required, 
then transfer to a V-bottom 96 well plate.  
6. Store plate on ice; cells are now ready for cell surface marker antibody staining. 
 




































































Samples are stained in 100 μl aliquots so prepare enough staining solution for 100 μl/sample + 1, e.g. 
if you need to stain 4 samples prepare 500 μl of each staining solution required. All centrifugation 
steps are carried out at 1300 rpm for 3 minutes. 
1. Prepare ICAM1/CD44 antibody staining solution as specified in Table 1 and foil cover/keep 
out of light on ice until use. 
2. Centrifuge 96 well plate and remove FACS buffer with an aspirator. 
3. Resuspend cells in 100 μl of ICAM1/CD44 staining solution and incubate plate on ice in the 
dark for 15 minutes (see Note 8). 
4. Prepare streptavidin PE-Cy7 secondary stain and foil cover/keep out of light on ice until use. 
5. Centrifuge plate and wash cells with 100 μl PBS. Repeat centrifugation and remove PBS. 
6. Resuspend cells in 100 μl of streptavidin PE-Cy7 secondary staining solution and incubate 
plate on ice in the dark for 5 minutes. 
7. Centrifuge and wash cells in PBS twice as above. 
8. Resuspend cells in 100 μl of FACS buffer, transfer to 5 ml FACS tubes and store on ice until 
analysis. 
 
3.4 Control samples required for FACS time course analysis 




































































1. Unstained E14 ES cells; this control should be negative for all markers. 
2. ICAM1 PE-Cy7 stained ES cells; this is a positive control for ICAM1. All cells should be 
ICAM1 positive. This control also allows for compensation of leakiness into the Red 670/30 
(CD44) and Yellow-Green 582/15 (mOrange) filters. 
3. CD44 stained MEFs; this is a positive control for CD44. All cells should be CD44 positive. 
This control also allows for compensation of leakiness into the Yellow-Green 780/60 
(ICAM1) filter. 
4. Unstained reprogramming (mOrange+) sample; this control allows for compensation of 
leakiness of the Yellow-Green 582/15 (mOrange) signal into the Blue 530/30 (Nanog-GFP) 
and Yellow-Green 780/60 (ICAM1) filters. 
 
3.5 FACS time course analysis of reprogramming samples 
This protocol is based on the use of a BD LSRFortessa cell analyser. The voltages suggested are for 
use with this machine and so optimization of parameters will be required for use of other flow 
cytometry analysers. 
1. Set the cytometer up with the parameters in Table 2 (see Note 10). 
2. Run all control samples first to set up appropriate compensation and base line acquisitions for 




































































3. Run your reprogramming sample(s) through the analyser and gate your cells firstly to isolate 
the intact/live cells (this will be your P1 gate) and then gate mOrange
+
 transfected 
(reprogramming) cells (this will be your P2 gate) (Figure 2, see Note 11).  
4. From the mOrange+ population you can observe Nanog-GFP+ cells when they arise (Figure 
2).  
5. A typical FACS data set for ICAM1/CD44 in our hands is shown in Figure 3 (see Note 12).  
 
4. Notes 
1. FCS lot affects reprogramming efficiency. We have experienced that all mOrange+ cells 
died off before expressing Nanog-GFP even with an FCS lot that supported ES cell 
self-renewal. If the above mentioned protocol does not make any iPSC-like colonies, we 
recommend testing other FCS.   
2. This condition gives the highest reprogramming in most of MEFs in our hands so if you are 
interested in observing the effects of a particular factor on reprogramming then having a lower 
efficiency by omitting Alki and/or vitC might be more appropriate. 
3. We use doxycycline in a range from 300 ng/ml up to 1 μg/ml depending on the condition of 
our starting MEF and experimental requirements. In general, we find that 300 ng/ml is 




































































concentrations of doxycycline are used when reprogramming conditions are less optimal, in 
order to maintain good induction of the four factors.  
4. It is important to keep the reprogramming cultures in a good condition. At later time points, if 
colour of media gets yellow quickly, change the media every day.  
5. CD44 down-regulation usually starts to be observed between day 6 and day 8. ICAM1 
up-regulation can be observed before day 10. 
6. This time of trypsin EDTA treatment does not affect staining with the antibodies described 
here. 
7. Counting cells is not strictly required, although it is useful; until you are familiar with the 
technique, it gives you a good idea of how many cells you can harvest from ‘X’ number of 
wells at ‘X’ time point during the preliminary experiments which will help you to plan and 
optimise future experiments. Also, if you are comparing the effect of additional factors on 
reprogramming, counting the cells at each time point will give some indication if your factor 
of interest is having any effect on proliferation of cells undergoing reprogramming 
(mOrange
+
) or MEFs (mOrange
-
). You can calculate absolute cell numbers of each gate 
based on the total number and % of cells in each gate.  
8. If using the antibodies specified in this protocol, you can prepare the ICAM1 and CD44 




































































9. This is important for 2 reasons: 1) over the duration of a time course experiment the power of 
the lasers in the FACS instrument may be reduced on any given day, even if the voltage is the 
same. This can produce variation in your time course data but can be identified by use of 
appropriate controls. 2) Sometimes some of the fluorophores we use emit light that is detected 
by filters other than the one we intend. This ‘leakiness’ can be detected by appropriate 
controls and compensated for.  
10. These settings are only a guide of the voltages we use in our lab. Take time to adjust the 
voltages accordingly to your own instrument, even if it is also a BD LSRFortessa. 
11. Ensure your settings allow 10,000 events from your P2 (mOrange+) gate to be saved. In this 
example we plotted the mOrange channel against the SSC channel to set P2. The mOrange 
population can be plotted against any other channel. It is advisable to use the channel with the 
clearest separation between the positive and negative cells. 
12. Variations between experiments due to MEF conditions, transfection efficiency etc. can cause 
the reprogramming kinetics to change and therefore the FACS data may vary by a day or two. 
In case you use this system to evaluate impact of factors of interest, always control 
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Figure 1. Typical wells at day 14 of reprogramming with PB-TAP IRI attP 2LMKOSimO vector. 
Top: whole well images from a 6 well plate. Bottom: high magnification images of the white square 
of the top images. Images were taken with Celigo S Imaging Cytometer (Nexceclom). In this 
system, mOrnage expression (red) is down-regulated when Nanog-GFP (green) is up-regulated 
without removing dox from the culture medium.  
Figure 2. Typical gating strategy for cells undergoing reprogramming. Gate firstly for intact/live 
cells in the SSC/FSC channels (P1) and then gate the mOrange
+
 transfected/reprogramming cells by 
plotting mOrange against SSC (P2). This plot was from day 10 samples and Nanog-GFP
+
 cells will 
typically emerge around 7-10 days of reprogramming. Note Nanog-GFP
+
 cells have lower mOrnage 
expression. 
Figure 3. ICAM1 and CD44 mark cells undergoing reprogramming. Cells initially exhibit 
heterogeneous expression of ICAM1 and high CD44. Decreasing ICAM1 expression is then followed 
by downregulation of CD44 around day 8. Finally, upregulation of ICAM1 marks cells entering the 
final ‘iPSC’ between day 8 and 14, which is concurrent with expression of Nanog-GFP (green). 
Figures are from reference [6] with modification. See [6] for more detail. 
 
Table Captions 




































































Table 2. Guide cytometer settings for BD LSRFortessa. 
 
Table1 
Antibody Fluorophore Dilution in FACS buffer 
CD44 APC 1/300 
ICAM1 biotinylated 1/100 
Streptavidin PE-Cy7 1/1500 
 
Table2 
BD LSR FortessaTM 
Excitation Line 
 
488 nm 561 nm 640 nm Voltage 
Band pass (BP) filter 
530±30 eGFP     300 
582±15   mOrange   455 
780±60   PECy7   470 
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